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Abstract 
Foetal exposure to semi-allogeneic cells from maternal microchimaerism (MMc) 
has been associated with the development of tolerance towards noninherited 
maternal antigens (NIMA) through a regulatory T cell response. This concept can 
be exploited in the selection of permissible Human Leukocyte Antigen (HLA) 
mismatches in cord blood (CB) transplantation (CBT) due to the availability of 
maternal samples for HLA typing and the identification of NIMA. CB virtual 
phenotypes (VPs) were generated by the substitution of 1-3 CB HLA (HLA-A, -B 
and/or –DRB1) for the corresponding NIMA, to permit the identification of virtual 
full HLA matches (VFM: 5/6 + 1 NIMA, 4/6 + 2 NIMA or 3/6 + 3 NIMA) for 457 
patients. Maternal HLA typing for 4,671 CB donors resulted in the generation of 
66,225 VPs and 52,875 of these were unique. When combined with the inherited 
phenotypes of 21,020 CB donors, the total unique phenotypes to increased to 
65,046. VFMs, with adequate cell dose, doubled the cumulative availability of a 
matched donor for European Caucasoid patients and tripled the availability for 
patients of other ethnicities. Analyses of NIMA matching and clinical outcomes 
were performed for 198 transplants but was statistically underpowered to detect 
an association. 
High levels of MMc have been associated with transplantation tolerance. HLA q-
PCR assays with 0.01% sensitivity were optimised. MMc was detected in 27% of 
96 samples tested. MMc was more frequent in CB from earlier gestational time 
points and appeared to be associated with bi-directional maternal-foetal HLA 
compatibility.  
The incorporation of NIMA in CB donor selection therefore increases the donor 
pool available to patients, particularly ethnic minorities, requiring CBT. 
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 An overview of the immune system 
The immune system is tasked with the recognition and elimination of infectious 
agents, whilst distinguishing these pathogens from self. It comprises a set of cells, 
tissues and molecules and in vertebrates, is broadly categorised into two arms: 
innate and adaptive immunity. Innate immunity offers a first line of defence by 
recognising highly conserved molecular motifs within broad classes of microbes. 
Binding between these molecular motifs and germ line encoded pattern 
recognition receptors, trigger signalling cascades that result in the phagocytosis 
and/or direct killing of pathogens and the recruitment of immune cells to the site 
of infection through the process of inflammation. If a pathogen is not eliminated 
or contained by these mechanisms, the adaptive immune response is initiated. 
This highly specialised, systemic response is mediated primarily by T and B 
lymphocytes and unlike innate immunity, results in immunological memory, 
allowing an enhanced response for subsequent encounters with the same 
pathogen. Once activated, B lymphocytes mature into antibody producing plasma 
cells which aid phagocytosis by innate immune cells and activate the complement 
system. T lymphocytes comprise T helper (TH) and cytotoxic T lymphocytes 
(CTLs), which function to help B cells make antibodies and kill viral infected cells, 
respectively. Unlike innate immune cells, T and B lymphocytes express a highly 
diverse receptor repertoire that can recognise a variety of molecular structures. 
Receptors specific to particular antigens are clonally distributed on individual 
lymphocytes. T cells are themselves unable to directly recognise the whole 
antigen but instead bind processed antigenic peptides in the context of the Major 
Histocompatibility Complex (MHC) molecules.  
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 Major histocompatibility complex 
1.2.1 Discovery of the MHC and early transplantation attempts 
The MHC is a complex genetic region that contains genes coding for molecules 
involved in the induction and regulation of immune responses. These were 
initially discovered because of their role in the rejection of organs and tissues. 
Early observations showed tumours could be transplanted between some strains 
of mice but were rejected between others, implying donor-recipient 
compatibility was genetically controlled. Snell and colleagues systematically bred 
strains of mice that were identical except from a single genetic region, allowing 
the effect of each region on tumour graft rejection to be examined (Snell 1948). 
He named the locus responsible the H locus (for histocompatibility), which he 
later realised was the same system encoding antigen II, an agglutinating antibody 
previously identified by Peter Gorer (Gorer 1938). Further work showed this 
region was actually composed of multiple genes closely linked together and was 
also present in other vertebrates. The human histocompatibility genes within the 
MHC are referred to as Human Leukocyte Antigens (HLA) and were discovered 
by the research groups of van Rood, Payne and Dausset in the 1950s from studies 
of leukocyte agglutinating antibodies in the sera of multiparous women and 
transfused patients (Dausset 1958, Payne 1957, Van Rood, et al 1958). These 
were characterised during the early international histocompatibility workshops 
that still exist today (Barker and Markmann 2013). 
The large number of burns victims from the First and Second World Wars and the 
failure of attempts to treat these patients with unrelated skin grafts propelled 
research into allograft transplantation. Medawar and Gibson found that, although 
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both autografts and allografts initially healed successfully, allografts were later 
rejected within two weeks. When a second allograft from the same donor was 
attempted, the graft rejected faster and Medawar postulated this was due to an 
immune response (Medawar 1944). Importantly, Medawar, Billingham and Brent 
later showed, in a seminal experiment, that if mice were exposed to allogeneic 
cells during foetal development, they were able to tolerate later skin grafts from 
this allogeneic donor as adults (Billingham, et al 1953). This formed the basis of 
immunological tolerance.  
1.2.2 The MHC genetic locus 
The MHC region is located on the short arm of chromosome 6 (6p21.31), spans 
approximately 4 megabases and is the most gene dense region of the human 
genome (Shiina, et al 2009). The MHC is organised into three clusters of genes 
whose gene products have a similar structure and function: class I, class II and 
class III (Figure 1.1). At the telomeric end of the MHC is the Class I region, which 
contains the classical HLA-A, -B and -C alpha (α)-chain genes (the class I beta (β)-
chain gene is located outside of the MHC on chromosome 15). Centromeric to this 
is the class II region, which contains the classical HLA-DR, -DQ and –DP genes. The 
α and β chain of class II molecules are both encoded in the MHC, designated A 
(e.g. DRA) and B (e.g. DRB), respectively. The A and B genes are organised into 
pairs and contribute to the same isotype (except for HLA-DOA and -DOB, which 
are separated by other genes). HLA-DR haplotypes are complex and contain a 
variable number of coding and pseudogenes. There are four DRB loci, DRB1, 
DRB3, DRB4 and DRB5. HLA-DRB1 is highly polymorphic and present in all 
haplotypes, whereas the others are present in only some haplotypes. Each DRB 
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gene encodes a functional β-chain that can pair with the DR α-chain, meaning a 
potential expression of four different class II molecules on the cell surface.  
Figure 1.1 Simplified map of the genetic structure of the human MHC 
region (Abbas, et al 2015). 
 
Among different ethnicities, certain combinations of HLA alleles occur more often 
on the same haplotype than would be expected on the basis of their individual 
gene frequencies alone, termed linkage disequilibrium (LD). 
1.2.3 HLA protein structure  
X-ray crystallography revealed HLA molecules are heterodimers consisting of 
two non-covalently associated glycoprotein chains, the α (heavy) chain and the β 
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(light) chain (Janeway, et al 2008). The two protein domains nearest to the 
membrane resemble an immunoglobulin domain and the two domains furthest 
away fold together to form a peptide binding cleft (Figure 1.2).  
Class I molecules consist of three α protein domains and a β-chain consisting of 
β₂-microglobulin. The peptide binding cleft is formed from the α-1 and α-2 helices 
and lies on a sheet of eight anti-parallel β strands. Class I molecules bind short 
peptides of 8 – 10 amino acids in length (Rudolph, et al 2006). The β-chain 
provides a platform for α-1 and α-2 and is required for stable cell surface 
expression.  
Class II molecules differ in structure in that the β-1 domain of the β-chain forms 
part of the peptide binding cleft with the α-1 domain in a non-covalent 
association.  The peptide-binding cleft is held into position by the both the α-2 
and β-2 domains and unlike class I, both the α- and β-chains have transmembrane 
and intracytoplasmic domains. The peptide binding cleft of class II molecules 
permits the binding of longer peptides because the helices bordering the peptide 
are shorter and less curved, allowing the peptide to protrude from the ends of the 
groove (Rudolph, et al 2006). 
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Figure 1.2 Structure of class I and class II HLA molecules (Abbas, et al 2015). 
 
1.2.4 Function of HLA molecules 
Class I and class II molecules differ in function and present peptides derived from 
separate antigen processing pathways. Class I molecules are expressed at 
variable levels on all nucleated cells and present intracellular-derived peptides, 
processed through the proteasome pathway, to the T cell receptor (TCR) of 
classification determinant (CD)8+ CTLs (Figure 1.3A). Class II molecules present 
extracellular-derived peptides, produced in acidic endocytic compartments that 
promote proteolysis (Figure 1.3B), to CD4+ TH cells. HLA class II molecules are 
constitutively expressed at low levels on antigen presenting cells (APCs), such as 
macrophages, immature dendritic cells (DCs) and B cells. Up-regulation in APCs 
can be induced by inflammatory cytokines and expression can also be up-
regulated in otherwise class II negative cells, such as activated T cells and 
endothelial cells (Neefjes, et al 2011). 
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Figure 1.3 Antigen processing and presentation pathways of (A) Class I 
and (B) Class II HLA molecules (Neefjes, et al 2011). 
(A)       (B) 
 
Abbreviations: APC, antigen presenting cell; β2m, β2-microglobulin; CLIP, class II-
associated Ii peptide; ER, endoplasmic reticulum; ERAD, ER-associated protein 
degradation; Ii, invariant chain; MHC, major histocompatibility complex; MIIC; 
MHC class II compartment; TAP, transporter associated with antigen 
presentation; TCR, T cell receptor. 
 
Peptide-HLA complexes are presented to T cells through the TCR and its co-
receptor, CD3. Each T cell expresses a clonal TCR that is specific for a peptide-
HLA complex, with more than 108 potential combinations achieved by somatic 
V(D)J recombination and gene conversion during early stages of development in 
the thymus (see section 1.4.2.2). TCR binding to the peptide-HLA complex 
initiates a signalling cascade that determines T cell fate through regulating 
cytokine production, cell survival, proliferation and differentiation and 
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ultimately leads to the activation of effector function (Krogsgaard and Davis 
2005).  
TCRs exist predominantly as αβ heterodimers containing a variable and a 
constant region belonging to the immunoglobulin superfamily. There is a two-
step model of TCR binding to peptide-HLA complexes, where the TCR is first able 
to bind the HLA α-helices and then efficiently “scan” for agonist peptide-HLA 
through substantial movement of the hypervariable region complementarity 
determining region 3 loops, the principle determinants of peptide specificity 
(Krogsgaard and Davis 2005). This causes a conformational change, known as an 
induced fit and the high energy contacts determine whether binding has enough 
stability to trigger T cell activation (Krogsgaard and Davis 2005). After docking 
and stabilisation, a signalling cascade is triggered through engagement of T cell 
co-receptors, CD3 and either CD4 (TH cells) or CD8 (CTL cells) (Krogsgaard and 
Davis 2005). 
1.2.5 Inheritance of the HLA genes 
Family studies have shown that recombination in the HLA region is rare (less 
than 1%) (Lam, et al 2013) and therefore a complete set of HLA alleles on the 
same chromosome are usually inherited as an HLA haplotype (Figure 1.4). 
Inheritance of HLA haplotypes is Mendelian, with an individual inheriting one 
haplotype from the mother (containing the inherited maternal antigens (IMA)) 
and one haplotype from the father (containing the inherited paternal antigens 
(IPA)). The HLA molecules of the mother and father that were not inherited are 
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known as the noninherited maternal antigens (NIMA) and the noninherited 
paternal antigens (NIPA), respectively. 
Figure 1.4 Inheritance of HLA haplotypes. The child has inherited the 
maternal haplotype C (IMA: A3, B7, DR15) and the paternal haplotype A (IPA: 
A1, B8, DR17). Haplotype B (NIPA: A2, B44 and DR4) and D (NIMA: A24, B57, 
DR7) were not inherited from the father and mother, respectively.  
 
Abbreviations: IMA, inherited maternal antigen; IPA, inherited paternal antigen; 
NIMA, noninherited maternal antigen; NIPA, noninherited paternal antigen. 
1.2.6 HLA polymorphism and evolution 
The MHC is polygenic and it is thought to have evolved from repeated gene 
duplication and deletion events (Trowsdale 2011). Each individual has the 
potential to express six different functional classical class I and eight class II gene 
products, which constitutes the phenotype. The MHC is also the most 
polymorphic region in the human genome and therefore an individual is likely to 
be heterozygous at each locus. This balancing selection/ heterozygote advantage 
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offers two chances at an HLA locus to detect an infectious pathogen. 
Polymorphisms include point mutations, insertion/deletions and microsatellites 
and are found within the exons encoding the peptide binding region (class I: 
exons 2 and 3 encoding the α-1 and α-2 domains respectively; class II: exon 2 
encoding the β-2 domain), whereas the exons encoding the protein domains 
involved in TCR and co-receptor interactions are generally conserved (Marsh, et 
al 1999). Many polymorphisms encode amino acid changes (nonsynonymous) 
and just one amino acid substitution can cause dramatic alterations in antigen 
binding affinity and consequently alter the efficiency of T cell activation (Khanna, 
et al 1999, Kubo, et al 1998). 
 Allogeneic haematopoietic stem cell 
transplantation 
1.3.1 Purpose and indications for transplant 
The primary aim of haematopoietic stem cell (HSC) transplantation (HSCT) is to 
re-establish haematopoietic and immune function in patients whose bone 
marrow (BM) or immune system is damaged or defective; or to repair single gene 
defects in metabolic disorders (Apperley, et al 2012). Prior to HSCT, a 
myeloablative conditioning (MAC) or reduced intensity conditioning (RIC) 
regimen is administered to provide sufficient immunoablation to make space for 
the graft, eradicate patient disease and prevent graft rejection (Apperley, et al 
2012).  
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1.3.2 Post-transplantation events 
1.3.2.1 Engraftment, immune reconstitution and infection 
Following allogeneic HSCT patients experience a period of profound 
immunodeficiency prior to complete immune reconstitution, which is heightened 
through the use of post-transplant immunosuppression (Merindol, et al 2011) 
(Figure 1.5). During this time there is a risk of opportunistic infections and viral 
induced malignancies (Merindol, et al 2011).  
Figure 1.5 Kinetics of immune reconstitution and transplant-related 
complications in children following cord blood transplantation (Merindol, 
et al 2011). 
 
Abbreviations: APC, antigen presenting cell; ATG, anti-thymocyte globulin; CMV, 
Cytomegalovirus; EBV, Epstein-Barr Virus; GvHD, graft-versus-host disease; HHV6, 
Human Herpes Virus 6; HSV, Herpes Simplex Virus; NK, natural killer; UCB, 
umbilical cord blood; VZV, Varicella zoster virus. 
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1.3.2.2 GvHD and relapse 
Graft-versus-host (GvH) disease (GvHD) is a major cause of morbidity and 
mortality after allogeneic HSCT and is classified into acute and chronic forms 
(Eapen, et al 2011b, Flomenberg, et al 2004, Furst, et al 2013, Jagasia, et al 2012, 
Kanda 2013, Lee, et al 2007, Woolfrey, et al 2011).The development of acute 
GvHD (aGvHD) is dependent on three requirements: 1) immunocompetent cells 
present in the graft, 2) recipient expression of tissue antigens that are absent in 
the donor and 3) the recipient must be unable eliminate the graft. Acute GvHD 
generally occurs within 100 days post-transplantation and occurs in three stages 
(Figure 1.6) (Ferrara, et al 2009). Chronic GvHD (cGvHD) generally occurs later 
and manifests de novo or as a progression from aGvHD and has a poorly 
understood pathophysiology (Ferrara, et al 2009). It is thought to be mediated by 
donor T cells but unlike aGvHD, tends to share features with autoimmune disease 
(Ferrara, et al 2009). 
GvHD is closely correlated with the beneficial graft-versus-leukaemia (GvL) 
effect. For malignant disease, the optimal conditioning regimen should provide 
reduced relapse risk without an increased risk of GvHD (Apperley, et al 2012).  
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Figure 1.6 Pathophysiology of aGvHD. The recipient conditioning regimen 
damages tissues and causes the release of inflammatory cytokines and 
activation of host APCs (phase I). Host APCs activate donor T cells, leading to 
activation, proliferation, differentiation and migration of alloreactive donor T 
cells (phase II). This results in a complex cascade of multiple cellular (e.g. CTL) 
and inflammatory (e.g. TNF-α) effectors that further modulate each other’s 
responses and ultimately leads to target organ damage. T cell effector 
mechanisms can be suppressed by Tregs (Ferrara, et al 2009). 
 
Abbreviations: APC, antigen presenting cell; CTL, cytotoxic T lymphocyte; IFN-γ, 
interferon-γ; IL-1, interleukin 1; LPS, lipopolysaccharide; Th1, T-helper 1 cell; TNF-
α, transforming growth factor beta; Treg, regulatory T cell. 
1.3.3 HSCT donors 
HSCs can be harvested from BM or peripheral blood (PB) from different types of 
donors. HLA compatibility is the predominant determinant of the success of HSCT 
and the optimal donor is an HLA genotype identical sibling (Table 1.1) but more 
than two thirds of patients require an unrelated donor (UD), facilitated through 
searching altruistic volunteer registries (Passweg, et al 2016). In the absence of 
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an HLA matched UD (MUD, 10/10 based on HLA-A, -B, -C, -DRB1 and –DQB1 at 
allelic resolution), an HLA mismatched UD (9/10) can be utilised, albeit with 
detrimental clinical outcomes (Lee, et al 2007, Petersdorf 2008). Alternative 
donors include an HLA haploidentical donor (family member) or cord blood (CB), 
which are more rapidly available compared to adult UD (Lown and Shaw 2013).  
Table 1.1 Related and unrelated donors for HSCT and their HLA matching 
criteria. 
Type of HSCT donor HLA matching 
Related donor  
HLA identical sibling 
Genotype matched – Patient and sibling share both HLA 
haplotypes.  
Haploidentical donor 
The patient and donor (parent or sibling) share one HLA 
haplotype, as shown from familial haplotype assignments. 
Unrelated donor  
Adult donor  HLA-A, -B, -C, –DRB1 and –DQB1 matched at allelic resolution 
Unrelated Cord Blood 
Historically matched for HLA-A and –B at antigenic or intermediate 
resolution and –DRB1 at allelic or high resolution. More recently 
matched for HLA-A, -B, -C and –DRB1 at allelic resolution. 
 
1.3.4 HLA matching and clinical outcome of transplantation 
In adult donor HSCT, single and multiple HLA mismatches (MMs) have been 
shown to increase the risk of GvHD (HLA-A, -B and -C), transplant related 
mortality (TRM; HLA-A, -C and -DRB1) and result in an additive 9 - 10% increase 
in mortality (HLA-A, -C and -DRB1) (Lee, et al 2007, Petersdorf 2008). Historically, 
a major clinical advantage of CB was the less stringent HLA matching 
requirements due to the lower associated incidence and severity of aGvHD 
compared with BM/PB (Brunstein, et al 2010, Eapen, et al 2010, Eapen, et al 
2007). This has been attributed to the lower lymphocyte content in CB grafts and 
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a limited response of CB naïve T cells activated by recipient alloantigen, possibly 
due to a pre-disposition towards tolerance (Mold, et al 2010), resulting in 
impaired cytokine production, limited cellular activation and a lack of clonal 
expansion of activated T cells (Brown and Boussiotis 2008). Although CB is 
associated with a lower incidence of GvHD, the risk of relapse is generally 
comparable between BM transplantation (BMT) and CB transplantation (CBT) in 
both children (Eapen, et al 2006, Eapen, et al 2007) and adults (Eapen, et al 2010, 
Takahashi, et al 2007). 
An increasing accumulation of evidence supports matching at HLA-C (Eapen, et al 
2014, Eapen, et al 2011a, Eapen, et al 2011b) and at allelic resolution for HLA-A, 
-B, -C and –DRB1 in CBT (Kogler, et al 2005, Kurtzberg, et al 2008, Matsuno, et al 
2009). Data indicates that 1 - 2 HLA allele MMs are acceptable but 3 - 5 allele MMs 
should be avoided (Eapen, et al 2014) and updated recommendations on the 
selection of cord blood units (CBUs) reflect these findings (Hough, et al 2016).  
Clinical outcome data also suggest that not all HLA MMs have a comparable 
detrimental effect on clinical outcome (Kawase, et al 2009, Kawase, et al 2007). 
Permissible HLA MMs identified for adult donor HSCT are based on amino acid 
substitutions at key regions of the HLA molecule involved in peptide binding or 
TCR interactions (Kawase, et al 2009, Kawase, et al 2007). Given that the 
identification of a MUD remains a challenge, especially for ethnic minorities, 
elucidating the differential effects of allele MM combinations may further aid 
donor selection (Gragert, et al 2014). In CBT, permissible HLA MMs are based on 
the concept of fetomaternal tolerance. 
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 Foetal development and tolerance towards NIMA 
In human pregnancy, exposure and interaction between the maternal (decidua) 
and foetal (trophoblast) tissues results in trans-placental cell traffic (Erlebacher 
2013). The presence of maternal cells in the foetus is termed maternal 
microchimaerism (MMc) and the presence of foetal cells in the mother is termed 
foetal microchimaerism. Both the mother and foetus are therefore exposed to 
each other’s semi-allogeneic molecules and for the pregnancy to be a success, 
must avoid immunological rejection of one another. Significant attention has 
focused on maternal acceptance of the semi-allogeneic foetus but far fewer 
studies have focussed on the reciprocal problem of how the foetus is able to 
tolerate its semi-allogeneic host (Erlebacher 2013, Mold and McCune 2012). 
Fetomaternal tolerance was previously hypothesised to be a consequence of an 
inert, functionally impaired foetal immune response with limited antigen 
experience and insufficient memory (Burt 2013). The evidence discussed below 
outlines that this hypothesis is no longer sufficient and rather, that the foetal 
immune system develops in such a way that it learns to tolerate non-self and 
specifically, the NIMA and that this can be exploited in the HLA mismatched 
transplantation setting.  
1.4.1 Pathways of foetal allorecognition of its mother 
There are three main mechanisms of allorecognition between the graft and host 
and these are described below in the context of the foetal host and the maternal 
microchimaeric cells expressing NIMA as the graft (Figure 1.7). The direct 
pathway involves the recognition of intact class I or class II NIMA molecules 
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expressed on maternal cells by foetal TH and CTL clones that express TCRs 
specific for allogeneic NIMA HLA-peptide complexes. Direct allorecognition is 
mainly thought to be due to the cross reactivity of a host TCR (specific for self-
HLA and a viral or bacterial peptide) with a non-self HLA due to TCR interaction 
outside the peptide-binding groove, regardless of the peptide present 
(Bracamonte-Baran and Burlingham 2015). The indirect pathway involves the 
phagocytosis of microchimaeric maternal cells by foetal APCs, which process 
soluble NIMA HLA and results in the expression of foetal HLA class II molecules 
with specific allogeneic NIMA-derived peptides bound on the surface of foetal 
APCs. Foetal TH clones recognise the NIMA peptide-self HLA class II complex and 
elicit an immune response.  
Figure 1.7 Pathways of allorecognition. In the context of pregnancy, the role 
of donor cells in the foetus is played by maternal cells expressing NIMA (red). 
Direct pathway implies the recognition of intact allo-HLA molecules and indirect 
pathway implies the recognition of allopeptide–self HLA II complexes. In the 
semi-direct pathway, allogeneic HLA molecules (NIMA) are acquired via 
exosomes/trogocytosis. IMA are shown in grey, NIMA in red, and IPA in blue. 
(Bracamonte-Baran and Burlingham 2015). 
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TH cells activated through the indirect pathway are able to amplify or regulate 
CTL cells that have been activated through direct allorecognition (Marino, et al 
2016b). This cross-talk relies on a ‘three-cell’ model, whereby both TH and CTLs 
are activated by the same APC. However, immune responses in transplantation 
appear to contradict this model because CTL and TH cells are activated through 
different APCs (donor/graft and recipient/host, respectively) and thus 
amplification appears to necessitate a fourth cell. A semi-direct pathway of 
allorecognition has more recently been proposed to solve this paradox (Marino, 
et al 2016b). In this pathway, maternal cells deliver exosomes containing 
allogeneic NIMA HLA molecules, which are acquired by a specific subset of foetal 
DCs. Foetal DCs expressing NIMA HLA molecules are then able to interact with 
maternal T cells in a direct-like fashion as well as through the indirect pathway. 
This process has recently been shown to be critical in direct pathway acute 
rejection of allografts (Liu, et al 2016, Marino, et al 2016a). 
DCs also have an additional pathway, known as cross-presentation (Joffre, et al 
2012). This involves the uptake and proteasome mediated-processing of 
extracellular antigens. The resulting peptides are presented on DCs by self-HLA 
class I molecules for recognition by CD8+ CTLs. During an immune response to an 
infection, cross-presentation permits the priming of naive CD8+ CTLs without the 
need for the APC to be infected by a virus (Joffre, et al 2012). 
Maternal T cells, B cells, DCs and macrophages have been detected in the PB and 
organs of the foetus, including the lymphoid organs (Drabbels, et al 2011). The 
developing foetus is therefore not antigen inexperienced (Dierselhuis, et al 2012, 
Dierselhuis, et al 2014, Vernochet, et al 2005) and each of the pathways of 
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allorecognition are possible. Subsequent effector responses towards the semi-
allogeneic mother therefore need to be either prevented, or far more likely given 
the requirement for the development of a normal, healthy immune response; 
controlled, such as through the development of immunological tolerance.  
1.4.2 Immunological tolerance 
1.4.2.1 Discovery of fetomaternal tolerance 
Seventy years ago, Owen made the remarkable discovery that most dizygotic twin 
cattle were born with a stable mixture of each other’s erythrocytes and that this 
chimaerism persisted into adulthood (Owen 1945). These cattle were later 
shown to be able to accept post-natal transplantation of each-others skin grafts 
(Billingham, et al 1952). These findings and the seminal experiments by 
Billingham, Brent and Medawar defined the principles underpinning the 
immunological basis of tolerance (Billingham, et al 1953).  
Owen made the observation that some Rh-negative women did not develop anti-
Rh antibodies during the pregnancy of a Rh-positive foetus if the mothers of the 
pregnant women were Rh-positive (Owen, et al 1954). This suggests the pregnant 
women had acquired tolerance towards the NIMA, which in this case was Rh. This 
phenomenon is referred to as fetomaternal tolerance. Broadly, there are two 
types of tolerance: central and peripheral. 
1.4.2.2 Central tolerance 
Central tolerance is the mechanism by which T and B lymphocytes are rendered 
non-reactive to self. Maturing lymphocytes are exposed to self-antigens in the 
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thymus (T cells) or BM (B cells) and auto-reactive clones are deleted before they 
develop into immunocompetent cells.  
During the early stages of T lymphocyte development, cells randomly generate 
unique clonal TCRs through somatic V(D)J recombination and gene conversion 
(which also occurs for the B cell receptor during B cell development). CD4-CD8- T 
cell precursors whose rearranged β-chain cannot associate with a rearranged α-
chain at the cell surface die by apoptosis. Those with successful associations 
receive survival signals, gain CD4+CD8+ expression and subsequently undergo 
thymic selection. Survival depends upon the interaction of the TCR with self-
peptide-HLA complexes. In a series of elegant experiments by Doherty and 
Zinkernagel, T cells were shown to be MHC restricted, that is, if the TCR cannot 
recognise self-peptide-MHC there is death by neglect (Doherty and Zinkernagel, 
1975) . Too much signalling (i.e. risk of autoimmunity) promotes acute apoptosis 
(negative selection). An intermediate level of TCR signalling initiates effective 
maturation (positive selection) and those expressing TCRs that bind self-peptide-
MHC class I complexes become CD8+ T cells, whereas those that bind self-peptide-
MHC class II complexes become CD4+ T cells. 
Deletion of T (and B) cell precursors reactive against NIMA during negative 
selection under the presence of MMc in the foetal thymus (and BM) (Srivatsa, et 
al 2003, Vernochet, et al 2005) may be one mechanism of tolerance towards 
NIMA. However, fetomaternal tolerance cannot be explained by clonal deletion 
alone because foetal CD4+ and CD8+ T cells are able to elicit an immune response 
against NIMA in vitro and therefore must have escaped clonal deletion (Hadley, 
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et al 1990, Jankowska-Gan, et al 2012, Mold, et al 2008, Roelen, et al 1995). To 
deal with this, there is a second line of response, known as peripheral tolerance. 
1.4.2.3 Peripheral tolerance 
Peripheral tolerance occurs after lymphocyte development in the peripheral 
tissues and lymph nodes (LN). Mechanisms of peripheral tolerance include 
immune privilege, anergy and regulation.  
Immune privilege refers to the ability of a tissue to actively regulate and direct 
immune responses that take place in its “territory.” The pregnancy environment 
may act as an immune privileged site, given that amniotic fluid is rich in the 
immunomodulatory cytokine, transforming growth factor beta (TGF-β), which 
can modulate DCs in such a way that they are unable to give a full stimulus to T 
cells (Erlebacher 2013, Guleria and Sayegh 2007). If there is not appropriate co-
stimulation or if the ligand for the TCR is of insufficient affinity to initiate the full 
spectrum of responses, the T cell is unresponsive upon TCR engagement, termed 
anergy. Anergic cells are unable to proliferate or secrete cytokines upon TCR 
mediated re-stimulation (Erlebacher 2013, Guleria and Sayegh 2007). 
The primary mechanism of peripheral tolerance involves a specialised 
population of T lymphocytes known as regulatory T cells (Tregs). The existence 
of Tregs was first proposed to explain the observation that peripheral tolerance 
towards foreign antigens could be induced in the absence of a functional thymus 
(Gershon and Kondo 1970) and were later identified as a subpopulation of CD4+ 
T cells that could prevent autoimmune disease (Sakaguchi, et al 1985). Multiple 
populations of Tregs have been characterised but the best known and most 
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extensively studied are CD4+ cells that express the high affinity interleukin (IL)-
2 receptor (CD25) and the transcription factor FOXP3. These natural Tregs 
become committed to a regulatory fate during thymic development, when they 
are identified as potentially self-reactive through high affinity binding to self-
peptide-HLA complexes. In the periphery, Tregs can also develop from 
conventional T cells under certain conditions (including strength of the antigen 
signal, the presence of TGF-β and IL-10 and other signals from DCs) and are 
termed peripheral or induced Tregs. 
Multiple Treg populations are likely to be involved in controlling response 
towards NIMA. CD4+CD25+FOXP3+ Tregs have been implicated in the suppression 
of anti-NIMA responses in humans and were proposed to have been induced in 
response to MMc in the LN rather than during thymic development (Mold, et al 
2008). However, in mice, a populaton of regulatory cells positive for TGF-β and 
LAP but not FOXP3, have been associated with a decreased response towards 
NIMA and these cells were proposed to be TH3 regulatory cells, thought to 
mediate mucosal tolerance (Molitor-Dart, et al 2007). These cells could arise after 
exposure to NIMA from drinking amniotic fluid containing soluble NIMA and TGF-
β or from breastfeeding (Andrassy, et al 2003, Campbell, et al 1984).  
Mechanisms of Treg mediated suppression are diverse and seem to be dependent 
on the context of their activation and the environment in which they are 
operating. Tregs generally act in a contact-dependent fashion and by secreting IL-
10 and TGF-β, which inhibit T cell proliferation (Shevach 2011). Tregs have been 
shown to suppress proliferative responses against NIMA via the production of 
TGF-β (Molitor-Dart, et al 2007, Mold, et al 2008). Other methods of suppression 
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include diminishing conventional T cell activation or function by limiting growth 
factors such as IL-2, cytotoxicity towards a target cell or by modulation of DC 
function (Shevach 2011).  
Regulatory responses towards NIMA may be promoted by the timing of exposure. 
The human foetal immune system has been shown to be enriched for Tregs at 
early stages during development, which decrease in frequency during the third 
gestation (Cupedo, et al 2005, Darrasse-Jèze, et al 2006, Darrasse-Jèze, et al 2005, 
Michaëlsson, et al 2006). These changes are hypothesised to occur because the 
human adaptive immune system is built from layers of haematopoiesis that differ 
in immunological function and occur at different stages of development (Mold, et 
al 2010). In an elegant study by Mold and colleagues, both foetal and adult T cells 
were shown to be highly proliferative in response to alloantigen in vitro but foetal 
CD4+ T cells expressed different gene signatures and were more likely to produce 
Tregs when stimulated with allogeneic PB cells in a mixed lymphocyte reaction 
(MLR) (Mold, et al 2010). Molecular and functional differences between foetal 
and adult HSCs were also identified and the authors speculated that foetal and 
adult CD4+ T cells were derived from two different pools of HSCs. The authors 
hypothesised that the foetal immune system is biased towards a state of tolerance 
and that a shift towards immune reactivity occurs during the transition to an 
adult immune system.  
Tolerance towards NIMA appears in some cases to last beyond foetal 
development. Lymphocytes of children have been shown to display a Treg 
mediated suppression of proliferation against maternal but not paternal cells, 
possibly due to long-lived memory T cells (Mold, et al 2008, Moretta, et al 1999, 
Chapter 1 
L Powley (2017)  -46- 
Tsafrir, et al 2000, Zhang and Miller 1993). Alternatively, new Tregs could have 
been generated from repeated exposure to NIMA through the persistence of MMc 
throughout childhood, which maintained NIMA-specific tolerance. HSCs of 
maternal origin have been detected in the BM of mice (Dutta, et al 2010, Dutta, et 
al 2009) and in humans, MMc has been detected decades after birth (Loubiere, et 
al 2006), which suggests the transfer of multipotent/pluripotent stem cells 
during pregnancy which are able to continuously divide and replenish the pool of 
MMc. Long-lasting tolerance towards NIMA has immunological implications to 
both related and unrelated transplantation. 
1.4.3 Clinical studies of NIMA matching in transplantation 
In haploidentical related donor transplantation, the mismatched haplotype can 
be either the NIMA or NIPA. For example, in Figure 1.8, the patient has inherited 
the paternal haplotype “A” (A1-B8-DR17) and maternal haplotype “C” (A3-B7-
DR15). Sibling 1 is an haploidentical match to the patient because they both share 
the paternal “A” haplotype. The mismatched haplotype between the patient and 
sibling 1, from the host-versus-graft (HvG) perspective, is the sibling 1 maternal 
haplotype “D” (A24-B57-DR7). This mismatched haplotype D of sibling 1 is 
matched to the patient NIMA and thus the transplant is termed a “NIMA match” 
(NIMA+) in the HvG direction. NIMA matching in the HvG direction is considered 
when evaluating the influence of NIMA in renal transplantation. In a similar 
manner, sibling 2 is a “NIPA match” (NIPA+) to the patient in the HvG direction 
for the “B” haplotype. 
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In haploidentical sibling HSCT, NIMA matching refers to the mismatched 
haplotype in the GvH direction i.e. the NIMA matched haplotype is the patient 
mismatched haplotype. In Figure 1.8, sibling 1 is a NIMA match to the patient 
because the mismatched patient “C” haplotype is matched to the sibling NIMA. In 
a similar manner, sibling 2 is a NIPA matched to the patient because the 
mismatched patient “A” haplotype is matched to the sibling 2 NIPA. 
Tolerance towards NIMA has been observed in the clinical setting of related and 
unrelated donor transplantation for both solid organ and HSC grafts. 
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Figure 1.8 HLA matching status between a patient and their siblings. The 
patient has inherited haplotype “A” (IPA) and “C” (IMA) from their father and 
mother, respectively. Sibling 1 is a haploidentical match to the patient because 
they have both share the paternal “A” haplotype. The mismatched haplotype 
between the patient and sibling 1, from the HvG perspective, is the sibling 1 
haplotype “D” but this is a match to the patient NIMA haplotype and termed a 
“NIMA match” in the GvH direction. Sibling 1 is also NIMA matched to the 
patient in the GvH direction because the mismatched patient “C” haplotype is 
matched to the sibling NIMA. Similarly, the patient and sibling 2 are NIPA 
matched in both the HvG (“B”) and GvH (“A”) directions. 
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1.4.3.1 Renal transplantation 
In a multi-centre study, Burlingham and colleagues reported a significant benefit 
to ten-year renal graft survival for NIMA+ grafts (77%) compared to NIPA+ grafts 
(49%) (Burlingham, et al 1998). Survival of NIMA+ grafts paralleled that of HLA 
identical grafts. The NIMA effect was especially apparent when patients were not 
taking cyclosporine, giving an early clinical indication that the NIMA effect may 
be partially dependent on a T cell response. Furthermore, the NIMA effect has 
also been reported in a retrospective study of over 600 patients that received an 
(unrelated) deceased donor renal transplant (Smits, et al 1998). Single HLA-A 
antigen mismatched renal grafts whereby the HLA-A MM was a NIMA+ were 
associated with a graft survival that was actually superior to that of zero 
mismatched grafts. This suggested that the NIMA effect was caused by an active 
process that down-regulated the allogeneic immune response, rather than a 
clonal deletion of NIMA reactive cells that caused a repertoire devoid of cells 
capable of an effector response towards NIMA alloantigens.  
In contrast to NIMA+ sibling grafts, maternal renal grafts have repeatedly not 
been associated with a graft survival advantage compared to paternal grafts and 
in some cases, maternal grafts have a poorer prognosis (Lim, et al 2016, Opelz 
1990, Panajotopoulos, et al 1990). This includes data from The Collaborative 
Transplant Study of over 5,000 parent-to-child renal transplants (Opelz 1990). In 
a more recent Australian retrospective analysis of 1,139 renal transplant 
recipients, maternal grafts were associated with greater than a 1.5-fold higher 
risk of early and multiple rejection episodes, with more than a 30% higher risk of 
graft loss (Lim, et al 2016). This analysis was particularly important because it 
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was the first study comparing maternal and paternal renal grafts in the era of 
modern immunosuppression and had a median follow-up time of seven years.  
This lack of a tolerogenic NIMA effect in maternal donor renal transplantation is 
known as the “NIMA paradox.” The association between maternal grafts and 
rejection appeared to be more apparent in adult recipients compared with 
younger recipients, suggesting an age-related immunological response towards 
NIMA (Lim, et al 2016). This parallels conflicting earlier MLR in vitro studies that 
failed to identify a decreased direct-pathway alloreactivity towards maternal 
versus paternal cells in adults and contrasts studies of fetomaternal tolerance 
(Hadley, et al 1990, Jankowska-Gan, et al 2012, Mold, et al 2008, Roelen, et al 
1995, van den Boogaardt, et al 2005).  
The poor survival of maternal renal grafts may relate to passenger lymphocytes 
in the renal graft that elicit an immune response in the recipient. The type of 
immune response may differ depending on the antigens that these passenger 
lymphocytes have encountered and at what time point during the donor’s life. In 
maternal donor renal transplantation, maternal passenger lymphocytes would 
have previously been exposed to the mismatched antigens of her offspring (the 
IPA) during a pregnancy that occurred in adult life and it is well established that 
mothers can become sensitised to foetal IPAs (Claas, et al 1988).  In contrast, in 
sibling donor transplantation, donor sibling passenger lymphocytes will have 
also been previously exposed to the recipient mismatched antigens but crucially, 
exposure would have occurred during foetal development from MMc. The 
recipient mismatched antigens are also a NIMA+ and therefore in addition to 
there being a HvG NIMA+, there is also a GvH NIMA+ mismatch. In the example 
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given earlier in Figure 1.8, if sibling 1 is the renal graft donor, passenger 
lymphocytes in the graft will recognise the recipient haplotype “C” IMA as non-
self but these recipient IMA are actually the NIMA of the donor passenger 
lymphocytes.  
Evidence that it is not just the recipient’s immune status that matters in renal 
transplantation and that the donor immune status may also contribute to post-
transplant outcome in what is termed “bi-directional alloreactivity” has come 
from a recent study by Jankowska-Gan and colleagues (Jankowska-Gan, et al 
2012).  Immune regulation in both the recipient anti-donor (HvG) and donor anti-
recipient (GvH) directions were analysed in 29 renal transplant pairs using a 
trans-vivo Delayed Type Hypersensitivity assay. The pre-transplant recipient 
response to the donor alone did not predict transplant outcome. However, the 
inclusion of the pre-transplant donor immune response to the recipient, together 
with the pre-transplant recipient response to the donor, identified in 9/18 
patients, was significantly associated with less rejection. Seven of the nine 
transplants with only unidirectional or no pre-transplant immune regulation 
experienced acute rejection. The assay measured regulation via the indirect 
pathway and therefore both donor tissue APC and passenger lymphocyte T cells 
were implicated as critical players in determining allograft outcome. 
1.4.3.2 Haploidentical HSCT  
Studies have also demonstrated a beneficial effect of NIMA matching in 
haploidentical sibling HSCT for patients with malignant disease, during an era 
when haploidentical transplants were very high risk (van Rood, et al 2002). 
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Historically, haploidentical sibling donor HSCT was performed with T cell 
depletion (TCD) or positive selection of CD34+ cells to overcome complications 
from severe aGvHD and these methods were associated with graft failure, fatal 
opportunistic infections and relapse. Early studies demonstrated that T cell 
replete haploidentical HSCT was possible by exploiting fetomaternal tolerance 
and NIMA+ sibling HSCT was proposed as an alternative to in vivo or ex vivo TCD 
(Ichinohe, et al 2004). In a 2002 retrospective analysis, clinical outcomes of non-
TCD BMT were compared in 269 recipients that received either an haploidentical 
graft from a parent or a NIMA+ or NIPA+ sibling and primarily a cyclosporine 
based GvHD prophylaxis (van Rood, et al 2002). NIMA matched sibling grafts 
were associated with a lower incidence of acute II-IV GvHD and improved 
survival compared to NIPA matched sibling grafts and parental grafts. Maternal 
grafts were associated with a lower incidence of cGvHD and TRM compared to 
paternal grafts.  
The lower incidence of aGvHD using NIMA+ sibling donors in non-TCD BMT has 
also been confirmed in a Japanese study of 35 patients with advanced malignant 
disease that received a PB sibling or maternal graft and a tacrolimus based GvHD 
prophylaxis (Ichinohe, et al 2004). All of these cases were selected on the basis of 
chimaerism present in the donor that was specific to the recipient mismatched 
antigens and assumed to be of maternal origin (sibling donors) or foetal origin 
(maternal donors). However, 10% of patients that received a NIMA+ graft still 
experienced severe aGvHD, despite the presence of MMc, demonstrating that the 
presence of MMc does not always correlate to a tolerogenic NIMA effect 
(Ichinohe, et al 2004) and highlighted a clinical need to predict the risk of GvHD 
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in NIMA+ HSCT. In a follow-up study, 16 Japanese patients were analysed for late 
complications, including the severity of cGvHD, requirement for 
immunosuppression and status of primary disease (Kanda, et al 2009). The 
authors identified that long-term survival without continuous 
immunosuppression is possible after non-TCD NIMA+ haploidentical HSCT using 
a MMc positive donor, despite the frequent occurrence of moderate-to-severe 
cGvHD. 
The significant improvements in clinical outcome associated with the recent 
development of new T cell replete protocols has led to an increase in the use of 
haploidentical donors (Chang, et al 2016). There has only been one study of NIMA 
matching in T cell replete haploidentical HSCT in the modern era. Wang and 
colleagues extensively analysed the outcomes of 1,256 haploidentical HSCT 
recipients with malignant disease that were treated at Peking University Institute 
of Haematology (Wang, et al 2014). NIMA+ sibling donors were associated with 
a lower incidence of aGvHD compared with parental and NIPA+ sibling donors. 
There was no significant impact of NIMA matching on non-relapse mortality, 
cGvHD, relapse or survival. Maternal donors were associated with a higher 
incidence of aGvHD compared to paternal donors, similar to the reported poor 
outcomes of maternal renal grafts compared to paternal grafts (Lim, et al 2016, 
Panajotopoulos, et al 1990). Poorer clinical outcomes (GvHD, non-relapse 
mortality and survival) of haploidentical HSCT were also observed for female 
donors and older donors (Wang, et al 2014). The authors concluded younger, 
male, NIMA+ donors should be the preferred donor choice for T cell replete 
haploidentical HSCT and that older mothers and NIPA+ donors should probably 
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be avoided. Given these findings and the renewed interest in haploidentical HSCT, 
a European study that compares the outcomes of different types of haploidentical 
donors, to identify if there was still a NIMA effect present, would be incredibly 
worthwhile.   
1.4.3.3 Unrelated CBT  
A possible extension to the observed NIMA effect in related haploidentical BMT 
is the setting of unrelated CBT because of the ability to determine the CB NIMA 
from maternal HLA typing. Re-exposure to NIMA can occur in CBT if the MM 
between the CB and recipient is a match for the donor NIMA. van Rood and 
colleagues retrospectively evaluated the influence of NIMA matching on 
outcomes after CBT using data on 1,121 patients with malignant disease that 
received a graft from the New York Cord Bank (NYCB) (van Rood, et al 2009). 
NIMA matching status was evaluated after the transplants were performed and 
of the 1,059 HLA mismatched grafts, 79 (7%) were NIMA+ at HLA-A, -B or –DRB1 
by chance. NIMA+ CB grafts were associated with a faster time to neutrophil 
engraftment, especially for recipients of a poor cell dose. TRM was also lower 
after NIMA+ CBT and this was especially apparent in patients younger than 10 
years old. These benefits translated to improved survival after NIMA+ CBT 
compared to NIMA-, HLA mismatched CBT. Intriguingly, despite the lack of an 
increase in GvHD, NIMA+ CB grafts also showed a trend towards a lower risk of 
relapse (van Rood, et al 2009). A subsequent multicentre case-control 
retrospective analysis by the Eurocord-European Blood and Marrow Transplant 
Group (EBMT) and the Centre for International Blood and Marrow Transplant 
Research (CIBMTR) confirmed the survival advantage in NIMA+ CBT (Rocha, et 
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al 2012). The five-year incidence of TRM in recipients of NIMA+ grafts was 18% 
compared to 32% in recipients of NIMA- mismatched grafts. Consequently, the 5-
year probability of overall survival (OS) was 55% after NIMA+ CBT compared to 
38% after NIMA- mismatched CBT. 
In contrast to related haploidentical transplantation, NIMA matching has not 
been associated with a decrease in aGvHD in CBT (van Rood, et al 2009). The 
authors argued that CBT was not comparable to haploidentical HSCT because of 
differences in HLA matching. Haploidentical donors share a complete HLA 
haplotype that is matched to the allelic level whereas CB grafts have only been 
historically matched to the phenotypic level at HLA-A and -B and to allele level at 
-DRB1. Similarly, the NIMA is mismatched at allelic level across a complete HLA 
haplotype between siblings but only at one, or rarely, two antigens at phenotype 
level in CBT. Furthermore, CB is already associated with a lower incidence of 
GvHD compared to haploidentical donors, possibly due to its Treg properties, 
which may have masked any beneficial effect of NIMA matching on GvHD 
incidence.  
Furthermore, foetal-maternal tolerance may benefit CBT recipients with 
malignant disease, irrelevant of NIMA matching status. It is hypothesised that 
maternal microchimaeric cells, sensitised against foetal IPA, are present in the CB 
graft and mediate a GvL response in the recipient (van Rood, et al 2012). 
Recipients that shared one or more HLA antigens (HLA-A, -B, or -DRB1) with their 
CB donor's IPAs had a significant decrease in relapse compared with those that 
did not, without an increase in GvHD (van Rood, et al 2012). The mechanism of 
reduced relapse after IPA matched CBTs was not established and MMc in the CB 
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graft was not quantified. However, almost all patients received calcineurin 
inhibitors and the majority also received anti-thymocyte globulin (ATG) and 
therefore the T or natural killer (NK) cell mediated GvL effect was shown not to 
be inhibited by either of these. 
1.4.4 NIMA matching in murine models of transplantation 
The potential tolerogenic role of NIMA has also been clearly demonstrated in 
mice. The injection of pregnant H-2d-negative female mice with an H-2d peptide 
can result in profound suppression of the offspring's alloreactive CD4+ T cell 
response (via the indirect pathway) to H-2d, demonstrating the formation of 
tolerance from foetal exposure to alloantigen (Andrassy, et al 2003). In a model 
of transplantation, H-2b/d females are bred with H-2b/b males to yield NIMAd 
exposed H-2b/b offspring and H-2b/b females are bred with H-2b/d males yield 
NIPAd exposed H-2b/b control offspring for comparison studies (Zhang and Miller 
1993). NIMAd skin allografts in H-2b/b offspring exhibit prolonged survival 
compared to NIPAd allografts transplanted in H2b/b offspring (Zhang and Miller 
1993). Recipients of NIMAd BM grafts exhibit a lower incidence of GvHD and 
improved survival compared to recipients of NIPAd grafts but this NIMA effect 
was abolished when CD4+CD25+ T cells were depleted from the NIMAd graft 
(Matsuoka, et al 2006). The NIMA effect does not appear to be due to the inability 
to mount an effector response. In a heart allograft model, both NIMAd exposed 
and control mice are capable of producing an allospecific T effector response 
(production of interferon-gamma (IFN-γ) and IL-2) but this is reduced in NIMAd 
mice (Molitor-Dart, et al 2007). NIMAd transplants are also associated with an 
increase in Tregs within the LN and heart allograft, which also produced an 
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abundance of TGF-β and IL-10 (Molitor-Dart, et al 2007). These NIMAd heart 
allografts remarkably survived for 180 days or more in 57% of cases, without any 
additional drugs or conditioning, compared to rejection of NIPAd allografts within 
11 days in control experiments (Molitor-Dart, et al 2007). These experiments 
demonstrate tolerance towards NIMA is a consequence of foetal exposure to 
NIMA during pregnancy and that this tolerance appears to be mediated by Tregs. 
However, NIMA-specific tolerance is not consistent between different genders 
and strains. NIMAd heart allografts show a 57% graft survival in male recipients 
(Andrassy, et al 2003) but just 25% graft survival in female recipients, albeit 
NIMAd graft survival in females is still higher than the NIPAd control (Molitor-
Dart, et al 2008). Female mice were speculated to exhibit weaker tolerance due 
to oestrogen-mediated enhancement of an effector response, which could 
outweigh any regulatory response. Furthermore, tolerance was only observed if 
the NIMA was H-2d and sensitisation occurred if the NIMA was H-2k or H-2b, which 
may be due to differences in the timings of immune system development between 
the different strains (Molitor-Dart, et al 2008). 
1.4.5 Maternal microchimaerism and a ‘split tolerance’ towards NIMA 
Tolerance towards NIMA+ grafts can occur despite the presence of functional 
NIMA specific alloreactivity (Opelz 1990, Ichinohe, et al 2004, Molitor-Dart, et al 
2007, Molitor-Dart, et al 2008, Kanda, et al 2009, Araki, et al 2010, Lim, et al 
2016). In a murine model, it has been possible to identify and distinguish between 
two separate groups: those that are tolerant towards NIMA and those that are 
sensitised towards NIMA, based on the release of IFN-γ in an MLR-ELISPOT assay 
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(Araki, et al 2010). Those that were tolerant had higher levels of MMc and 
produced significantly less IFN-γ when stimulated with NIMA. This raises the 
possibility that in vitro assays that measure IFN-γ production in response to 
stimulation against NIMA could have a clinical role in predicting the outcome of 
NIMA+ transplants. 
Furthermore, studies have failed to demonstrate reduced alloreactivity towards 
NIMA in adults through MLRs that measure direct pathway responses (Hadley, et 
al 1990, Roelen, et al 1995, Akiyama, et al 2011), yet others have shown a Treg 
mediated tolerance associated with indirect allorecognition (Akiyama, et al 2011, 
Jankowska-Gan, et al 2012, van Halteren, et al 2009). Taken together, this 
suggests the existence of a “split tolerance” phenomenon associated with the 
NIMA effect, in which regulation to a NIMA-specific indirect pathway is induced 
without tolerogenic impact on the direct pathway (Bracamonte-Baran and 
Burlingham 2015). 
How such a small proportion of maternal microchimaeric cells can lead to 
profound tolerance in transplantation, especially in the presence of “split 
tolerance,” remains unclear. The semi-direct pathway of allorecognition may 
provide a mechanistic link (Bracamonte-Baran and Burlingham 2015). Maternal 
microchimaeric monocytes, macrophages and DCs have been identified in mice 
(CD11c and CD11b subsets in flow cytometry analyses) and these can release 
exosomes containing intact NIMA MHC that can be acquired by host DC in a 
phenomenon known as “cross-dressing” (Campana, et al 2015). APCs dimly 
expressing allogeneic intact NIMA MHC have been detected in mice that are 
tolerant of NIMA+ grafts but this APC population is more transient in rejecters of 
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NIMA+ grafts (Dutta, et al 2009, Molitor-Dart, et al 2007). APC acquisition of 
intact NIMA MHC may require a certain threshold and/or quality of MMc and this 
may explain why low levels of MMc are associated with sensitisation towards 
NIMA (Andrassy, et al 2003, Bracamonte-Baran, et al 2017, Molitor-Dart, et al 
2008, Molitor-Dart, et al 2007). An elegant study exploring the mechanisms 
behind this phenomenon and a proposed model of split-tolerance, shown in 
Figure 1.9, has recently been published (Bracamonte-Baran, et al 2017). 
Membrane alloantigen acquisition (m-AAQ) by DCs was shown to occur in some 
but not all mice and positively correlated with MMc levels. In those positive for 
m-AAQ, a split tolerance was observed, where the direct pathway of 
allorecognition remained intact but stimulation through the indirect pathway of 
allorecognition resulted in anergy (shown to be through T cell cycle arrest after 
one round of cell division). A heart allograft model paralleled previous 
observations, where in m-AAQ+ mice, an acute rejection pathway was present but 
if mice survived this effector response, they remained free from chronic rejection 
and exhibited prolonged survival (Bracamonte-Baran, et al 2017, Burlingham, et 
al 1998). In contrast, m-AAQ- mice exhibited alloreactivity through the direct and 
indirect pathways and succumbed to acute rejection.  
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Figure 1.9 Proposed models for microchimaerism and exosome-mediated 
split tolerance. Models of DC nonclassical (cross-dressing) and classical MHC-II 
pathways of allopresentation in mice having non-mAAQ (A) and mAAQ+ (B) 
forms of microchimaerism. (A) In a non-mAAQ condition, MMc-derived soluble 
allo-MHC molecules (red) are classically processed and presented in a self–
MHC-II–restricted manner, leading to active indirect pathway (TEa) cells, 
whereas scarcity of intact allo-MHCs makes direct recognition (4C) inactive. The 
exosomes are all derived from self-tissue–resident DC, with ample CD86 and 
low PD-L1 coexpression, reinforcing self-MHC–restricted alloreactivity (* 
indicates a membrane fusion process that may occur on contact or only after 
exosome internalization, with recycling of the fused patch to the cell surface). 
(B) In mAAQ+ settings, not only are soluble allo-MHCs released from MMc, but 
also exosomes, generating a “Janus-faced” DC. On the left, nonclassical side, 
exosome-acquired intact allo-MHCs are colocalized with acquired CD86 in 
microdomains that exclude PD-L1, leading to activation of direct T-cell clones 
(4C). On the right, exosome acquisition leads to reprogramming of the classical 
MHC II pathway (“?” indicates that exosome-associated miRNA effects on PD-L1 
mRNA translation are postulated), such that PD-L1 is present in the 
microdomains expressing the allopeptide/self–MHC-II complexes, generating 
abortive activation/anergy of indirect T-cell clones (TEa; red X) via PD-1 and 
TcR microclustering (Bracamonte-Baran, et al 2017). 
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The differences in stimulation by these two pathways of allorecognition acting 
via the same DC in m-AAQ+ mice appeared to be due to differences in the 
microdomain environments where the different T cell interactions were taking 
place (Bracamonte-Baran, et al 2017). DC microdomains with intact acquired 
MHC alloantigen (and the serum enriched for extracellular vesicle fractions) were 
enriched for CD86, a ligand that provides the co-stimulatory signal necessary for 
T cell activation and survival. The immunomodulator, PD-L1 was absent from 
these microdomains. In contrast, PD-L1 was localised to microdomains 
containing allopeptide+self-MHC, which binds to PD-1 on T cells and delivers a 
signal that inhibits TCR-mediated activation and proliferation. It therefore seems 
the lack of proliferation of T cells stimulated via the indirect pathway was due to 
the presence of PD-L1 and indeed, if PD-L1 was blocked in the cultures, T cells 
were able to proliferate in response to allopeptide+self-MHC. Given that 
increased expression of PD-L1 was observed in these m-AAQ+ mice but was 
absent from the vesicles themselves, the authors hypothesised that vesicle 
microRNA had somehow reprogrammed the DC to upregulate endogenous 
expression of PD-L1. 
The biological reasons for a naturally occurring split-tolerance towards NIMA are 
unclear. However, some speculation may be made based on the recent finding 
that in mice, MMc-induced Treg development impacts cross-generational 
reproductive fitness through NIMA-specific Tregs in female offspring (Kinder, et 
al 2015). This is in agreement with the observation that increased levels of MMc 
in adult women are associated with a reduced rate of preeclampsia and recurrent 
miscarriage (associated with aberrant foetal tolerance), in what is termed the 
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grandmother effect (Gammill, et al 2011, Gammill, et al 2015). Although such 
tolerance appears to protect against foetal loss, an acute inflammatory response 
is however, required to facilitate embryo implantation and the presence of a split-
tolerance to NIMA may be the best approach to facilitate both (Bracamonte-
Baran, et al 2017, Kinder, et al 2015). This may explain why MMc has been 
associated with autoimmune diseases such as scleroderma (Lambert, et al 2004). 
Furthermore, split-tolerance towards NIMA may also explain why Rh-negative 
women exposed to Rh from their mothers, did not go on to develop anti-Rh 
antibodies (dependent on the classical pathway of peptide-MHC-II and 
processing and presentation to TH cells) during pregnancy of a Rh-positive foetus 
and yet this did not prevent haemolytic disease of the new-born (Owen, et al 
1954).  
In summary, the foetus develops immunological tolerance towards NIMA, likely 
though the induction of NIMA specific Tregs. The foetus retains the capability of 
NIMA specific alloreactivity and overall tolerance appears to be dependent on 
levels and/or type of MMc, possibly mediated through the semi-direct pathway. 
This tolerance can be exploited in the setting of HLA mismatched transplantation.  
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 Aims of this thesis 
The central aim of this thesis is to explore the role of NIMA matching in unrelated 
CBT, with regards to donor availability and clinical outcome and to also develop 
a sensitive method to quantify the levels of MMc present in CBUs. The main sub 
aims of this thesis are as follows: 
1. To define the HLA-A, -B and -DRB1 NIMA of banked CBUs with maternal 
HLA types available, to generate virtual phenotypes derived from the 
NIMA and to evaluate whether these increase the number and diversity of 
HLA phenotypes available for donor searches. 
2. To determine whether the inclusion of these virtual phenotypes can 
provide virtual full matches that can improve donor availability for 
patients of various ethnicities requiring CBT. 
3. To retrospectively determine whether NIMA matching for HLA-A, -B, -C 
and –DRB1 had any effect on clinical outcomes after single CBT in 
recipients with malignant and non-malignant disease. 
4. To develop a sensitive q-PCR assay for the detection and quantification of 
MMc in CB, to determine the levels of MMc in transplanted CBUs and to 
investigate variables associated with its presence and/or absence. 
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Chapter 2 Materials and methods  
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 Stock solutions and commercial kits 
Agarose gel (1%) 
200mL x1 Tris Borate EDTA (TBE) Buffer [Sigma Aldrich]  
2g Agarose Powder [Helena Bioscience]  
20μL GelRed [Biotium] 
Agencourt AMPure XP [Beckman Coulter] 
Ethanol (>99.8%) [Sigma Aldrich] 
Ethanol, 70% 
Ethanol (>99.8%) [Sigma Aldrich] was mixed with de-ionised water in a ratio 
of 7:3 
Illustra ExoProStar [GE Healthcare Life Sciences] 
Long Range PCR kit [Qiagen] 
Nuclease free H2O [Ambion] 
Performa DTR plates [EdgeBio] 
QiaAmp DNA Maxi kit [Qiagen] 
QiAmp DNA Mini Kit [Qiagen] 
Sequence Based Typing (SBT) Excellerator kits (HLA-A, -B, -C, -DRB1) [GenDx]  
SYBR Select Master Mix [Life Technologies]   
 Equipment 
3130 sixteen capillary genetic analyser [Applied Biosystems] 
MicroAmp optical 96-well reaction plate [Applied Biosystems] 
MicroAmp optical adhesive film [Applied Biosystems] 
FrameStar semi-skirted 96 well plate [4titute] 
Nanodrop [Applied Biosystems] 
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PCR seal [4titude] 
Quant Studio 7 Flex Real-Time PCR System [Thermofisher] 
SBTengine [Gendx] 
Veriti thermal cycler [Applied Biosystems] 
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 Definitions and terminology 
Terminology frequently used throughout this thesis are defined in Table 2.1. 
Table 2.1 Definitions of HLA typing resolution 
Resolution Definition Example(s) 
Serological 
HLA antigenic specificity (i.e. at the phenotypic level) 
determined by serological assays. Defined at the broad and 
split level (closely related but distinct specificities). Broad 
antigens are given in parenthesis after the split antigen. 
Many HLA alleles have the same serological specificity and 
conversely, many HLA alleles have no serological 
equivalent. 
A1 
Low 
Molecular based HLA typing result corresponding to the 
first field of HLA nomenclature. 
A*01 
Intermediate 
Molecular based HLA typing result that includes a group of 
alleles sharing the same first field but excludes some other 
alleles with the same first field. Sometimes include a 
minimum number of alleles with a different first field to the 
rest of the group. 
A*01:01/01:0/
01:14/36:04 
High 
Molecular based typing result that contains a set of alleles 
that encode the same protein sequence for the peptide 
binding region of the HLA molecule and excludes non-
expressed HLA alleles. 
Includes groups of alleles with a P designation (encode 
same protein sequence in exon 2 and 3 for HLA class I and 
exon 2 for HLA class II) 
Includes groups of alleles with a G group designation (same 
nucleotide sequence across the exons encoding for peptide 
binding region). Does not include non-expressed alleles 
with same nucleotide sequence. 
A*01:01Pa  
 
 
 
A*01:01:01Gb 
Allelic 
Molecular based tying result consistent with a single allele, 
defined as a unique nucleotide sequence for a gene and 
using all fields in the current allele name and defined in a 
given version of the WHO HLA Nomenclature Report. 
A*01:01:01:01 
 
A*02:07 
a 01:01:01:01/01:01:02/01:01:03/01:01:04/01:01:05/01:01:06/01:01:07/01:01:08/01:01:09/ 
01:01:10/01:01:11/01:01:12/01:01:13/01:32/01:37/01:45 
b 01:01:01:01/01:01:01:02N/01:04N/01:22N/01:32/01:34N/01:37/01:45 
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NIMA:  
The maternal HLA not inherited by the foetus. For example, if the CB donor HLA-A 
type is A*01, 03 and the CB donor mother is A*01, 02, the CB has inherited A*01 from 
the mother and but has not inherited the mother’s A*02. The A*02 is the NIMA. The 
NIMA is informative if the mother is heterozygous and the NIMA is mismatched 
to the CB IPA. 
Phenotypes: 
• Inherited phenotype: The expressed HLA profile of both HLA 
A~B~DRB1 haplotypes. 
• Virtual phenotype (VP): CB inherited HLA phenotype with 1, 2 and/or 3 
CB HLA at HLA-A, -B and/or –DRB1 substituted for the corresponding 
NIMA.  
Donor-recipient HLA matching: 
• Inherited HLA match: The number of HLA-A, -B (traditionally at antigenic or 
intermediate resolution) and –DRB1 (traditionally at high resolution) donor-
recipient matches, determined as a count of six (6/6, 0 mismatch; 5/6, 1 
mismatch; 4/6 2 mismatch; 3/6, 3 mismatch). A 6/6 is designated an 
inherited full match (IFM). Matching which additionally includes HLA-C is 
determined as a count of eight and can be based on low or high resolution. 
• NIMA match (NIMA+): A donor-recipient HLA MM that is matched to the 
donor NIMA. For example, if the recipient is A*01, 02, the CB and recipient are 
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mismatched at A*02. If the CB NIMA is A*02, the HLA MM is designated a 
NIMA+. 
• Virtual full match (VFM): When each of the donor-recipient MMs are 
matched to the NIMA. These include 5 inherited HLA matches plus 1 NIMA 
match (5/6 + 1 NIMA), four inherited HLA matches plus 2 NIMA matches 
(4/6 + 2 NIMA) and three inherited HLA matches plus 3 NIMA matches 
(3/6 + 3 NIMA). 
 Patients, donors and mothers 
2.4.1 Active donors in the NHS-CBB 
At the time of this research, 21,020 CBUs were banked with the NHS-Cord Blood 
Bank (CBB) and listed with the British Bone Marrow Registry (BBMR). Maternal 
HLA types were available for a proportion of these CB donors (n= 4,671).  
NHS-CBB methods for CB collection, processing, testing, freezing and storage 
have been described previously elsewhere (Armitage 1999, Davey 2004, 
Navarrete 2009). Mothers were interviewed to obtain informed written consent 
for clinical and/or research use and the testing of CB in two stages. Consent to 
collect, evaluate and process CB and place it in short term storage was obtained 
prior to active labour. Consent for testing, use and long-term storage was 
obtained post-labour.  
2.4.2 Donor-recipient transplant cohort 
The NHS-CBB issued 499 CBUs between 1999 and June 2014, both nationally and 
internationally, to patients requiring CBT using one (single CBT) or two (double 
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CBT) units. Recipient disease indications comprised malignant and non-
malignant types.  
Demographic and clinical outcome data was available from multiple sources. As 
part of this research, a collated database containing all relevant information was 
developed. Recipient demographics and clinical outcome were available from 
Eurocord and transplant centres have previously provided written consent for 
the NHS-CBB to receive this data. Recipients (or their guardians) provided 
written consent for research. Additional recipient demographics were available 
from hard copies of patient files (stored at NHSBT) or from the laboratory 
information management system, Hematos (Savant). Demographics of mothers 
and their CBUs were available from Hematos or from hard copies of medical 
questionnaires.  
2.4.3 Healthy male platelet donors 
Whole blood collected in EDTA was obtained from NHSBT male platelet donors 
for DNA extraction to be used as controls in quantitative-polymerase chain 
reaction (q-PCR) assays. Donors were bled for the purpose of HLA typing by the 
clinical histocompatibility and Immunogenetics (H&I) laboratory and aliquots 
were taken of surplus blood not required. HLA typing results and gender of these 
donors were available from Hematos. Consent for research is obtained from 
blood donors.  
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 Sample preparation 
2.5.1 Whole blood DNA extraction 
DNA was extracted from whole blood in EDTA using the QiaAmp DNA Maxi kit, as 
per the manufacturer’s spin protocol. Briefly, 5 millilitres (ml) of whole blood was 
added to a 50ml conical tube (Fisher Scientific) containing 500µl QIAGEN 
Protease and mixed. 6ml of buffer AL was added, mixed by inverting 10 times and 
vigorous shaking for 2 minutes. The mixture was heated using a water bath to 
70°C for 10 minutes to allow DNA lysis to occur. 5 ml of molecular grade ethanol 
was added and mixed as before. The mixture was spun in a QiaAmp Maxi column 
at 1850 x g for 3 minutes.  The filtrate containing impurities was discarded, and 
further impurities were removed with two wash steps using buffer AW1 and 
AW2 and spun at 4500 x g for 1 minute and then 15 minutes. The Maxi column 
was transferred into a new 50 ml conical tube and the DNA was eluted using 600 
microliter (µl) Buffer AE, with a 5-minute incubation step and centrifugation at 
4500 x g for 2 minutes. To obtain highly concentrated DNA, the eluted DNA was 
reloaded onto the Maxi column and the elution step was repeated again.  
2.5.2 Umbilical cord tissue DNA extraction 
DNA extraction was performed using the QiAmp DNA Mini Kit (Qiagen) as per the 
manufacturer’s spin protocol. Tissue from the inner layer of the cord tissue including 
the Wharton’s jelly and blood vessels was dissected and homogenised in the 
manufacturer’s lysis buffer. Due to the general age and physiology of the cord tissue 
samples, it was particularly difficult to extract high quality genomic DNA and results 
were inconsistent (dependent on starting material). Twenty-four-hour lysis with 
proteinase K resulted in a higher yield of genomic DNA when compared to 3-hour 
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lysis (12.3 nanogram (ng)/µl and 4.9 ng/µl respectively). Starting tissue weight had 
no effect on the concentration of genomic DNA extracted (data not shown). Personal 
observation suggested the highest yields of genomic DNA were achieved when 
thawed tissue appeared pink in colour (indicative of freezing soon after collection). 
Poor 260 nm/280 nm wavelength absorption wavelengths were also observed and 
it was necessary to purify genomic DNA prior to downstream molecular analysis.  
2.5.3 DNA purification 
Poor quality DNA samples were purified using Agencourt AMPure XP (Beckman 
Coulter) magnetic beads, as per the manufacturer’s instructions. Briefly, beads were 
equilibrated to room temperature and added to DNA in a 1µl : 1.8µl ratio on a 96 well 
plate, mixed gently by pipetting up and down 10 times and incubated at room 
temperature for 5 minutes to allow the beads to bind to the DNA. The plate was 
placed onto a 96 well magnetic plate, left for 2 minutes to allow the bead-DNA 
complexes to move to the edge of the well and the clear liquid containing impurities 
was aspirated off. The bead-DNA complexes were then washed using 200µl of 80% 
molecular grade ethanol twice, with the ring of beads then allowed to air dry for 3 
minutes. The plate was removed from the magnet and nuclease free water was 
added, mixed by pipetting up and down 10 times and the plate was incubated for 5 
minutes to allow the beads and DNA to separate. The volume of water added was 
variable depending on the starting DNA concentration but ranged from 30 – 70µl. 
The plate was placed back onto the magnet for 2 minutes and the purified DNA was 
transferred to an Eppendorf tube.    
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2.5.4 DNA quantification 
Sample absorbance of ultraviolet light was measured by spectrophotometry 
using a Nanodrop to determine sample concentration and quality. DNA 
concentration was calculated from the optical density at 260 nm. The ratio of 
absorbances at 260 nm (nucleic acids) and 280 nm (proteins) was used to assess 
purity and an A260/280 ratio of 1.8 was deemed optimal. The ratio of absorbance 
at 260 nm and 230 nm was used to check for other contaminants (for example 
from the nucleic acid extraction method) and an A260/230 ratio of 2.0 – 2.2 was 
deemed optimal.    
Genomic DNA was diluted to the required concentration using distilled H2O. 
 HLA reports and typing techniques 
2.6.1 Recipient, CB and maternal HLA types 
Recipient and CB HLA typing was performed at a minimum of low resolution at 
HLA-A and -B and at high resolution at -DRB1 loci. Maternal HLA typing was 
performed to a minimum of low resolution at HLA-A and -B and -DRB1 loci. All 
donor-recipient HLA types of transplanted pairs were confirmed. Initial CB and 
maternal HLA typing was completed internally by the H&I laboratory at Colindale 
by polymerase chain reaction (PCR)-sequence specific primers (PCR-SSP), PCR-
sequence specific oligonucleotides (PCR-SSO) or PCR-sequenced based typing 
(PCR-SBT). Recipient HLA typing was performed externally in the majority of 
cases and typing data was provided by Eurocord. Hard copies of recipient files 
were checked for additional HLA typing information. If HLA typing of the 
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recipient was performed internally by NHSBT, the data was also downloaded 
from Hematos. CB and maternal HLA types were downloaded from Hematos. 
The majority of recipients, CB donors and mothers did not have allelic resolution 
HLA-A, -B, -C and -DRB1 types. For the purpose of this thesis, if recipient DNA was 
not available at Colindale, pre-transplant recipient DNA and/or allelic level HLA 
typing results were requested from UK transplant centres or the local H&I 
laboratory serving the transplant centre. For non-UK transplant centres, 
recipient allelic level HLA typing results were requested from Eurocord. 
Individual non-UK transplant centres were not contacted because the NHS-CBB 
is under agreement that all requests for data should be done via Eurocord, who 
are responsible for contacting the transplant centre. Retrospective allelic 
resolution HLA-A, -B, -C and -DRB1 typing for recipients, CB donor and mothers 
was performed by myself as required and when samples were available (see 
below). 
2.6.2 Sequenced based typing 
Allelic resolution typing of HLA-A, -B, -C and -DRB1 genes was performed using a 
commercial method, SBT Excellerator. All reactions were performed as per the 
manufacturer’s instructions, unless otherwise stated. Thermal cycling was 
performed using a thermocycler and sequencing was performed by capillary 
electrophoresis using a genetic analyser. 
An initial PCR amplification targeting the gene of interest was performed using a 
Long Range PCR Kit and SBT Excellerator amplification primers. Reactions mixes for 
96 samples +10% additional dead volume and without template DNA were made as 
Chapter 2 
L Powley (2017)  -75- 
one master mix for each HLA locus and these were aliquoted as a single reaction per 
well in a semi-skirted 96 well plate for each HLA locus. Amplification reactions 
containing approximately 50 ng of genomic DNA were prepared according to Table 
2.2 and cycling was performed according to Table 2.3. A non-template control 
(NTC) was included for all reactions. Amplification was confirmed by gel 
electrophoresis. Class I amplicons were 3.1 – 3.4 kb and class II amplicons were 3.7 
– 4.8 kb in size. 
Table 2.2 Class I and Class II amplification reaction mix per reaction. 
Amplification was performed single-plex for each HLA gene. HLA-A, –B and –
DRB1 reaction mixes were made at half the volume given below. HLA-C reaction 
mixes were made at the recommended volume below. *Less than 50 ng of 
template DNA was added if the stock concentration was less than 25 ng/µl. 
Component Volume (µl) Final concentration 
Long Range PCR buffer with Mg2+ 2.5 1X, 2.5 mM Mg2+ 
dNTP mix (10mM each)  1.25 500 µM each dNTP 
HLA amplification primers 1 - 
Long Range PCR enzyme mix 0.4 2 units 
Nuclease free H2O 17.85 - 
Template DNA 2 50 ng* 
 
Table 2.3 Class I and class II thermal cycling amplification protocol. Time is 
shown in minutes and seconds. 
Parameter Temperature (⁰C) Class I time Class II time 
Initial denaturation 95 3:00 3:00 
3 step cycling (x35):    
- Denaturation 95 0:15 0:15 
- Annealing 65 0:30 0:30 
- Elongation 68 3:00 5:00 
Final extension 68 10:00 10:00 
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Hold 4  ∞ 
 
Illustra ExoProStar was used to remove unincorporated primers and nucleotides 
post-amplification. Three µl ExoProStar was added to PCR products on ice, vortexed 
and incubated at 37°C for 15 min to activate the exonuclease I and alkaline 
Phosphatase, followed by 15 min at 80°C to inactivate the enzymes.  
Sequencing was performed in both directions for exons 2 – 4 for HLA-A, -B and -
DRB1 and exons 1 – 7 for HLA-C as a minimum. After the first round of sequencing, 
if genotype ambiguities were present, additional reactions were performed using 
group specific primers (GSSPs) to resolve the cis/trans ambiguity. Additional 
exons (e.g. exon 1 and 5 for HLA-B) were sequenced if allele ambiguities were 
present. Sequencing reactions containing 1 µl product were prepared for n + 10% 
as shown in Table 2.4 and cycle sequencing was performed as detailed in Table 
2.5. 
Table 2.4 Class I and Class II sequencing reaction mix. Individual sequencing 
reactions were performed single-plex for each exon in each direction. 
Component Volume (µl) 
BDT Ready reaction mix, 2.5X 1 
BDT Buffer, 5X 1.5 
Nuclease free H2O 5.5 
Sequencing primer 1 
Purified PCR product 1 
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Table 2.5 Class I and class II thermal cycling protocol for cycle sequencing. 
Time is shown in minutes and seconds. 
Parameter 
Temperature 
(⁰C) 
Time 
Initial denaturation 96 0:10 
3 step cycling (x25):   
- Denaturation 96 0:10 
- Annealing 50 0:10 
- Elongation 60 2:00 
Hold 4 ∞ 
 
Dye terminators, dNTPs, salts and other low molecular weight materials from 
sequencing reactions removed from products using a gel filtration system. 
Sequencing products were loaded onto a 96 well Performa DTR plate, spun for 5 
minutes at 850 x g and the elute containing purified sequencing products was 
transferred to an optical 96 well plate. Purified sequencing products were run on a 
sixteen capillary 3130 genetic analyser. 
HLA alleles were assigned using SBTengine software (Gendx), which compares 
the sample sequence with the most recent reference sequence from the IMGT 
HLA database (http://www.ebi.ac.uk/imgt/hla).  
2.6.3 In silico HLA allele prediction 
The feasibility of predicting HLA alleles from low resolution HLA types using a 
computational method was investigated by comparing molecularly defined 
alleles to imputed alleles from first field HLA. The HLAMatchmaker four-digit 
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convertor (http://www.hlamatchmaker.net), designed by Duquesnoy (University of 
Pittsburgh), converts serologically defined HLA antigens to the most likely allele 
based on allele frequencies, available from the IMGT/HLA database, from four 
major population groups: European Caucasoid, African-American, Hispanic and 
Asian.  
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 Quantification of microchimaerism by real-time 
quantitative-PCR 
CB DNA was tested for the presence of MMc by q-PCR targeting HLA 
polymorphisms and using SYBR® Green chemistry (Life Technologies). Assays 
targeted HLA polymorphisms informative for NIMA and quantification was from 
the quantification of the starting template using an endogenous control, human 
cell kinase (HCK) and an absolute quantification method. 
2.7.1 Primers 
HLA primer sequences were kindly provided by Dr Michael Eikmans, Department 
of Immunohematology and Blood Transfusion, Leiden University Medical Centre, 
the Netherlands (Drabbels, et al 2011, Eikmans, et al 2014). Assay targets were: 
HLA-A*01, -A*02, -A9, -A*11, -A*24, -A*30, -A*33, -B*08, -B*27, -B*35 and -
DRB1*03. High performance liquid chromatography (HPLC) purified primers 
were synthesised by Eurofins Genomics. Details of primer sequences, targets and 
specificity are given in chapter 6. Primers targeting the endogenous control, HCK, 
were obtained directly from Sigma-Aldrich (Gene ID: 3055, RefSeqID: 
NM_001172129). All primers were ordered lyophilised and were reconstituted 
in nuclease free water to a stock concentration of 100µM (100 picomoles per µL). 
2.7.2 HLA and HCK amplification 
The q-PCR was performed using 200 ng of purified template DNA (see section 
2.5.3), added to SYBR® Select Master Mix and both forward and reverse primers 
(Table 2.6). Reactions were performed in an optical 96-well reaction plate and 
with an optical seal. The thermal cycling protocol consisted of target 
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amplification followed by a continuous dissociation curve (Table 2.7). All 
changes in temperature were achieved with a ramp speed of 1.6⁰C per second to 
increase sensitivity (fast ramp speeds have been associated with lower 
sensitivity and higher variability (Hilscher, et al 2005)). Reactions were 
performed on a QuantStudioTM 7 Flex Real-Time PCR System (Applied 
Biosystems). 
Table 2.6 Master Mix for HLA q-PCR. *Less than 200 ng of template DNA was 
added if the stock concentration was less than 100 ng/µl. 
Component Volume (µl) Concentration 
SYBR® Select Master Mix 10 2X 
Forward and reverse primer mix 0.3 Variable 
DNase free water 5.7 - 7.7 - 
Template DNA 2 – 4 200ng* 
 
Table 2.7 HLA q-PCR cycling protocol 
Parameter Temperature (⁰C) Time 
Initial denaturation 95 08:30 
Cycling (x40)   
- Denaturation 95 0:15 
- Annealing 60 1:00 
- Extension 55 1:00 
Dissociation curve 55 – 95 Continuous 
 
2.7.3 Primer specificity 
HLA primer specificity was tested by setting up q-PCR reactions using DNA 
samples of male platelet donors positive and negative for the target of interest. A 
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panel of HLA typed male platelet donors was carefully constructed to represent 
a broad range of HLA types and overcome LD as much as possible (Table 2.8). 
Specificity was determined by the presence of a single, narrow peak in the post-
amplification dissociation curve and the absence of amplification in the non-
template control (NTC) and samples negative for the target of interest. Cross 
reactivity was defined as the presence of a melting temperature that fell within 
the range of the target of interest. 
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Table 2.8 HLA types of the male platelet donor panel used to test HLA 
primer specificity. Donors were selected to represent a broad range of HLA 
types. HLA typing was previously performed by the H&I service laboratory 
using PCR-SSOP for clinical purposes. 
Donor HLA-A HLA-B HLA-C HLA-DRB1 
1 *02 *66 *08 *41 *07 *17 *08 *13 
2 *26 # *14 *44 *07 *08 - - 
3 *02 *68 *07 *27 - - - - 
4 *03 *68 *07 *53 *04 *07 - - 
5 *02 *31 *40 # *03 # *01 *03 
6 *03 # *07 # *07 # - - 
7 *01 *02 *07 *44 *07 # - - 
8 *02 *25 *13 *18 *06 *12 *01 *08 
9 *01 # *08 # *07 # - - 
10 *02 # *49 # *07 # - - 
11 *02 *31 *44 *52 *02 *12 - - 
12 *30 # *42 *49 *07 *17 *03 *07 
13 *02 *74 *08 *45 *07 *16 - - 
14 *01 *03 *56 *57 *01 *06 - - 
15 *01 # *41 # *17 # - - 
16 *31 *32 *15 *50 *03 *06 - - 
17 *02 *31 *57 *58 *06 *07 - - 
18 *32 # *27 # *01 # - - 
19 *29 # *44 # *16 # *07 # 
20 *11 # *44 *51 *15 *16 - - 
21 *02 # *15 # *03 # *07 *13 
22 *11 *24 *55 # *03 # - - 
23 *03 *11 *35 # *04 # - - 
24 *01 *02 *08 *47 *06 *07 - - 
25 *02 *03 *37 *38 *06 *07 - - 
26 *02 *24 *40 *48 *03 *08 - - 
27 *01 *32 *08 *14 *07 *08 - - 
28 *02 *24 *39 *51 *07 *14 - - 
29 *24 *25 *44 # *05 # *01 *07 
30 *02 *31 *35 *78 *04 # - - 
31 *24 # *55 *57 *03 *06 - - 
32 *11 *32 *15 # *03 # *04 # 
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2.7.4 Artificial spiking experiments and standard curves 
Serial dilutions were generated by artificial spiking experiments and were used 
to generate a standard curve. Standard curves were used to evaluate the assay 
performance to in calculations of quantification. A male platelet donor positive 
for the HLA target of interest (the minor component) was serially diluted five 
times by 1:10 with an additional 0.05% dilution, in a background DNA that was 
negative for the target of interest (the major component) and from a starting 
concentration of 100 ng/µl (Figure 2.1). 200 ng of total template was added to 
each q-PCR reaction. 
Figure 2.1 Serial dilution of a sample positive for the target into a 
background of DNA negative for the target of interest. 
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Amplification efficiency can be calculated from the standard curves of q-PCR 
reactions with a serial dilution of template quantity. The quantitation cycle (Cq) 
is defined as the cycle at which the fluorescence crosses the background level and 
is directly proportional to the amount of starting template. In this way, the 
amount of starting target DNA can be quantified and two samples that differ by 
1:2 in template quantity should differ by one Cq value. The starting quantities of 
a series of dilutions can therefore be plotted against their respective Cq values to 
generate a standard curve. A standard curve whereby each cycle corresponds to 
a doubling of PCR product has a slope of –3.32, although in principle this does not 
occur. The actual amplification efficiency (E) of a q-PCR reaction is optimised to 
have an efficiency of 90 – 110% and is calculated from the slope of the standard 
curve by using the following formula: 
E = 10-1/slope 
2.7.5 MMc quantification assay design 
MMc in CB DNA was quantified by an absolute quantification method that 
determined the amount of NIMA HLA template relative to the amount of HCK 
template present in the sample. The amount of HLA and HCK template were 
quantified from standard curves that were run on each plate (Figure 2.2). 
Individual q-PCR plates were set up for each NIMA HLA target. Each CB sample 
containing an unknown quantity of NIMA template was tested in triplicate for 
NIMA HLA amplification and in duplicate for HCK amplification and eight CB 
samples were tested per plate. Controls for HLA and HCK amplification and 
quantification were a reference sample positive for the target, a sample negative 
for the target and a NTC.  
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Figure 2.2 qPCR 96 well plate layout for MMc testing. Key: Blue, HLA; 
Orange, HCK; (S), Standard serial dilutions of male platelet donor DNA positive 
for target of interest or HCK, (U), Unknown CB DNA; POS, positive DNA for 
target of interest; NEG, negative DNA for target of interest; NTC, non-template 
control. 
 1 2 3 4 5 6 7 8 9 10 11 12 
A 
(S) Target HLA standard curve  
(U) CB #1 HLA (U) CB #1 HCK NEG  
HCK 
 B (U) CB #2 HLA (U) CB #2 HCK 
C (U) CB #3 HLA (U) CB #3 HCK 
 
NTC 
HLA 
 
D 
(U) HCK of HLA standard curve samples 
(U) CB #4 HLA (U) CB #4 HCK 
E (U) CB #5 HLA (U) CB #5 HCK 
F 
(S) HCK standard curve 
(U) CB #6 HLA (U) CB #6 HCK 
NTC 
HCK 
 
G (U) CB #7 HLA (U) CB #7 HCK 
H POS HLA POS HCK NEG HLA (U) CB #8 HLA (U) CB #8 HCK 
 
2.7.6 Analysis 
Analyses of q-PCR were performed using the Quant Studio 7 version 1.3 software 
and in the corresponding Applied Biosystems™ qPCR analysis app available 
in the Thermofisher cloud (https://www.thermofisher.com).  
 Computational and statistical analyses 
2.8.1 Generation and characterisation of virtual phenotypes 
2.8.1.1 HLA allele and haplotype segregation 
HLA-A, -B and –DRB1 HLA types of mothers and their CBUs were compared to 
define alleles using a pedigree analysis algorithm in collaboration with a 
bioinformatician, John Ord, who then wrote the SQL command in MS Access. HLA 
typing was previously performed by the H&I laboratory at NHSBT Colindale. The 
intermediate and high resolution HLA typing results were collapsed back to the 
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first field to remove ambiguous typing data and to permit statistical analyses. 
HLA alleles in common between the CBU and mother (identical by descent) were 
identified as the IMA. The CBU HLA alleles not shared with the mother were 
identified as the IPA. The maternal HLA alleles not shared with the CBU were 
identified as the NIMA. An example is shown in Figure 2.3, Example 1A. At each 
HLA locus, NIMA could only be identified and therefore deemed informative if the 
mother was heterozygous and the NIMA was mismatched to the CBU IPA at first 
field resolution. An example of a CBU and maternal pair where the NIMA was non-
informative is shown in Figure 2.3, Example 2A. The algorithm was validated by 
comparison with manual assignment of NIMA using Microsoft Excel, which was 
performed by myself.
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HLA-A HLA-B HLA-DRB1 
CBU 01,24 08,40 03,09 
Mother 01,02 08,15 03,13 
    
IPA 24 40 09 
IMA 01 08 03 
NIMA 02 15 13 
 
HLA-A HLA-B HLA-DRB1 
CBU 01,32 08,49 01,03 
Mother 01,29 08,44 01,03 
    
IPA 32 49 - 
IMA 01 08 - 
NIMA 29 44 - 
1 NIMA substitution 2 NIMA substitutions 3 NIMA substitutions 
A – B – DRB1 A – B – DRB1 A – B – DRB1 
02,24 - 08,40 - 03,09 02,24 - 15,40 - 03,09 02,24 - 15,40 - 09,13 
01,02 - 08,40 - 03,09 01,02 - 15,40 - 03,09 02,24 - 15,40 - 03,13 
01,24 - 15,40 - 03,09 02,24 - 08,15 - 03,09 01,02 - 15,40 - 13,09 
01,24 - 08,15 - 03,09 01,02 - 08,15 - 03,09 01,02 - 15,40 - 03,13 
01,24 - 08,40 - 09,13 02,24 - 08,40 - 13,09 02,24 - 08,15 - 09,13 
01,24 - 08,40 - 03,13 01,02 - 08,40 - 13,09 02,24 - 08,15 - 03,13  
02,24 - 08,40 - 03,13 01,02 - 08,15 - 13,09  
01,02 - 08,40 - 03,13 01,02 - 08,15 - 03,13  
01,24 - 15,40 - 09,13 
 
 
01,24 - 08,15 - 13,09 
 
 
01,24 - 15,40 - 03,13 
 
 
01,24 - 08,15 - 03,13 
 
1 NIMA substitution 2 NIMA substitutions 
A – B – DRB1 A – B – DRB1 
29,32 - 08,49 - 01,03 29,32 - 44,49 - 03,01 
01,29 - 08,49 - 01,03 01,29 - 44,49 - 03,01 
01,32 - 44,49 - 01,03 29,32 - 08,44 - 03,01 
01,32 - 08,44 - 01,03 01,29 - 08,44 - 03,01 
Figure 2.3 Examples of CBU and maternal pairs (1) informative and (2) non-informative for NIMA at HLA-A, -B and –DRB1 and 
the generation of CBU virtual phenotypes. (A) Comparison of CBU and maternal HLA types allowed the identification of allele 
segregation and therefore the NIMA (yellow), unless the mother was homozygous or a 0 MM to the CBU. (B) Inherited CBU HLA were 
substituted for the corresponding NIMA at 1 or more HLA loci. Maximum number of virtual phenotypes per CBU is 26: 1 NIMA 
substitution, 6; 2 NIMA substitutions, 12 and 3 NIMA substitutions, 8 virtual phenotypes. This is reduced if the NIMA is non-informative. 
A. Identify 
NIMA 
B. Generate 
virtual 
phenotypes 
Example 2. HLA-A and -B informative, –DRB1 non-
informative for NIMA 
Example 1. HLA-A, -B and –DRB1 informative 
for NIMA 
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2.8.1.2 Generation of virtual phenotypes 
A VP algorithm was developed in collaboration with John Ord. I designed the 
strategy of generating the virtual VPs and he implemented this using SQL in MS 
Access. VPs were generated by substituting 1, 2 or 3 CBU HLA for the 
corresponding NIMA at HLA-A, -B and/or –DRB1 (Figure 2.3, Example 1B). If the 
CBU was informative for NIMA at a given HLA locus (allele x, allele y), a 
substitution for NIMA was made at allele x, to yield one VP and at allele y, to yield 
a second VP. If HLA-A, -B and –DRB1 were all informative for NIMA, 26 VPs per 
CBU were generated. The number of VPs was reduced if the NIMA was non-
informative (Figure 2.3, Example 2B and Table 2.9). The algorithm was 
validated by myself by the comparison with manual assignment of VPs in 
Microsoft Excel and against a previously published example (Van der Zanden, et 
al 2014). 
Table 2.9 Maximum number of virtual phenotypes per CBU according to the 
number of informative NIMA and substitutions made at HLA-A, -B and –
DRB1. Sub., substitution. 
 Number of virtual phenotypes  
Informative NIMA 1 sub. 2 sub. 3 sub. Total 
0 NIMA 0 0 0 0 
1 NIMA 2 0 0 2 
2 NIMA 4 4 0 8 
3 NIMA 6 12 8 26 
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2.8.2 Searches for HLA and NIMA matched CB donors 
Searches for an IFM (6/6, 0 mismatch), 5/6 (1 mismatch) and 4/6 (2 MMs) and 
VFM (1 – 3 NIMA) were performed on the UK-BBMR and Bone Marrow Donors 
Worldwide (BMDW) registries. At the time of search, 4,707 of the total 21,020 
UK-BBMR and 26,735 of the total 621,893 BMDW listed CB donors had maternal 
HLA typing available. HLA matching was based on HLA-A and –B at antigenic or 
intermediate resolution and –DRB1 at high resolution level. Only CB donors with 
the required level of HLA typing were recorded as potential donors. The BMDW 
CBU Match Program was used to identify inherited HLA matches using the 
“identical and one allele/antigen mismatch” and “two antigen/allele MMs” 
functions.  
VFMs were identified using the BMDW NIMA Match Program with “Identical 
Matches” and “Include 2 and 3 NIMA in match” functions selected. If multiple 
NIMA matched donors were identified for a patient, the donor with the highest 
level of inherited HLA matching was selected. 
Searches for single CBUs, with adequate total nucleated cell (TNC) dose, were 
performed on a subset of patients weighing 50 kg or less (n= 204). The median 
weight of these patients was 16 kg. IFMs were identified first. Patients with only 
a mismatched donor were evaluated for a NIMA match. Patients without a NIMA 
match were assessed for a 5/6 or 4/6 inherited HLA match. Only donors which 
met a minimum TNC dose of 2.5 x107 per kg for malignant diseases and 4.0 x 107 
per kg for non-malignant diseases (Rocha and Gluckman 2009) were recorded as 
potential donors. 
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2.8.3 Retrospective analyses of clinical outcome after NIMA matched CBT 
The clinical outcomes of CBT were compared between HLA matched, NIMA 
matched and non NIMA matched categories in a retrospective analysis.  
Analyses were performed in collaboration with an NHSBT statistician, Elinor 
Curnow. I coded the dataset demographics and determined the HLA matching 
status between donors and recipients. I also coded the time-to-event outcomes 
data and we discussed and resolved discrepancies in data reporting, non-sense 
values and unusual cases together. I performed preliminary outcomes analyses 
between the groups and identified variables significantly associated with 
outcomes. Elinor confirmed and extended these analyses and performed the 
sample size analysis.  
2.8.3.1 Definitions of statistical endpoints  
The primary endpoint was 5 year OS. Secondary endpoints were TRM, relapse, 
myeloid engraftment, aGvHD and cGvHD. Definitions of endpoints and 
descriptions of the censoring, competing events and the patients evaluated are 
shown in Table 2.10.  
The experience of the various outcomes, dates of onset and other relevant 
information e.g. grade of aGvHD were provided by Eurocord. All data were 
checked for discrepancies and non-sense values. Time-to-event (or time-to-
censorship) was calculated by the time difference between the date of transplant 
and the date of the event (or date of last follow-up) using the DATEDIFF function 
in Microsoft Excel 2013.  
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Table 2.10 Definition of transplant endpoints 
Endpoint Definition Censoring 
Competing 
event 
Patients 
5-year OS 
Probability of survival 
at 5 years post-
transplant irrespective 
of disease. 
Patients alive at 
date of last follow 
up. 
None All patients 
5-year TRM 
Death from any cause 
apart from the original 
disease. 
Patients alive 
without relapse 
at date of last 
follow up. 
Relapse All patients 
5-year 
Relapse 
Recurrence of original 
disease. 
Patients alive and 
without relapse 
at date of last 
follow up. 
Death without 
evidence of 
relapse. 
Patients 
with 
malignant 
disease 
Myeloid 
engraftment 
Absolute neutrophil 
count > 0.5 × 109/l on 
three consecutive days. 
Patients alive and 
without myeloid 
engraftment at 
date of last follow 
up. 
Death before 
myeloid 
engraftment. 
All patients 
aGvHD 
Clinical diagnosis that 
may be supported by 
biopsies. Graded I-IV 
based on organ 
involvement and 
usually occurs within 
100 days. 
Patients alive and 
without aGvHD at 
date of last follow 
up. 
Primary or 
secondary graft 
failure. Death 
without aGvHD. 
All patients 
CGvHD 
Clinical diagnosis 
supported by biopsies 
and exclusion of other 
diagnoses. Usually 
occurs after 100 days. 
Patients alive and 
without cGvHD at 
date of last follow 
up. 
Primary or 
secondary graft 
failure. Death 
without aGvHD. 
Patients 
alive at day 
100 
 
2.8.3.2 Statistical analyses 
OS at 5-years post-transplant was determined using the Kaplan-Meier estimate 
and the log-rank test was used to compare estimates between match categories. 
The incidence of TRM at 5 years, relapse at 5 years, myeloid engraftment, aGvHD 
at 100 days and cGvHD at 5 years post-transplant were calculated using the 
cumulative incidence estimator and these were compared between match 
categories using Gray’s test of regression (Scrucca, et al 2010). Death due to non-
transplant related causes and relapse were competing risks for TRM; death from 
any cause was the competing risk for relapse; death from any cause and graft 
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failure prior to the outcome of interest were competing risks for engraftment, 
aGvHD and cGvHD.  Cumulative incidence of cGvHD was estimated conditional on 
transplant survival to 100 days. 
The relationship between match category and each outcome was further 
investigated using Cox regression (OS) and the Fine-Gray regression model (all 
other outcomes) (Scrucca, et al 2010).  Hazard ratios were reported for Cox 
regression and sub-distribution hazard ratios were reported for Fine-Gray 
regression models. Results were adjusted for risk factors associated with CBT 
outcomes: log(TNC dose), recipient age, conditioning regimen (MAC vs. RIC), year 
of transplant and whether the recipient was being treated for a malignant 
disease.  Regression analyses were repeated for the sub-group of cases with at 
least one HLA mismatch, adjusting for the number of MMs (1-2 vs. 3-4) and 
whether there was a MM at HLA-C, as well as the other risk factors previously 
listed.  
The median time to acute or chronic GvHD was used in cases where acute or 
chronic GvHD was reported but the date of GvHD occurrence was unknown.  
Recipients for whom risk factors were not reported were excluded from 
regression modelling.  
Statistical analyses were undertaken using SAS/STAT version 9.4 (SAS Institute 
Inc.) and R version 3.2.0 (R Foundation for Statistical Computing) and SPSS 
version 23 (IBM).  
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2.8.3.3 Sample size required to reach a statistically significant difference 
in the primary end-point 
The sample size required to determine a statistically significant difference in OS 
between NIMA matched and non-NIMA matched cases was calculated using a 
method based on the log-rank test (Collett 2015). An 80% power and 5% 
significance was assumed and a ratio of NIMA-matched to non-NIMA matched 
cases of 1:7. 
2.8.4 Statistical differences between categorical variables 
Differences between categorical values were tested by the X2 or Fisher’s Exact 
test statistic in SPSS. The Z test with corrected P values using the Bonferroni 
method was used to compare column proportions. P values are two sided. 
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Chapter 3 Maternal HLA typing of 
banked CBUs to identify NIMA HLA and 
generate virtual phenotypes available 
for donor searches 
 
Key points: 
• Development of in-house algorithms to identify the IMA/IPA and NIMA 
alleles and haplotypes of CBUs and to generate VPs. 
• 66,225 VPs (14-fold increase) were generated from 4,671 CBUs with 
maternal HLA types and of these 52,875 were unique. 
• 48,221 of these VPs were not represented as inherited phenotypes in the 
total 21,020 banked CBUs and thus increased the total number of unique 
phenotypes in the NHS-CBB to 65,046 (3.9-fold increase). 
• HLA-A/-B/-DRB1 allele and haplotype frequencies of the NHS-CBB 
mothers and CBUs were diverse. 
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 Introduction 
A greater degree of HLA disparity is tolerated in CBT but HLA MMs are still 
associated with an increased risk of aGvHD and mortality (Eapen, et al 2011b, 
Flomenberg, et al 2004, Furst, et al 2013, Jagasia, et al 2012, Kanda 2013, Lee, et 
al 2007, Woolfrey, et al 2011). Despite the listing of over 700,000 CB donors with 
BMDW, a 6/6 HLA matched CB donor is available for only 38% of Caucasian, 16 - 
20% of Asian and 5 - 6% of Black patients (Barker, et al 2010b, Gragert, et al 
2014). An improvement in the availability of HLA matched CBUs is therefore 
clinically needed. One method to increase the number of phenotypes available for 
CB donor searches is to increase the number of HLA typed banked CBUs (Querol, 
et al 2009). This resource intensive approach may not be economically feasible, 
especially given that many banks are struggling to maintain financial stability 
(Magalon, et al 2015).  
A possible alternative or complementary approach is to identify permissible HLA 
MMs such as NIMA, which have shown improved clinical outcomes compared to 
non-NIMA HLA MMs in retrospective analyses (Rocha, et al 2012, van Rood, et al 
2009). In CBT, NIMA matching has previously occurred by chance in 
approximately 7 - 10% of HLA mismatched transplants but HLA typing the 
mothers of banked CBUs would enable the prospective provision of a NIMA 
match, although the probability of this is currently unknown. It will likely depend 
on the frequency of the NIMA HLA in the donor population searched and whether 
it is found in LD with the HLA at other patient/CB HLA loci. Population specific 
HLA allele and haplotype frequencies have previously been used to model HLA 
match rates for patients requiring HSCT (Gragert, et al 2014) and similarly, 
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knowledge of NIMA HLA allele and haplotype frequencies could be a useful tool 
for modelling NIMA match rates. The NHS-CBB has been completing maternal 
HLA typing of banked CBUs but a population genetics analysis of CBUs and 
mothers has not yet been performed. 
A NIMA match whereby each donor-recipient HLA MM at HLA-A, -B and/or -DRB1 
is a match to the donor NIMA is termed a VFM (see M&M section 2.3) (Van der 
Zanden, et al 2014). VFMs can be identified from VPs of the CBU, generated by the 
substitution of 1 - 3 inherited (IMA/IPA) CBU HLA for the corresponding NIMA at 
HLA-A, -B and/or –DRB1. This identifies all the possible positions where a NIMA 
match could occur and up to 26 VPs can be generated for each CBU with a 
maternal HLA type (Van der Zanden, et al 2014, van Rood, et al 2009). The NHS-
CBB and others have recently started to list maternal HLA types with BMDW and 
in 2012 an algorithm that searches for VFMs for patients, the BMDW NIMA Match 
Program, was launched.  
There is very little information regarding VPs and the probability of identifying a 
VFM in the literature since a minority of CBBs are performing maternal HLA 
typing. In the only published study, van der Zanden and colleagues analysed the 
maternal HLA of 6,827 CBUs in the NYCB (Van der Zanden, et al 2014). They 
reported a yield of 122,180 VPs, which was lower than 177,502 expected if 26 
VPs were generated for each of the 6,827 CBUs. A VP is not generated if the NIMA 
is non-informative at an HLA locus, either because the mother is homozygous or 
a 0 HLA MM with the CBU (Van der Zanden, et al 2014). The authors did not 
explore non-informative NIMA in any detail and left many questions unanswered. 
Since it is unlikely that resources will be available to perform maternal HLA 
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typing for all of the currently banked CBUs, selection should be based on those 
most likely to be informative for NIMA and thus able to yield the maximum 
potential of 26 VPs. Furthermore, is not known whether there are differences in 
the number of VPs between different populations, or whether these VPs provide 
an increase to the pool of unique phenotypes available for donor searches. 
 Aims  
The aim of this chapter was to define the HLA-A, -B and -DRB1 NIMA of banked 
CBUs with maternal HLA types available, to generate VPs derived from the NIMA 
and to evaluate whether these increase the number and diversity of HLA 
phenotypes available for donor searches. This required the development of two 
in house algorithms to identify the CBU IMA/IPA/NIMA HLA alleles and 
haplotypes and to generate the VPs, which was carried out in collaboration with 
a bioinformatician, John Ord.  
Several questions were formulated and answered to address the aim of this 
chapter (Figure 3.1). The first question, “what is the HLA diversity of mothers 
and their CBUs in the NHS-CBB?” was evaluated by an analysis of HLA alleles and 
A~B~DRB1 haplotypes and their frequencies amongst the different populations. 
HLA types of mothers and CBUs were compared to identify allele segregation and 
thus the IMA/IPA and NIMA HLA haplotypes. To the best of the author’s 
knowledge, this is the first time donor registry HLA haplotype frequencies in 
multiple populations have been reported without the need to estimate HLA 
haplotypes using models such as Expectation-Maximisation (E-M) and instead 
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were determined through allele segregation, as reported for small scale family 
studies (Gragert, et al 2013, Tang, et al 2007, Tu, et al 2013).  
The identification of CBU IMA/IPA and NIMA HLA haplotypes led to the ability to 
answer the second question, “when and how often are the CBU NIMA non-
informative?” The occurrences of maternal homozygosity and CBU-maternal 0 
MM at HLA-A, -B and -DRB1 were determined and results were compared 
between the broad populations. Identification of informative NIMA permitted the 
substitution of 1 - 3 CBU HLA for the corresponding informative NIMA at HLA-A, 
-B and/or –DRB1 to generate VPs. The third question was “how many VPs are 
present in the NHS-CBB and do these increase the donor pool available for 
searches?” The total number of VPs generated from 4,671 CBUs was compared to 
the maximum expected, 26-fold increase, if all CBUs were informative for three 
NIMA at HLA-A, -B and -DRB1. Unique VPs were identified and the value of these 
to the donor pool of the NHS-CBB was evaluated by determining whether these 
VPs represented new phenotypes that were not yet present as inherited 
phenotypes.  
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Figure 3.1 Chapter 3 aim and the questions proposed to address this aim 
 
• Quantification of the total 
virtual phenotypes 
• Number of unique virtual 
phenotypes 
• Virtual phenotypes not yet 
represented as IPs in the 
NHS-CBB 
Aim:  
To define the HLA-A, -B and -
DRB1 NIMA of banked CBUs 
with maternal HLA types 
available, to generate virtual 
phenotypes derived from the 
NIMA and to evaluate 
whether these increase the 
number and diversity of HLA 
phenotypes available for 
donor searches. 
What is the 
HLA 
diversity of 
mothers and 
CBUs? 
When and 
how often 
are the CBU 
NIMA non-
informative? 
How many virtual 
phenotypes are in 
the NHS-CBB and 
do these increase 
the donor pool 
available for 
searches? 
• Proportion that are 
non-Caucasian 
• Unique haplotypes 
• New unique 
haplotypes provided 
by NIMA 
• Haplotype 
frequencies 
• Rare haplotypes 
 
• Most frequent reason for the NIMA 
being non-informative 
• Proportion of CBUs non-informative at 
one or more HLA locus 
• Comparison of non-informative NIMA 
between HLA loci 
• Comparison between donor ethnicities 
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 HLA and ethnic diversity of mothers and their CBUs 
3.3.1 Mapping self-reported ethnicities to broad population groups 
There were 4,671 CBUs with maternal HLA types of the total 21,020 banked in 
the NHS-CBB. Self-reported ethnicities were mapped to broad population groups 
with the aim to 1) create groups which made best use of the sample size available 
to allow comparisons between the groups, 2) reflect the population diversity in 
the NHS-CBB and 3) group on a similar basis to population groups used 
worldwide to allow comparison with other registry datasets such as the 
American National Marrow Donor Program (NMDP). Broad populations chosen 
were Caucasian (CAU), Asian (ASI), South and East Asian (SEA), Black (BLK) and 
Mixed (MIX). Just under 40% of CBUs mapped to a non-Caucasian or mixed broad 
population (ASI, 16.9%; SEA, 1.0%; BLK, 5.5%; MIX, 13.0%). An additional 1.8% 
were grouped as other ethnicity (OE) and 1.3% were unknown or not declared 
(UNK) (Table 3.1).  
Table 3.1 Self-reported ethnicities and their mapping to broad population 
groups. Broad populations and their percentages of the total population 
included are shown in bold. Self-reported ethnicities and their percentages 
within the mapped broad group are shown below the broad populations. Total 
CBUs n= 4, 671. 
Population N % 
Caucasian (CAU) 2,831 60.6 
Caucasian 1,761 62.2 
UK/North Europe 653 23.1 
White British 7 0.2 
South Europe White 35 1.2 
Mediterranean White 15 0.5 
Middle East Arab 40 1.4 
Jewish 43 1.5 
Other White 277 9.8 
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Population N % 
Asian (ASI) 790 16.9 
Asian 232 29.4 
Asian- Indian 154 19.5 
Asian- Pakistani 150 19 
Asian- Bangladeshi 11 1.4 
Indian Subcontinent 126 15.9 
Other Asian Background 117 14.8 
South and East Asian (SEA) 47 1 
South East Asian 11 23.4 
Chinese 19 40.4 
Japanese 6 12.8 
Oriental 11 23.4 
Black (BLK) 256 5.5 
Black 41 16 
African Black 144 56.3 
Caribbean Black 48 18.8 
USA Black 1 0.4 
Other Black 22 8.6 
Mixed (MIX) 605 13 
Mixed 241 39.8 
Mixed White and Asian 101 16.7 
Mixed White and Black Caribbean 74 12.2 
Mixed White and Black African 58 9.6 
Other Mixed Background 131 21.7 
Other ethnicity (OE) 83 1.8 
Native America/Australia/New Zealand 14 16.9 
South America 21 25.3 
Other 48 57.8 
Unknown (UNK) 59 1.3 
Unknown/Not disclosed 59 - 
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3.3.2 Addition of NIMA to inherited CBU HLA A~B~DRB1 haplotypes 
An identical-by-descent (IBD) algorithm that compared the maternal and CBU 
HLA types was developed to identify the CBU IMA/IPA and NIMA HLA 
A~B~DRB1 haplotypes at first field resolution (as described in M&M section 
2.8.1.1). HLA A~B~DRB1 haplotypes were identified only for cases whereby the 
mother and CBU were mismatched at each of the three HLA loci (74.7%, n= 
3,491). The number of unique CBU IMA/IPA and NIMA HLA A~B~DRB1 
haplotypes were identified, by running queries in MS Access, to give an indication 
of the diversity present amongst the CBUs with maternal HLA types. Results are 
shown in Figure 3.2. There were 1,702 unique CBU IMA/IPA HLA haplotypes 
from the total 6,982 (2n) and almost half (n= 798, 46.9%) of these were only 
observed once in the cohort (Figure 3.2A). There were 1,243 unique NIMA HLA 
haplotypes and these were added to the 1,702 CBU IMA/IPA haplotypes to form 
a combined dataset. HLA A~B~DRB1 haplotypes common to both groups were 
identified (n= 884, 42.8%). Importantly, the inclusion of NIMA identified HLA 
haplotypes that were not present amongst the CBU IMA/IPA haplotypes (n= 361, 
17.5%) and these increased the number of unique HLA A~B~DRB1 haplotypes 
from 1,702 to 2,065 (1.2-fold) in the combined IMA/IPA/NIMA dataset. Of these, 
859 (50.5%) HLA A~B~DRB1 haplotypes were only observed once, 
demonstrating a large diversity. 
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Figure 3.2 Unique CBU IMA/IPA and NIMA first field HLA A~B~DRB1 
haplotypes in the (A) Total, (B) CAU, (C) ASI, (D) SEA, (E) BLK and (F) MIX 
populations. Maternal and CBU HLA types were compared in an identical-by-
descent algorithm to identify allele segregation and haplotypes. Unique 
IMA/IPA haplotypes were combined with unique NIMA haplotypes to identify 
haplotypes common to both groups and those that were limited to either group. 
*Total also includes OE and UNK. 
(A) Total* n= 3,491     
 
(B) CAU n= 2,093     (C) ASI n= 580    
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Figure 3.2 continued 
(D) SEA n= 32     (E) BLK n= 202     
  
(F) MIX n= 471 
 
 
NIMA provided a comparable increase in the number of unique HLA A~B~DRB1 
haplotypes in each of the broad populations, despite differences in sample size 
(Figure 3.2B-F). The number of unique HLA A~B~DRB1 haplotypes increased 
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CAU (n= 652, 47.7%) (p<0.001), likely due to the smaller sample size of these 
groups. 
An exploration of the CBU and maternal HLA allele and A~B~DRB1 haplotype 
frequencies are given in more detail in Appendix A. These were generally 
comparable to the top HLA A~B~DRB1 haplotype frequencies in the NMDP 
registry, except for the BLK population (Gragert, et al 2013). This was possibly 
due to the heterogeneity or differences in the American and British BLK 
populations. Rare HLA haplotypes that ranked in the bottom 25th centile of the 
corresponding broad populations in the NMDP registry, or were absent in the 
reported NMDP haplotype frequencies altogether, were also identified. 
 Informative and non-informative NIMA at HLA-A, -B 
and –DRB1 
The degree of CBU-maternal MM at HLA-A, -B and –DRB1 is shown in Table 3.2. 
The incidence of a CBU-maternal 0 MM was comparable at HLA-A (n= 517, 
11.1%), -B (n= 359, 7.7%) and –DRB1 (n= 502, 10.7%) (p= 0.717), despite the 
more polymorphic nature of HLA-B. However, when stratified by population, 
significant differences were observed between populations at HLA-B (p= 0.01). 
The highest incidence of CBU-maternal 0 MM at HLA-B was observed in the ASI 
population (n= 81, 10.3%) and the lowest observed in the MIX population (n= 35, 
5.8%). No significant difference was observed between broad populations at 
HLA-A (p= 0.155) and –DRB1 (p= 0.068).  
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Table 3.2 Maternal homozygosity and histocompatibility to the CBU at first field HLA-A, -B and –DRB1.  Chi-squared (X2) analyses: 
d.f. = 6 for individual loci and d.f. = 9 for totals. Significant values are shown in bold. Percentages are given in parenthesis. *SEA were not 
included in the statistical analysis due to the small sample size. 
 
Total 
Population Statistics* 
 CAU ASI SEA BLK MIX X2 P 
CBU-Maternal 0 MM   
HLA-A 517 (11.1) 328 (11.6) 74 (9.4) 9 (19.1) 21 (8.2) 68 (11.2) 5.235 0.155 
HLA-B 359 (7.7) 218 (7.7) 81 (10.3) 3 (6.4) 15 (5.9) 35 (5.8) 11.422 0.01 
HLA-DRB1 502 (10.7) 308 (10.9) 99 (12.5) 7 (14.9) 29 (11.3) 49 (8.1) 7.118 0.068 
Total MM at HLA-A, -B and –DRB1 
 
 
11.835 0.223 
0 33 (0.7) 18 (0.6) 10 (1.3) 1 (2.1) 2 (0.8) 2 (0.3) - - 
1 132 (2.8) 80 (2.8) 24 (3.0) 2 (4.3) 7 (2.7) 14 (2.3) - - 
2 1,015 (21.7) 640 (22.6) 176 (22.3) 12 (25.5) 45 (17.6) 118 (19.5) - - 
3 3,491 (74.7) 2,093 (73.9) 580 (73.4) 32 (68.1) 202 (78.9) 471 (77.9) - - 
   
Maternal homozygosity   
HLA-A 720 (15.4) 473 (16.7) 109 (13.8) 10 (21.3) 25 (9.8) 81 (13.4) 11.055 0.011 
HLA-B 413 (8.8) 248 (8.8) 84 (10.6) 4 (8.5) 23 (9.0) 39 (6.4) 7.506 0.057 
HLA-DRB1 615 (13.2) 371 (13.1) 126 (15.9) 7 (14.9) 34 (13.2) 64 (10.6) 8.800 0.032 
Total homozygous loci 
 
 
17.559 0.041 
0 3,249 (69.6) 1,940 (68.5) 542 (68.6) 29 (61.7) 188 (73.4) 446 (73.7) - - 
1 1,148 (24.6) 723 (25.5) 191 (24.2) 15 (31.9) 52 (20.3) 137 (22.6) - - 
2 222 (4.8) 135 (4.8) 43 (5.4) 3 (6.4) 15 (5.9) 19 (3.1) - - 
3 52 (1.1) 33 (1.2) 14 (1.8) 0 1 (0.4) 3 (0.5) - - 
Total 4,671 2,831 790 47 256 605   
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The majority of CBUs and mothers had 1 MM at HLA-A, -B and –DRB1 (1-1-1) and 
3 MM in total (n= 3,491, 74.7%). Zero MM at only one HLA locus and 2 MM overall 
(1-1-0, 1-0-1 or 0-1-1) was also frequent (n= 1,015, 21.7%). Zero MM at two HLA 
loci (1-0-0, 0-1-0 or 0-0-1) (n= 132, 2.8%) and three HLA loci (0-0-0) (n= 33, 
0.7%) occurred significantly less frequently (p< 0.00001). No significant 
difference in the sum of MMs across the three HLA loci was observed between the 
broad population groups (p= 0.223).  
In the total population, incidences of maternal homozygosity were significantly 
lower at HLA-B (n= 413, 8.8%) when compared to HLA-A (n= 720, 15.4%) and 
HLA-DRB1 (n= 615, 13.2%) (p< 0.00001). Statistical differences in the incidence 
of maternal homozygosity between the broad populations at HLA-A (p=0.011) 
and HLA-DRB1 (p=0.032) were also observed and a trend towards significance 
was observed at HLA-B (p=0.057). Maternal homozygosity at HLA-A was lower in 
the BLK population (n= 25, 9.8%) compared to CAU (n= 473, 16.7%) and 
homozygosity at HLA-DRB1 was lower in the MIX population (n= 64, 10.6%) 
compared to ASI (n= 126, 15.9%).  
The total number of homozygous HLA loci across HLA-A, -B and –DRB1 was also 
determined. In the total population, the majority of mothers were heterozygous 
across HLA-A, -B and –DRB1 (n= 3,249, 69.6%). A quarter of mothers were 
homozygous at one HLA locus (n= 1,148, 24.6%), 4.8% (n= 222) at two loci and 
1.1% (n= 52) at three loci. The total number of homozygous loci was significantly 
lower in the MIX population compared to CAU and ASI populations (p= 0.041). 
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It was reasoned that the incidence of CBU-maternal 0 MM may be a consequence 
of probability of two alleles occurring at an HLA locus due to the frequencies of 
these alleles. The frequencies of first and second position (x, y e.g. A*01, A*02 
where A*01 is x and A*02 is y) allele combinations were therefore determined by 
a direct count method. To determine if 0 MM was more likely for high frequency 
allele combinations, these were ranked in order of frequency and then split into 
cumulative 25% quartiles (Q1: bottom 25%, Q2: 25-50%, Q3: 50-75%, Q4: 75-
100%) and comparisons were made between the quartiles. Results are shown in 
Figure 3.3 for (A) HLA-A, (B) HLA-B and (C) HLA-DRB1. The incidence of 0 MM 
between a mother and CBU was highly associated with the frequency of the allele 
combination in the total population for HLA-A, -B and -DRB1. Allele combinations 
at an HLA locus in the upper quartile (i.e. occurred more frequently in the total 
population) were more likely to be identified as a 0 MM between the mother and 
CBU for HLA-A (p<0.0001), HLA-B (p<0.0001) and HLA-DRB1 (p<0.001). When 
further stratified by ethnicity, CBU-maternal 0 MM was significantly associated 
with the frequency of an allele combination at HLA-A across all ethnic groups, 
except for the smaller population size of SEA. However, at HLA-B and –DRB1, CBU-
maternal 0 MM was only significantly associated with the frequency of an allele 
combination in the CAU population. The top 10 ranking x, y allele combinations 
at HLA-A, -B and -DRB1 and the proportion of these that were a CBU-maternal 0 
MM in each of the populations are given in Appendix A. The heterozygous allele 
combinations with the highest frequency in the total CBU population were as 
follows for HLA-A, -B and -DRB1: A*01, A*02 (9.7%, n= 392/4,042) and this was a 
0 MM to the mother in 20.2% of cases (n= 79/392); B*07, B*44 (3.3%, n= 
139/4,269) and this was a 0 MM to the mother in 10.8% of cases (n= 15/139) and 
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DRB1*04, DRB1*15 (5.3%, n= 218/4,076) and this was a 0 MM to the mother in 
15.1% of cases (n= 33/218).  
Figure 3.3 Percentage of heterozygous CBU-Maternal 0 MM according to x, 
y allele frequencies at (A) HLA-A, (B) -B and (C) –DRB1. Frequencies of 
individual heterozygous x, y allele combinations were calculated by a direct 
count. The cumulative frequencies of the highest to lowest ranking were used to 
split the data into quartiles (Q). Q1: bottom 25%, Q2: 25-50%, Q3: 50-75%, Q4: 
75-100%. Results show the percent of 0 MM out of the total x, y alleles in each 
quartile. Total also includes OTH and UNK categories. * P <0.05, ** P <0.01, *** P 
<0.001, **** P <0.0001. 
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Figure 3.3 continued 
(C) HLA-DRB1  
  
 
Maternal homozygosity and histocompatibility to the CBU were used to identify 
the number of CBUs informative for 0, 1, 2 or 3 NIMA at HLA-A, -B and –DRB1 and 
results are given in Figure 3.4. In the total population, 4,535 (97.1%) CBUs were 
informative for 1 - 3 NIMA. There were 2,307 (49.4%) CBUs informative for NIMA 
at 3 HLA loci, 1,742 (37.3%) informative at 2 loci and 486 (10.4%) informative at 
1 locus. The remaining 136 (2.9%) CBUs were not informative for NIMA at any of 
the three HLA loci. Significant differences in the total number of informative 
NIMA were observed between the broad populations (p< 0.0001). A greater 
proportion of BLK (55.5%) and MIX (54.9%) CBUs were informative for 3 NIMA 
compared to CAU (47.5%) and ASI (49.2%). The inverse was observed for the 
proportion of CBUs informative for 0 NIMA.  
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Figure 3.4 CBUs informative for 0 – 3 NIMA at HLA-A, -B and –DRB1. NIMA 
were informative to first field at an HLA locus if the mother was heterozygous 
and mismatched to the CBU. *Total also includes SEA (n= 47), OE (n= 83) and 
UNK (n= 59) CBUs. **** p < 0.0001. 
 
In summary, incidences of non-informative NIMA at each HLA locus and due to 0 
MM between the mother and CBU (7 – 11%) or maternal homozygosity (8 – 15%) 
were comparable. There were no statistically significant differences between the 
HLA loci, except maternal homozygosity was significantly higher at HLA-B 
compared to HLA-A and –DRB1. When comparisons were made between 
populations, CAU and ASI populations were less likely to be informative for NIMA 
compared to BLK and MIX populations. 
Total CAU ASI BLK MIX
Total 4,671 2,831 790 256 605
0 NIMA 136 83 38 4 8
1 NIMA 486 294 96 28 46
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 Generation of VPs and the subsequent increase to 
the pool of phenotypes in the NHS-CBB 
3.5.1 Quantification of VPs  
The number of VPs provided by HLA typing 4,671 mothers of CBUs compared to 
the maximum expected (ME) if all CBUs were informative for NIMA at HLA-A, -B 
and –DRB1 is shown in Figure 3.5. The ME number of VPs from 4,671 CBUs if all 
were informative for 3 NIMA was 121,446 (26-fold increase). The actual 
observed fold increase was lower - 14.2-fold, giving a total of 66,225 VPs. In 
accordance with the differences observed in the number of informative NIMA 
between the broad populations described in the previous section, some 
differences were also observed in the number of VPs generated. Both the CAU and 
ASI populations yielded a comparable fold increase in VPs (13.9 fold and 13.7 
fold, respectively). The 2,831 CAU CBUs yielded 39,283 VPs and the 790 ASI CBUs 
yielded 10,860 VPs. Both the BLK and MIX populations showed a higher fold-
increase (15.6 and 15.5 fold, respectively) in the number of VPs because these 
populations were more likely to be informative for NIMA. The 256 BLK CBUs 
yielded 3,987 VPs and the 605 MIX CBUs yielded 9,406 VPs. 
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Figure 3.5 Maximum expected versus observed number of VPs. VPs were 
generated from an in-house algorithm by substituting 1 – 3 of the CBU HLA for 
the corresponding NIMA at HLA-A, -B and/or –DRB1. A substitution at an HLA 
locus is only made if the NIMA is informative (mother is heterozygous and 
mismatched to the CBU). The maximum expected number of VPs is based on the 
generation of 26 per CBU if the 3 loci were each informative for NIMA. Total also 
includes SEA, OE and UNK. 
 
 
3.5.2 Representation of new phenotypes amongst CBUs with maternal 
HLA typing from the generation of VPs  
VPs were next compared to the existing inherited phenotypes (IPs) of the 4,671 
CBUs with maternal HLA (Figure 3.6A–E). There were 4,304 unique IPs at first 
field HLA-A, -B and -DRB1 from the total 4,671 CBUs (A). There were 66,225 VPs 
generated from these and 52,875 were unique VPs (B). When the IPs and VPs 
were combined to form a single dataset, the number of unique phenotypes 
increased 13-fold from 4,304 to 55,783 unique phenotypes (A + B). There were 
1,396 (2.5%) phenotypes represented as both IPs and VPs. There were 2,908 
(5.2%) represented as only an IP. The remaining 51,479 (92.3%) were new VPs 
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that were not yet represented as IPs amongst the 4,671 CBUs with maternal HLA 
in the NHS-CBB. 
Figure 3.6 Addition of virtual phenotypes (VPs) to the inherited 
phenotypes (IPs) of CBUs with maternal HLA typing. (A) Total* n= 4,671 (B) 
CAU n= 2,831 (C) ASI n= 790 (D) BLK n= 256 and (E) MIX n= 605. HLA 
phenotypes refer to first field HLA-A, -B and -DRB1. Unique phenotypes are the 
total phenotypes with duplicates removed. VPs have 1 – 3 substitutions of the 
CBU inherited HLA for the corresponding NIMA at HLA-A, -B and/or –DRB1 and 
were generated from an in-house algorithm. IPs are the CBU phenotypes from 
the inherited maternal and paternal haplotype and without substituting for 
NIMA. Phenotypes common or unique to the inherited (A) and virtual (B) 
phenotypes were identified by running queries in MS Access. Total VPs 
(includes duplicates): Total, 66,225; CAU, 39,283; ASI, 10,860; BLK, 3,987; MIX, 
9,406. *Includes SEA, OE and UNK CBUs and mothers. 
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Figure 3.6 continued 
(B) CAU      (C) ASI 
  
(D) BLK     (E) MIX 
   
 
 
Comparisons were made between the broad populations (Figure 3.6B–E). The 
increase in the number of unique phenotypes was comparable between the CAU 
and ASI populations: 12.8-fold from 2,569 IPs to 32,794 unique IPs plus VPs 
(IPs+VPs) in the CAU population and 13.8-fold from 777 IPs to 10,729 unique 
IPs+VPs in the ASI population. There was a greater increase in the number of 
unique phenotypes in the BLK and MIX population: 16.3-fold from 255 IPs to 
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4,148 unique IPs+VPs in the BLK population and 16.3-fold from 599 IPs to 9,747 
unique IPs+VPs in the MIX population. 
3.5.3 Representation of new phenotypes to the NHS-CBB from the 
generation of VPs 
It was next determined whether the 66,225 VPs provided from the 4,671 CBUs 
with maternal HLA represented new phenotypes that were not yet present as IPs 
from the total 21,020 banked CBUs in the NHS-CBB (Figure 3.7). The NHS-CBB 
CBUs showed a diverse range of inherited first field HLA-A, -B and -DRB1 
phenotypes, with 16,825 (80.0%) unique IPs from the total 21,020 CBUs (A). The 
VPs also showed little duplication, with 52,875 (79.8%) unique phenotypes (B) 
from the total 66,225 VPs. The unique IPs and unique VPs were added together 
to create a combined pool of phenotypes (A+B, IPs+VPs) available for both 
inherited and virtual matched donor searches. Maternal HLA typing just a quarter 
of the CBUs in the NHS-CBB increased the number of unique phenotypes present 
by 3.9 fold to 65,046 (A + B). There were 4,654 (7.2%) phenotypes present in 
both the inherited and VPs, demonstrating that these VPs also exist as IPs in the 
NHS-CBB donor population. There were 12,171 (18.7%) that were only present 
in the IPs. The remaining 48,221 (74.1%) were new VPs that were not yet 
represented as IPs in the NHS-CBB. 
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Figure 3.7 Addition of virtual phenotypes (VPs) to the inherited 
phenotypes (IPs) of the entire NHS-CBB. HLA phenotypes refer to first field 
HLA-A, -B and -DRB1. Unique phenotypes are the total phenotypes with 
duplicates removed. VPs have 1 – 3 substitutions of the CBU inherited HLA for 
the corresponding NIMA at HLA-A, -B and/or –DRB1 and were generated from 
an in-house algorithm. IPs are the CBU phenotypes from the inherited maternal 
and paternal haplotype and without substituting for NIMA. Phenotypes common 
or unique to the inherited (A) and virtual (B) phenotypes were identified by 
running queries in MS Access. Unique IPs: 16,825 out of 21,020 CBUs. Unique 
VPs: 52,875 out of 66,225 VPs generated from 4,671 CBUs. 
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 Discussion 
3.6.1 NHS-CBB mothers and their CBUs are diverse in terms of ethnicity 
and HLA frequencies 
The probability of identifying a NIMA match is likely to be aided by knowledge of 
the HLA allele and haplotype frequencies present in the registry. For patients 
with only a mismatched donor available, knowledge of NIMA will help facilitate 
the most appropriate HLA(s) to MM and target as a possible NIMA match. This 
study describes the first field NIMA HLA allele and A~B~DRB1 haplotype 
frequencies present in the NHS-CBB. In addition to the identification of the NIMA, 
the unique opportunity to assign registry HLA haplotypes by the comparison of 
mother and CBU HLA types meant it was possible to evaluate actual, rather than 
estimated, HLA haplotype frequencies for 75% (n= 3,491/4,671) of CBUs with 
maternal HLA typing available.  
Mathematical models such as E-M are invaluable tools for predicting HLA 
haplotype phasing but several problems arise when used in registry datasets 
(Gragert, et al 2013, Kollman, et al 2007). The frequencies of common HLA 
haplotypes can be overestimated and rare haplotypes are sometimes 
systemically excluded from analysis due to the possibility of algorithm artefacts, 
especially in the context of multiple loci or mixed HLA typing resolution data 
(Bettencourt, et al 2008, Castelli, et al 2010). Accurate estimation of HLA 
haplotypes also assumes the population studied is in Hardy-Weinberg 
Equilibrium, which is not always true for small sample sizes or if admixture is 
present (Bettencourt, et al 2008). Comparison of mother and child HLA types 
does not require this assumption and I was able to include mothers and CBUs of 
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mixed ethnicity, which make up a large proportion of the NHS-CBB. It should be 
noted that paternal HLA typing data was not available and a small number of HLA 
haplotypes could have arisen from recombination, although this is generally 
thought to have a frequency of less than 1% (Lam, et al 2013). 
The NHS-CBB targets the recruitment of minority ethnic populations and around 
40% of banked CBUs are from a non-CAU background, compared to 2% in the 
adult BBMR (Armitage, et al 1999, Davey, et al 2004). The small number of CBUs 
with maternal HLA typing are very heterogeneous, demonstrated by the 
observation that 1,702 unique first field IMA/IPA HLA A~B~DRB1 haplotypes 
were identified from 3,491 CBUs, of which 46.9% were only observed once in the 
cohort. Rare HLA A~B~DRB1 haplotypes were also identified, judged by their 
absence in the estimated frequencies in the NMDP registry. Continuing to 
perform maternal HLA typing for additional CBUs is likely to further increase the 
representation of CBU IMA/IPA and NIMA HLA haplotypes in the NHS-CBB.  
3.6.2 The number of informative NIMA differed between broad 
populations 
This study has explored reasons why the NIMA is non-informative and whether 
any differences were observed between HLA loci and donor populations. One or 
more NIMA were non-informative to first field at HLA-A, -B and/or -DRB1 for half 
(50.6%, n= 2,454/4,761) of CBUs. This was most often because the NIMA was 
non-informative at just one of the three HLA loci (37.3%, n= 1,742/4,671) and it 
was rare that the CBU was not informative at any of the three HLA loci considered 
(2.9%, n= 136/4,671). This means that in the overwhelming majority of cases, 
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VPs could still be generated if the maternal HLA type was defined, albeit below 
the maximum potential of 26 per CBU.  
It seems reasonable that the CBU IMA/IPA and maternal NIMA HLA could readily 
be distinguished given their natural function and that the HLA genes are the most 
polymorphic region of the human genome. Polymorphisms are likely to have 
arisen from natural selection and an individual that is heterozygous at an HLA 
locus is likely to have an advantage, with regards to presentation of peptides from 
an infectious agent, compared to those that are homozygous (Buhler and 
Sanchez-Mazas 2011, Sommer 2005). For example, HIV positive patients that are 
homozygous at one or more class I HLA loci have shown faster progression to 
AIDs compared to heterozygous patients (Carrington, et al 1999). The production 
of offspring with an HLA heterozygous advantage may be enforced through mate 
choice, with several studies suggesting that humans may prefer HLA dissimilar 
mates, possibly mediated through body odour attraction, although results are 
conflicting (Chaix, et al 2008, Wedekind, et al 1995, Winternitz, et al 2016).  
Significant differences in the incidences of informative and non-informative 
NIMA were identified between the different broad populations. Non-CAU donors 
and their phenotypes are exceptionally valuable with regards to NHS-CBB 
diversity and the aim to improve donor availability for ethnic minorities 
requiring HSCT. Importantly, the total number of informative NIMA and 
generation of VPs was not lower for non-CAU populations and rather, BLK and 
MIX populations were more likely to be informative for NIMA. This most probably 
a reflection of the multiple ethnic background of MIX CBUs and extensive genetic 
diversity within the African population (Cao, et al 2004, Testi, et al 2015) but 
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contrasts a previous analysis that found European American couples from the 
Mormon community exhibited HLA dissimilarity compared to random 
individuals (controls) but African couples did not (Chaix, et al 2008). As a 
consequence to the incidence of informative NIMA, the fold-increase in 
phenotypes observed was actually higher in the BLK and MIX populations (15.6) 
compared to CAU (13.9) and ASI (13.7), suggesting a greater yield to the bank in 
maternal HLA typing these CBUs. Donor searches of VPs may be particularly 
beneficial to BLK patients requiring CBT, for whom donor availability is 
considerably lower (Gragert, et al 2014).   
The reasons why there were differences between the broad populations in 
informative and non-informative NIMA are unclear. It may be due to differences 
in population genetics and heterogeneity amongst the populations. At HLA-A, the 
incidence of 0 MM between the CBU and mother did not differ between 
populations. However, the incidence of 0 MM at HLA-A was significantly 
associated with allele frequencies, which suggests the occurrence of 0 MM was 
due to the mathematical chance based on population frequencies. Alternatively, 
the differences in broad populations may be due to social, cultural or biological 
differences. At HLA-B, allele frequencies were not associated with the incidence 
of CBU-maternal 0 MM in non-CAU populations, suggesting there may be 
additional factors other than chance affecting histocompatibility in these 
populations. However, the highly selective population grouping for this thesis 
may not be reflective of mating groups. The small sample size of non-CAU 
populations could have also meant the reported allele frequencies were not 
reflective of the general population and indeed, BLK allele and haplotype 
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frequencies were very different to those reported for the NMDP (see Appendix 
A).  
3.6.3 HLA typing 4,671 mothers of CBUs yielded 66,225 VPs and 
increased the pool of unique phenotypes in the NHS-CBB four-fold 
At the start of this study, the number of VPs present in the NHS-CBB was 
unknown. Although NIMA substitutions could potentially provide up to 26 VPs 
per CBU, the actual increase from 4,671 CBUs was fourteen-fold, to 66,225 VPs, 
which confirms the findings of a previous study (Van der Zanden, et al 2014) and 
for the first time, identifies differences between populations. The vast majority of 
VPs were unique phenotypes and were not yet present amongst the IPs of the 
NHS-CBB.  
The 4,654 VPs that were also present as IPs in the NHS-CBB demonstrate that 
these can exist as true phenotypes in the donor population. However, the 
considerable proportion of VPs that were not represented as IPs in the NHS-CBB 
warrant further investigation. Two possibilities exist, either they are not present 
as genuine phenotypes in the population and thus will never be utilised as a 
virtual match for a patient, or they do exist as phenotypes but these are not 
present in the NHS-CBB and thus could be identified as a virtual match for a 
patient with such a phenotype. Given that the number of unique VPs (52,875) is 
far greater than the number of unique IPs (16,825) amongst the CBUs in the NHS-
CBB, it seems sensible to determine the proportion of VPs represented as IPs in a 
much larger bank/registry, such as BMDW, which currently has over 29 million 
donors registered. 
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It seems likely that not all VPs will be represented as IPs in BMDW (especially 
given the results of the next chapter) and whether VPs are likely to exist as true 
IPs in the population will require novel methods of analyses. This could include 
testing whether the VPs could theoretically consist as two HLA blocks that are 
known to exist as two haplotypes from previous registry estimations of haplotype 
frequencies. The E-M algorithm cannot be used to estimate artificial phasing of 
the VPs because this method identifies common patterns of alleles within the 
dataset and these patterns would not be from actual IPs within a population. A 
more appropriate method would be to develop a tool that identifies all the 
possible combinations of alleles within a VP and checks if any of these have been 
reported as haplotypes in the population.   
Estimating the artificial phasing of VPs (i.e. possible haplotype combinations) 
would also permit analyses of whether HLA-B/C combinations of VPs differ to 
those normally found in LD. The chance of identifying an HLA matched donor is 
not just hindered by the presence of a rare patient HLA allele - patients with 
unusual combinations of frequent HLA alleles (i.e. a rare phenotype) will also 
have a low probability of finding a match (Tiercy 2012). It is not known whether 
there are any potential benefits of NHS-CBB VPs to donor availability for patients 
with unusual associations, although it seems likely based on a previous analysis. 
Van der Zanden and colleagues used a computer model to assign haplotype 
frequency-based simulated VPs for 167,201 CBUs and predicted that a virtual 
match would be found for 42 out of 103 patients for whom no donor was available 
(9/10 or 10/10 MUD or 6/6 CBU) (Van der Zanden, et al 2014). Similar analyses 
of donor availability from the NHS-CBB VP pool for patients with rare 
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phenotypes, or indeed, patients in general, would be a valuable tool in assessing 
the benefit to patients by performing maternal HLA typing of banked CBUs.  
3.6.4 Limitations  
This study included only first field resolution HLA-A, -B and –DRB1 in the 
description of HLA allele and haplotype frequencies and calculation of the VPs 
present in the NHS-CBB due to the presence of heterogeneous HLA typing 
resolution data. Distinct serological specificities encoded by alleles with the same 
first field molecular type were not distinguished from one another, yet donor-
recipient matching at this level is clinically relevant (Eapen, et al 2014). Antigens 
B62, B63, B75, B76 and B77 are protein products of HLA-B*15, encoded by 
different alleles. For example, the B*15:01 gene product is B62 and the B*15:02 
gene product is B75. These differ in population distribution patterns and are 
associated with different haplotypes. B*15:01 is frequent in CAU populations and 
is associated with C*03:03 or C*03:04 (encoding Cw9 and Cw10, respectively), 
whereas B*15:02 is frequent in ASI populations and is associated with C*08:01 
(Gragert, et al 2013).  
Inclusion of second field HLA types will yield a greater number of unique VPs 
because there will be fewer duplicates. It is plausible the second field resolution 
will further increase the proportion of mothers and CBUs whereby complete 
NIMA haplotypes can be identified because if there is a 0 MM at an HLA locus 
between the mother and CBU at first field, there may be differences at second 
field and thus the NIMA could be identified. For example, if both the mother and 
CBU are A*01, 02 but second field resolution reveals the mother as A*01:01, 02:01 
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and the CBU as A*01:01, 02:07 then A*01:01 can be identified as the IMA and the 
maternal A*02:01 as the NIMA. The Singapore CBB has previously reported the 
ability to assign four loci haplotypes to second field resolution for 72% of 174 
mothers and CBUs (Tang, et al 2007) and a study of African mothers and CBUs 
reported second field five loci haplotypes for 69% of 374 mothers and CBUs (Tu, 
et al 2013). These are comparable to the identification of three loci first field 
haplotypes for 75% of mothers and CBUs in this study, despite the inclusion of 
additional HLA loci, which was possibly compensated by the higher HLA typing 
resolution evaluated. The advent of next-generation HLA typing technology will 
likely improve the availability of unambiguous five or six loci HLA data for CBUs 
and mothers. 
3.6.5 Conclusions 
Performing maternal HLA typing on banked CBUs provides a substantial increase 
in the number and diversity of phenotypes available for donor searches, without 
the financial cost of recruiting, processing, testing and banking of additional 
CBUs. The next chapter will explore whether the VPs in the NHS-CBB are able to 
provide a virtual 6/6 HLA match for patients.   
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patients of various ethnicities 
Key points: 
• A virtual full match (5/6 + 1 NIMA, 4/6 +2 NIMA or 3/6 + 3 NIMA) was 
identified for 28.4% and 48.4% of 457 patients by searching the VPs in 
the BBMR and BMDW registries respectively. 
• Virtual full matches provided a greater benefit to other ethnicity patients 
compared to European Caucasoid patients due to the lower availability of 
an inherited full match but a comparable availability of a virtual full 
match for other ethnicity patients. 
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Consideration of noninherited maternal Ags as permissible HLA mismatches in 
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 Introduction 
The previous chapter showed that the identification of the CB NIMA from 
maternal HLA typing provided a substantial increase in the number of 
phenotypes present in the NHS-CBB from the generation of VPs. Crucially, a large 
proportion of these VPs were new phenotypes not yet represented as inherited 
phenotypes in the NHS-CBB. However, it is not yet clear whether these VPs are 
able to provide a virtual full match (VFM, 5/6 + 1 NIMA, 4/6 + 2 NIMA or 3/6 + 3 
NIMA) for patients requiring CBT. 
A previous study evaluating NIMA match likelihoods identified VFMs for 32% of 
2,020 Dutch patients (Van der Zanden, et al 2014). This study demonstrated for 
the first time that VFMs could indeed be identified for patients. However, it did 
not address two significant factors in donor availability: patient ethnicity and 
TNC dose. Inherited HLA matched donor availability is known to differ between 
patients of various ethnicities due to the HLA frequencies in the patient and donor 
populations (Gragert, et al 2014, Gragert, et al 2013) and it seems feasible to 
extend this to the availability of NIMA matched CB donors. A major limitation of 
CB as a graft source has been the lower TNC dose, which is associated with a 
higher risk of graft failure and delayed engraftment, particularly in the context of 
a poor HLA match (Barker, et al 2010b) and thus recommendations exist for the 
minimum cell dose requirements (Hough, et al 2016).  
Modelling HLA matched donor availability is important for ensuring that CBBs 
are able to provide suitable donors for the population that they serve and thus 
aids the strategic planning of CBBs with regards to size and recruitment 
Chapter 4 
L. Powley (2017)   -128- 
strategies. This is a particularly important for the NHS-CBB because the UK 
population is ethnically diverse, with 20% of respondents for the 2011 census 
self-identifying with an ethnic group that was not White British 
(www.ons.gov.uk). HLA matched donor availability models can also aid with 
designing a treatment plan for a patient by giving an indication of whether a 
suitable donor is likely to be found. For example, if an HLA matched CB donor is 
not identified during the initial search, waiting for a 6/6 HLA match (or indeed 
an HLA matched adult donor) could cause a delay in proceeding to transplant, 
during which there is a risk of developing more advanced disease or for 
malignant diseases, relapsing before a transplant is arranged (Gratwohl, et al 
2009). Indeed, in adult donor HSCT, if an HLA matched donor is not identified 
early on during the search process; it is unlikely that a new donor that is a match 
will be added to the registry in a timely manner. In cases where the transplant is 
urgent, an HLA MM strategy would be preferred and in CBT, one option is to select 
a NIMA+ HLA mismatch. Obviously, this also requires knowledge of NIMA match 
probabilities.  
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 Aims 
The primary aim of this chapter was to determine whether the inclusion of VPs, 
to identify VFMs, can improve donor availability for patients of various ethnicities 
requiring CBT. There were 457 patients who were previous recipients of an NHS-
CBB CBU and they were treated as newly presenting patients requiring CBT. The 
existing BMDW NIMA match program was used to manually search for potential 
VFMs and inherited full matches (IFMs) based on matching at HLA-A and –B at 
antigenic resolution and –DRB1 at high resolution, from the CB donors listed with 
the BBMR or BMDW.  
Several questions were formulated to address the primary aim (Figure 4.1). The 
first question was “what is the probability of identifying a VFM for patients of 
various ethnicities requiring CBT?” The VPs generated from the previous chapter 
were searched to provide a VFM, that was a 5/6 + 1 NIMA, 4/6 + 2 NIMA or 3/6 
+ 3 NIMA match, for patients of various ethnicities. Given that a greater number 
of inherited HLA matches are likely to be preferred and that when HLA 
mismatching, class I MMs tend to be preferred over class II MMs, the locus and 
total number of NIMA matches (1, 2 or 3) for VFMs were also determined. This 
led to the second question, “can VFMs provide an alternative for patients of 
various ethnicities without an IFM?” This required a comparison of the inherited 
HLA matched donors identified (6/6, 5/6, 4/6 or 3/6) from searches of banked 
CBUs; to the VFM donors identified by searching the VPs. Given that TNC dose is 
also crucial for CB donor identification, the third question was “can VFMs, with 
adequate cell dose, provide an alternative for patients of various ethnicities 
without an IFM and requiring a single graft?” 
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Figure 4.1 Chapter 4 aim and the question proposed to address this aim 
  
• Number of NIMA matches (1, 2 or 3) 
• HLA loci of NIMA matches (HLA-
A/B/DRB1) 
• Patients with rare HLA alleles 
• Inherited HLA match grades of CB donors 
identified. 
• Proportion of patients without an inherited 
full match but with a virtual full match 
Aim: To determine if the 
inclusion of virtual 
phenotypes, to provide 
virtual full matches, can 
improve donor 
availability for patients 
of various ethnicities 
requiring CBT. 
Can virtual full 
matches, with 
adequate cell dose, 
provide an alternative 
for patients of various 
ethnicities without an 
inherited full match 
and requiring single 
CBT? 
What is the probability 
of identifying a virtual 
full match for patients 
of various ethnicities 
requiring CBT? 
Can virtual full 
matches provide an 
alternative for patients 
of various ethnicities 
without an inherited 
full match? 
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 Patient demographics 
Four hundred and fifty-seven previous recipients of an NHS-CBB issued CBU 
were treated as newly presenting patients requiring CBT. The median patient age 
and weight were 19 years and 55 kg, respectively, and 80.7% (n= 369) were 
treated for malignant indications (Table 4.1). Self-reported ethnicities were 
available for 341 patients and were mapped to broad population groups. The 
majority (80%) were European Caucasoid (EC) (n= 274). The remaining 20% 
included non-EC (n= 35), Black (n= 13), South and East Asian (n= 6) or mixed 
ethnicity (n= 13) and due to the small cohort size, were grouped as a single 
category, other ethnicity (OE), for all further analyses.   
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Table 4.1 Patient demographics. Percentages are given in parenthesis unless 
otherwise stated. 
Demographic Number of patients 
Gender  
Male 274 (60.0) 
Age  
< 16 years 218 (47.7) 
Median age (range) 19 (0 - 70) 
Weight (kg)  
<50 kg 204 (44.6) 
Median weight (range) 55 (3 - 146) 
Ethnicity (unknown/not declared n= 116)  
European Caucasoid 274 (80.4) 
Other ethnicity 67 (19.6) 
- Non-European Caucasoid 35 
- South and East Asian 13 
- Black 6 
- Mixed 13 
Disease indication  
Malignant 369 (80.7) 
- ALL 93 
- AML 132 
- MDS or MDS/MPD 81 
- Lymphoproliferative disorder 46 
- Plasma cell disorder 7 
- Histiocytic disorder 9 
- Solid tumour 1 
Non-malignant 88 (19.3) 
- Bone marrow failure syndrome 26 
- Haemoglobinopathy 3 
- Primary immune deficiency 30 
- Inborn error of metabolism 29 
Total patients 457 
Abbreviations: ALL, acute lymphoblastic leukaemia; AML, acute myeloid leukaemia; 
MDS, myelodysplastic syndrome; MPD, myeloproliferative disorder 
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 BMDW and BBMR virtual full matches 
Donor searches for VFMs were performed using the BMDW NIMA Match Program 
and by searching donors listed with the BBMR or BMDW (see M&M section 
2.8.2). The BMDW NIMA Match Program uses an algorithm to generate the VPs 
of a CB donor (using the same methodology described in the previous chapter) 
and then uses these VPs to search for a VFM to the patient. A VFM was identified 
for 28.4% of 457 patients by searching the 4,707 CB donors with maternal HLA 
listed with the BBMR at the time of search (August 2014) (Figure 4.2). In all, 
15.5% were a 5/6 +1 NIMA match, 10.3% were a 4/6 +2 NIMA match and 2.6% 
were a 3/6 +3 NIMA match.  
The availability of an IFM is significantly lower for ethnicity minorities compared 
to EC patients due to the population specific frequencies of HLA alleles and 
haplotypes and the predominantly EC donor population (Barker, et al 2010b, 
Gragert, et al 2014). It seemed plausible that the availability of a VFM would also 
be lower for ethnic minorities. A VFM was available for a slightly lower 
proportion of OE patients (25.4%) compared to EC (31.4%) patients by searching 
the BBMR but this difference was not statistically significant (p= 0.34). However, 
EC patients had a higher median number of VFMs (2, range 1 – 45) compared to 
OE patients (1, range 1 – 4) from the BBMR registry.  
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Table 4.2 Availability of virtual full match from the BBMR CB donors. 
Searches were performed of 4,707 CB donors with maternal HLA banked in the 
NHS-CBB and listed in the BBMR through the BMDW NIMA Match Algorithm.  
  
Patient ethnicity 
Total  
(n= 457) 
European 
Caucasoid  
(n= 274) 
Other ethnicity 
(n= 67) 
Unknown  
(n= 116) 
Virtual full 
match 
86 (31.4) 17 (25.4) 27 (23.3) 130 (28.4) 
5/6 + 1 NIMA 51 (18.6) 6 (9.0) 14 (12.1) 71 (15.5) 
4/6 + 2 NIMA 29 (10.6) 9 (13.4) 9 (7.8) 47 (10.3) 
3/6 + 3 NIMA 6 (2.2) 2 (3.0) 4 (3.4) 12 (2.6) 
No virtual full 
match 
188 (68.6) 50 (74.6) 89 (76.7) 327 (71.6) 
 
Extending the search to include the 26,735 CB donors with maternal HLA listed 
on BMDW increased the proportion of patients with a VFM to 48.4%, although 
this was not directly proportional to the increase in the size of the registry 
searched compared to the BBMR (Figure 4.3). By searching the larger and 
international registry, which presumably has a wider genetic diversity compared 
to the BBMR, a greater proportion of patients (33.5%) had a 5/6 + 1 NIMA match. 
The remaining patients with a VFM had a 4/6 +2 NIMA match (11.4%) or a 3/6 
+3 NIMA match (3.5%). A VFM was available for a comparable proportion of EC 
(49.6%) and OE patients (44.8%) by searching the BMDW registry (p= 0.63). 
Searching the larger BMDW registry yielded a greater number of VFMs for 
patients compared to searching the BBMR. EC patients had a median number of 
4 (range 1 – 83) VFMs and OE patients had a median number of 2 (range 1 – 26) 
VFMs from the BMDW registry. 
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Table 4.3 Availability of virtual full match from the BMDW CB donors. 
Searches were performed of 26,735 CB donors with maternal HLA (banked in 
the NHS-CBB plus other banks) through the BMDW NIMA Match Algorithm. 
  
Patient ethnicity 
Total  
(n= 457) 
European 
Caucasoid  
(n= 274) 
Other ethnicity 
(n= 67) 
Unknown  
(n= 116) 
Virtual full 
match 
136 (49.6) 30 (44.8) 55 (47.4) 221 (48.4) 
5/6 + 1 NIMA 103 (37.6) 15 (22.4) 35 (30.2) 153 (33.5) 
4/6 + 2 NIMA 26 (9.5) 13 (19.4) 13 (11.2) 52 (11.4) 
3/6 + 3 NIMA 7 (2.6) 2 (3.0) 7 (6.0) 16 (3.5) 
No virtual full 
match 
138 (50.4) 37 (55.5) 61 (52.6) 236 (51.6) 
 
The HLA class (I or II) of NIMA+ HLA MMs for the VFMs identified are shown in 
Table 4.4. A total of 1,654 VFMs were identified for 221 patients by searching the 
BMDW registry. For 5/6 + 1 NIMA matched CB donors (n= 585), the NIMA+ was 
at HLA-A or HLA-B in 74% of cases and the majority of these were at HLA-A (n= 
254, 59%). For 4/6 + 2 NIMA matched CB donors (n= 600), 39% were NIMA 
matched at class I and 61% were NIMA matched at both class I and class II loci. 
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Table 4.4 Class I and class II NIMA matches of BMDW virtual full match 
donors. A total of 1,654 virtual full matches were identified for 221 of 457 
patients. Searches were performed of 26,735 CB donors with maternal HLA 
(banked in the NHS-CBB plus other banks) through the BMDW NIMA Match 
Algorithm. 
Virtual full 
match 
NIMA-match 
Total 
HLA-A or -B HLA-DRB1 Class I & II 
5/6 + 1 NIMA 433 (74) 152 (26) N/A 585 
4/6 + 2 NIMA 236 (39) N/A 364 (61) 600 
3/6 + 3 NIMA N/A N/A 469 (100) 469 
 
 Cord blood virtual full matches for patients without 
an inherited full match 
4.5.1 BMDW registry searches according to patient ethnicity and disease 
indication 
Since it was determined that VFMs were available for patients, these were 
included in the traditional CB donor search strategy of identifying an IFM through 
the BMDW Match Programs (see M&M section 2.8.2). Patients were first 
evaluated for an IFM and if none were available, VFMs (in order of preference: 
5/6 + 1 NIMA, 4/6 + 2 NIMA and 3/6 + 3 NIMA) were considered. If neither an 
IFM or VFM were identified, the donor search was extended to include inherited 
5/6 and 4/6 HLA matches. 
BMDW CB donor search results are shown in Figure 4.2. An IFM was identified 
for 46.6% of the total 457 patients evaluated (Figure 4.2A). A VFM was identified 
for an additional 14.2%, increasing the cumulative availability of an IFM or VFM 
to 60.8%. Of these, 6.3% had a 5/6 + 1 NIMA match, 6.1% had a 4/6 + 2 NIMA 
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match and 1.8% had a 3/6 + 3 NIMA match. The remaining patients did not have 
an IFM or a VFM, most of which had an inherited 5/6 match and 2% of patients 
only had an inherited 4/6 match.  
Donor availability was then stratified by patient ethnicity and the HLA match 
grades for EC and OE patients (Figure 4.2B-C), respectively. In agreement with 
previous reports (Gragert, et al 2014), OE patients had a lower availability of an 
IFM (37.3%) compared to EC patients (48.5%). Surprisingly however, VFMs were 
identified for a comparable proportion of OE (16.5%) and EC (13.8%) patients, 
increasing the cumulative availability of an IFM or VFM to 53.8% and 62.3%, 
respectively.  
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Figure 4.2 HLA match grade of BMDW CB donors identified for A) All 
patients n= 457 B) European Caucasoid n= 274 and C) Other Ethnicity n= 
67. Inherited matches refer to HLA matching without considering NIMA. 
Patients with only a mismatched donor (4/6 or 5/6) were evaluated for a 
virtual full match (1 - 3 NIMA substitutions at HLA-A, -B and/or –DRB1). 
Searches of the 621,893 listed CB donors in the BMDW and 26,735 donors with 
maternal HLA were performed using the BMDW Match Programs. 
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The immunological consequences of HLA MMs and their effect on clinical 
outcome can differ depending on the patient disease. In patients with malignant 
disease, the harmful effect of GvHD can partially be offset by the beneficial GvL 
response and HLA mismatched transplants are associated with a lower risk of 
relapse (Petersdorf 2008). However, in patients with non-malignant disease, 
there is no immunological benefit to GvHD or HLA mismatching. The availability 
of HLA matched CB donors was also therefore evaluated according to patient 
disease (Figure 4.3). A higher proportion of patients with non-malignant disease 
had an IFM (56.8%) compared to those with malignant disease (44.2%). VFMs 
were identified for a similar proportion of patients with malignant disease 
(14.9%) compared to those treated for non-malignant indications (11.3%), 
increasing the cumulative availability of an IFM or VFM to 59.1% and 68.1%, 
respectively. 
Figure 4.3 HLA match grade of BMDW CB donors identified for patients 
with A) malignant (n= 369) and B) Non-malignant (n= 88) disease 
indications. Inherited matches refer to HLA matching without considering 
NIMA. Patients with only a mismatched donor (4/6 or 5/6) were evaluated for a 
virtual full match (1 - 3 NIMA substitutions at HLA-A, -B and/or –DRB1).  
Searches of the 621,893 listed CB donors in the BMDW and 26,735 donors with 
maternal HLA were performed using the BMDW Match Programs. 
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4.5.2 Inclusion of TNC dose into donor searches 
Inadequate TNC dose has been linked to a higher risk of graft failure and delayed 
engraftment and immune reconstitution after CBT and effective balancing 
between HLA and TNC dose is required for optimal CB graft selection (Barker, et 
al 2010b). TNC dose was therefore incorporated into the CB donor search 
strategy and only donors which met the TNC dose recommendations were 
considered as suitable (see M&M section 2.8.2). The likelihood of achieving this 
dose reduces with increasing patient weight and a suitable graft with adequate 
cell dose tends to come in the form of a double graft for heavier weighted children 
and adults. An upper patient weight limit of 50 kilograms was therefore applied 
and patients above this limit were excluded from this part of the analysis.  
The availability of an HLA matched CB donor that met the minimum TNC dose 
requirements for the 204 patients weighing 50 kg or less is shown in Figure 4.4A. 
The inclusion of TNC dose had little effect on donor availability. An IFM donor 
with adequate TNC dose was available for 49.5% of the 204 patients eligible for 
inclusion. A VFM with adequate TNC dose was identified for an additional 13.8% 
of patients, increasing the cumulative availability of an IFM or VFM to 63.3%. The 
remaining patients did not have either an IFM or VFM and 29.9% had an inherited 
5/6 match, 5.9% had an inherited 4/6 match and 1.0% did not have a donor 
available. The HLA match grades for EC and OE patients are shown in Figure 
4.4B-C. OE patients had a lower availability of an IFM (37.2%), compared to EC 
patients (55.2%). Consideration of VFMs helped a comparable proportion of 
patients regardless of ethnicity (EC, 13.6% versus OE, 14%). These increased the 
cumulative availability of an IFM or VFM from 55.2% to 68.8% for EC patients 
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and from 37.2% to 51.2% for OE patients. For EC patients, this equates to one 
additional patient benefiting from a VFM for every four patients with an IFM. OE 
patients saw a greater benefit due to their lower availability of an IFM, with one 
additional patient benefiting from a VFM for every three patients with an IFM. 
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Figure 4.4 HLA match grade of BMDW CB donors with adequate TNC dose 
identified for A) All patients n= 204 B) European Caucasoid n= 125 and C) 
Other Ethnicity n= 43. Inherited matches refer to HLA matching without 
considering NIMA. Patients with only a mismatched donor (4/6 or 5/6) were 
evaluated for a virtual full match (1 - 3 NIMA substitutions at HLA-A, -B and/or –
DRB1).  Only patients likely to be eligible for single unit cord blood 
transplantation and therefore weighing 50 kg or less were included. TNC dose 
threshold was 2.5 x 107 / kg for patients with malignant disease (n= 127) and 
4.0 x 107 / kg for patients with non-malignant disease (n= 77). Searches of the 
621,893 listed CB donors in the BMDW and 26,735 donors with maternal HLA 
were performed using the BMDW Match Programs. 
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The donor search was also restricted to the BBMR CB donors to evaluate the 
potential benefit of performing maternal HLA typing for NHS-CBB CBUs (Figure 
4.5). An IFM with an adequate TNC dose was available for 20.1% of the total 
patients weighing 50 kg or less, which was considerably lower than when the 
larger international BMDW registry was searched (49.5%). Restricting the donor 
search to the BBMR did not however, have a detrimental effect on the availability 
of a VFM and instead, a higher proportion of patients had a VFM from the BBMR 
(19.6%) compared to BMDW (13.7%). The inclusion of VFMs doubled the 
cumulative availability of an IFM or VFM from the BBMR to 39.7%. Of these, 8.8% 
had a 5/6 + 1 NIMA match, 7.4% had a 4/6 + 2 NIMA match and 3.4% had a 3/6 
+ 3 NIMA match. The remaining patients did not have an IFM or VFM from the 
BBMR and 30.9% had an inherited 5/6 match, 26.5% had an inherited 4/6 match 
and 2.9% did not have a donor available.  
Results were then stratified according to patient ethnicity and the HLA match 
grades for EC and OE patients are shown in Figure 4.5B-C. IFMs with adequate 
TNC dose were available for a quarter (24.0%) of EC patients but for OE patients, 
this availability was 2.5 fold lower (9.3%). VFMs were again available for a 
comparable number of EC (21.6%) and OE (18.7%) patients. This meant OE 
patients saw a greater increase in donor availability because the cumulative 
availability of an IFM or VFM tripled from 9.3% to 28.0%. For EC patients, VFMs 
doubled the cumulative availability of an IFM or VFM from 24.0% to 45.6%.  
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Figure 4.5 HLA match grade of BBMR CB donors with adequate TNC dose 
identified for A) All patients n= 204 B) European Caucasoid n= 125 and C) 
Other Ethnicity n= 43. Inherited matches refer to HLA matching without 
considering NIMA. Patients with only a mismatched donor (4/6 or 5/6) were 
evaluated for a virtual full match (1 - 3 NIMA substitutions at HLA-A, -B and/or –
DRB1). Only patients likely to be eligible for single unit CBT and therefore 
weighing 50 kg or less were included. TNC dose threshold was 2.5 x 107 / kg for 
patients with malignant disease (n= 127) and 4.0 x 107 / kg for patients with 
non-malignant disease (n= 77). Searches of the 21,020 listed CB donors in the 
BBMR and 4,707 donors with maternal HLA were performed using the BMDW 
Match Programs. 
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4.5.3 Virtual full matches for difficult to match patients 
To understand if VFMs improved donor availability for difficult to match patients, 
CB donor availability for patients characterised by the presence of one or more 
infrequent alleles (at first field) was explored. Infrequent HLA-A, -B and -DRB1 
alleles were defined as being in the lowest cumulative frequency of 1%, 5% or 
10% in the patient population (see Appendix B). The availability of a VFM for 
these “difficult to match” patients was compared to the availability of an IFM 
when either the BBMR or BMDW registry was searched (Table 4.5). There were 
239 patients with at least one HLA allele in the lowest 10% of the cumulative 
allele frequency and only 7 (2.9%) of these had an IFM from the BBMR. However, 
VFMs were identified for 30 (12.6%) patients. There were 127 patients with at 
least one HLA allele in the lowest cumulative 5% frequency and only 1 of these 
had an IFM but a VFM was identified for 10 patients. There were 54 patients with 
at least one HLA allele in the lowest cumulative 1% frequency and none of these 
had an IFM match but 3 patients had a VFM. 
Table 4.5 Inherited full match (IFM) and virtual full match (VFM) CB donor 
availability for difficult to match patients. TNC dose was not included in 
donor selection.  
Patient HLA 
with a 
cumulative 
frequency in 
the lowest: 
BBMR BMDW 
IFM VFM P IFM VFM P 
1%a 0/54 3/54 0.079 8/54 8/54 1.000 
5%b 1/127 10/127 0.006 32/127 31/127 0.884 
10%c 7/239 30/239 0.008 70/239 72/239 0.841 
a A*34, A*36, A*66, A*69, A*74, B*46, B*48, B*54, B*60, B*62, B*67, B*73, B*81, DRB1*10 
b A*23, A*25, A*31, B*41, B*42, B*45, B*47, B*53, DRB1*09, DRB1*12 and those in a 
c A*30, A*32, B*37, B*50, B*55, B*56, DRB1*08, DRB1*16 and those in b 
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Extending the search to the BMDW registry increased the number of patients 
with allele(s) in the lowest cumulative 10% frequency for whom an VFM could be 
identified from 7 (BBMR) to 70 (29.3%, BMDW) but the benefit of NIMA matching 
diminished and a VFM was identified for just 2 additional patients (n= 72, 30.1%). 
A similar trend was observed for patients with allele(s) in the lowest 5% or 1% 
cumulative frequency and IFMs and VFMs were identified for comparable 
numbers of patients (5%: IFM, 32; VFM, 31 and 1%: IFM, 8; VFM, 8).  
 Discussion 
4.6.1 Virtual full matches were identified for patients from the BBMR and 
BMDW registries 
Initial analyses demonstrated that VPs in the BBMR were able to provide VFMs 
for 28.4% of patients and searching the BMDW registry increased availability to 
48.4%, likely due to the larger number of VPs present. The majority of VFMs 
identified from the BBMR were a 5/6 + 1 NIMA match (54.6%, n= 71/130) and 
this increased when the search was extended to BMDW (69.2%, n= 153/221). 
This is important because due to the current limited availability of clinical 
evidence, a VFM should not be preferentially selected over a donor with a higher 
degree of inherited match (for example, a 4/6 + 1 NIMA should not be chosen 
over a 5/6 with no NIMA matches). This recommendation may change if more 
clinical evidence becomes available. 
Comparison of EC patients to those of other ethnicities revealed OE patients had 
a slight but non-statistically significant reduction in the availability of a VFM 
compared with EC patients for BBMR searches (EC, 31.4%; OE, 25.4%; p= 0.34). 
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This contrasts with the wide differences in the availability of an IFM described in 
this study and as published elsewhere (Gragert, et al 2014). There were three 
times the number of VPs than inherited phenotypes in the BBMR and a large 
proportion of these were from ethnic minorities (chapter 3) and this larger donor 
pool could explain why OE patients were not at a disadvantage with regards to 
VFM donor availability. However, when BMDW was searched, which has a higher 
number of inherited phenotypes compared to VPs, OE patients were again not at 
a disadvantage compared to EC patients (p= 0.63). Furthermore, despite the 
differences in size between the BMDW inherited and VPs, patients had a similar 
availability of an IFM (EC, 48.5%; OE, 37.3%) compared to a VFM (EC, 49.6%; OE, 
44.8%). The size of the VP donor pool therefore seems not the only contributing 
factor to the availability of a VFM. It is possible there is an increased diversity 
amongst VPs, possibly because they presumably do not show patterns of LD and 
indeed, the previous chapter showed a large proportion of VPs were unique. 
Patients with less common phenotypes, at least amongst the predominantly 
Caucasian registries, could therefore benefit from the phenotype diversity 
amongst VPs. 
When modelling NIMA match probability on a case-by-case basis, knowledge of 
the likelihood of identifying a NIMA match at each HLA locus and for individual 
HLA alleles will be important; particularly if maternal HLA typing is to be 
requested on individual CB donors as part of a further typing when searching for 
an appropriate donor. The majority (74%) of NIMA matches for 5/6 + 1 NIMA CB 
donors identified in this study were at HLA-A or HLA-B. Class I MMs are thought 
to be less detrimental than HLA-DRB1 MMs and are generally the preferred MM 
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(Eapen, et al 2011b). It therefore seems feasible that if an IFM was unavailable, a 
class I antigen could be selected as a potential MM and this MM could readily be 
targeted for a NIMA+ during the donor search and selection process.  
4.6.2 Virtual full matches improved donor availability for patients 
without an inherited full match and met the recommended 
minimum TNC dose recommendations 
The relevance of VFMs in the traditional CB donor search strategy was explored 
by evaluating the availability of a VFM for patients without an IFM. When donor 
searches were performed using the BMDW registry, an IFM was available for 
49.5% of patients. This is comparable to a recent analysis whereby an IFM from 
BMDW was identified for 46.4% of 2,020 Dutch patients (Van der Zanden, et al 
2014). However, this study identified a VFM from BMDW for fewer patients 
without an IFM compared to 32.0% of Dutch patients (Van der Zanden, et al 
2014). This is unlikely to be a reflection of my inclusion of TNC dose because this 
was shown to have little effect on the availability of a VFM for patients without 
an IFM (HLA only, 14.2%; TNC model, 13.8%). There could have been differences 
between the patient populations but if so, this did not lead to differences in the 
availability of an IFM between populations. There were however, significant 
differences in the pool of VPs searched. In this thesis, only VPs for the 26,735 
BMDW CB donors with known maternal HLA were included, whereas van der 
Zanden and colleagues used the haplotype frequencies of the entire BMDW CB 
registry to estimate the VPs of 167,201 donors (Van der Zanden, et al 2014).  
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VFMs from the BBMR doubled the cumulative availability of a matched donor for 
EC patients and tripled the availability for OE patients. Incorporation of VFMs 
into the CB donor search strategy therefore provided a larger relative benefit to 
donor availability from BBMR searches compared to BMDW searches. This has 
implications for UK patients requiring CBT, whereby if an IFM was not identified 
from the BBMR, patients could potentially benefit from a VFM from the BBMR as 
opposed to initiating an international search for an IFM.  In the BBMR analysis, 
VFMs also significantly increased donor availability for difficult to match patients 
with one or more infrequent HLA alleles. In contrast, IFMs and VFMs were 
available for a comparable proportion of patients with infrequent HLA alleles 
when the BMDW registry was searched. This indicates that there remains a pool 
of patients with rare phenotypes and for whom it is very difficult to identify a 
matched CB donor, despite the inclusion of VPs and warrants continuing to 
perform maternal HLA typing of banked CBUs to generate additional VPs 
available for donor searches.  
For patients with malignant disease, 44.2% had an IFM and a further 14.9% had 
a VFM available. HLA mismatching can offer a beneficial GvL effect for patients 
with malignant disease and preliminary evidence suggests that, for myelogenous 
diseases, a stronger GvL response may be elicited after NIMA+ CBT (van Rood, et 
al 2009). The precise cellular and molecular mechanisms of this remain unclear 
but an anti-NIMA immunity may be upregulated after re-exposure to the NIMA 
MM of the recipient. If confirmed, there could be disease-specific cases where a 
VFM is preferred over an IFM or 5/6 match.  
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4.6.3 Limitations and further work 
Although the availability of two (4/6 + 2 NIMA) and three (3/6 + 3 NIMA) NIMA 
matches were included in this analysis, their clinical relevance in CBT remains 
unclear. NIMA matching has previously occurred by chance and hence the 
majority of NIMA+ CB transplants to date have been 5/6 + 1 NIMA or 4/6 + 1 
NIMA matches. However, 4/6 + 1 NIMA matching in unrelated CBT and 3/6 + 3 
NIMA matching in haploidentical sibling HSCT and renal transplantation have 
shown positive clinical outcomes, which could extend to two and three NIMA 
matches in CBT (Burlingham, et al 1998, van Rood, et al 2002, Wang, et al 2014). 
Indeed, this rationale was applied when the decision was made to include these 
in the BMDW NIMA Match Program, which will allow future clinical evaluation of 
these NIMA match categories.  
Matching one of two donor-recipient HLA MMs to the CB NIMA i.e. a 4/6 + 1 NIMA, 
to give a virtual 5/6 match, has also been shown to benefit clinical outcomes (van 
Rood, et al 2009) and are available for triple the number of patients with a VFM 
(Rocha, et al 2012, Van der Zanden, et al 2014). Virtual 5/6 matches were not 
considered in this analysis because at the time of search, they were not included 
in the BMDW NIMA Match Program but their availability warrants further 
investigation. Virtual 5/6 matches could be beneficial for patients with rare 
phenotypes and/or the 26.5% of the patients weighing 50 kg or less for whom 
the most compatible CB donor with an adequate TNC dose identified from the 
BBMR was an inherited 4/6 match.  
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CB donor searches were based on the recommended HLA matching criteria (HLA-
A and –B at antigenic or intermediate resolution and –DRB1 at high resolution) at 
the time of this study. However, recent evidence in favour of matching at HLA-C 
and at allele level for class I and class II HLA in CBT (Eapen, et al 2014) has 
resulted in a change in UK donor selection recommendations (Hough, et al 2016). 
Allele level matching at HLA-A, -B, -C and -DRB1 was not considered in these 
analyses owing to the lack of maternal and CB allelic HLA typing and the absence 
of allelic matching in the BMDW Match algorithm (this has since been 
implemented). Although improved donor-recipient histocompatibility may 
reduce the clinical benefit to NIMA matching, the inclusion of more stringent HLA 
matching criteria may further reduce the availability of an optimally HLA 
matched CB donor and it is feasible that NIMA matching may still prove 
advantageous when selecting preferential HLA MMs.  
Previous analyses have indicated wide differences in the probability of finding an 
IFM for patients of different ethnic backgrounds (Gragert, et al 2014). However, 
Non-European Caucasoid, Black, South and East Asian and those of mixed 
ethnicity were grouped together in this study due to the small patient cohort. 
Further investigations into donor availability of VFMs should therefore exploit a 
larger patient cohort to permit further stratification according to individual 
patient ethnic groups.  
In this study, only previous recipients of an NHS-CBB were evaluated and 
importantly will not include patients that may not have proceeded to transplant 
due to the unavailability of a suitable donor. Match rates in this study could 
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therefore be overestimated, although the cohort did include a clinically 
heterogeneous group of patients with a broad range of HLA phenotypes. 
4.6.4 Conclusions 
VFMs were available for patients without an IFM and thus when incorporated 
into the inherited match donor search strategy, VFMs, with adequate TNC dose, 
were able to extend the availability of a suitable donor for patients requiring a 
transplant and in particular, for patients of ethnicities other than EC. This 
provides evidence for the existence of VPs as true phenotypes in the patient 
population that were not yet present in the BBMR or BMDW registries. NIMA 
matching could therefore be considered prospectively during the donor search 
and selection process. Further work should focus on a larger patient cohort to 
allow stratification according to ethnicity and include HLA-C and allele level 
resolution in matching probabilities. However, there is also a need for clinical 
evidence supporting the inclusion of NIMA matching at HLA-C and in the context 
of donor-recipient allelic resolution matching at HLA-A, -B, -C and -DRB1. 
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Chapter 5 Retrospective analysis of 
NIMA matching at HLA-A, -B, -C and –
DRB1 and recipient outcomes after 
single cord blood transplantation 
 
Key points: 
• Development of a database containing recipient, donor and maternal 
demographics, HLA and recipient clinical outcomes  
• Inclusion of HLA-C identified additional HLA MMs 
• 16 of 168 transplants were NIMA matched 
• The study was underpowered to detect a difference in overall survival, 
TRM, relapse, neutrophil recovery and acute and cGvHD 
• A large international collaboration is needed to evaluate NIMA matching 
at allelic resolution for HLA-A/-B/-C/-DRB1 on recipient outcomes 
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 Introduction 
Numerous studies on the regulation of responses towards NIMA in vitro and on 
the influence of NIMA on clinical outcomes in the related HSCT and renal 
transplantation setting have been published (Burlingham, et al 1998, Mold, et al 
2008, van Rood, et al 2002, Wang, et al 2014). However, there have only been two 
studies regarding the influence of NIMA matching on clinical outcome after 
unrelated CBT (Rocha, et al 2012, van Rood, et al 2009), partly due to 
unavailability of maternal HLA typing for transplanted CBUs. HLA and NIMA 
matching for these studies considered HLA-A and –B antigens and –DRB1 alleles 
and not the recently introduced class I allele matching that also considers HLA-C 
(Hough, et al 2016). The probability of NIMA matching by chance was associated 
with high frequency HLA alleles (Rocha, et al 2012, van Rood, et al 2009). It is 
possible that the beneficial effect of NIMA matching in CBT could be a 
consequence of improved degree of high resolution HLA matching at HLA-A/-B/-
C/-DRB1 in the NIMA matched group; that was not identified through further HLA 
typing and therefore not adjusted for in statistical analyses (Brady, et al 2015).  
It is also possible that the beneficial effect of NIMA matching may be diminished 
in the context of improved HLA matching in CBT, where non-HLA factors are 
likely to be limiting an improvement in OS. The less stringent HLA matching 
requirements in CBT have historically improved donor availability for ethnic 
minorities without an MUD (Barker, et al 2010a, Gragert, et al 2014) but the change 
in HLA matching for CBT, to reflect that of adult donor sources (Hough, et al 
2016), could reverse this trend. If NIMA matching maintains its advantage on 
clinical outcome in the context of high resolution HLA matching, then it is possible 
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that NIMA matching could become even more valuable for recipients with a 
decreased degree of inherited high resolution HLA matches, as shown in the 
previous chapter (Powley, et al 2016). 
The NHS-CBB has issued over 500 CBUs for transplantation, receives regular 
updates on the clinical outcome of these transplants, and has the ability to 
perform maternal HLA typing. This enables the rare opportunity to study the 
impact of NIMA matching on clinical outcomes after CBT.  
 Aims 
The primary aim of this chapter was to retrospectively determine whether NIMA 
matching was associated with improved clinical outcomes after single CBT, in 
recipients issued with an NHS-CBB CBU to treat malignant and non-malignant 
disease (Figure 5.1). It was hypothesised that HLA mismatched, NIMA+ 
transplants would be associated with a lower TRM and faster neutrophil recovery 
compared to HLA mismatched, NIMA- transplants. The original intention was to 
perform the analysis of NIMA matching using donor-recipient allele matching at 
HLA-A, -B, -C and -DRB1. However, despite attempts to increase the size of the 
cohort, the number of transplant pairs eligible for inclusion remained small and 
the analysis was therefore performed using matching based on HLA-A, -B and -C 
antigens and -DRB1 alleles. The study remained statistically underpowered using 
the less stringent matching criteria but given the data collected and methodology 
training provided the bases for other parts of this thesis and future work, a 
retrospective survival analysis of NIMA matching was still performed.   
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To address the research aim, the first question was “what is the incidence of NIMA 
matching HLA-A, -B, -C and –DRB1 by chance?” The majority of recipients, CBUs 
and mothers did not have the required level of HLA typing and where possible, 
allelic level HLA typing was completed by SBT and missing data was obtained 
from external sources. The donor-recipient HLA match grades were then 
determined, the CBU NIMA were identified and each HLA MM was checked for a 
NIMA match.  
This enabled the second research question to be addressed, “what are the 
probabilities of OS (primary endpoint) and TRM, relapse, neutrophil recovery 
and acute and cGvHD (secondary endpoints) after HLA matched, NIMA+ and 
NIMA- CBT?” The influence of NIMA matching on these endpoints was considered 
after adjustment for other statistically associated variables in a multivariate 
analysis. Clinical outcomes data were provided by Eurocord and required data 
coding and calculation of the endpoints with censoring and inclusion of 
competing events.  
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Figure 5.1 Chapter 5 aim and questions proposed to address this aim 
 
  Aim. Retrospectively 
determine whether 
NIMA matching at 
HLA-A, -B, -C and –
DRB1 was associated 
with improved 
clinical outcomes 
after single CBT 
Q1. What is 
the incidence 
of NIMA 
matching by 
chance? 
Q2. What were the 
probabilities of 
the primary and 
secondary 
endpoints after 
HLA matched, 
NIMA+ and NIMA- 
CBT? 
• NIMA matching at HLA-
A/B/C/DRB1 
• Allelic level match grades of 
NIMA+ and NIMA- CBT 
• Primary endpoint: OS 
• Secondary endpoints: 
neutrophil recovery, acute 
and cGvHD, relapse, TRM 
Abbreviations: CBT, cord blood transplantation; GvHD, graft-versus-host-disease; 
OS, overall survival; TRM, treatment-related mortality. 
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 HLA typing and determination of donor-recipient 
matching 
5.3.1 HLA typing of recipients, CBUs and mothers 
A total of 244 recipients received a single graft for first transplantation and were 
eligible for inclusion, as described in M&M section 2.4.2. There were 39 
recipients with missing clinical outcome data for all endpoints, either due to a 
loss of follow-up, the absence of recipient consent for research or the absence of 
transplant centre consent for providing outcome data to the NHS-CBB. The 
incidence of NIMA matching and its effect on clinical outcomes after CBT could 
therefore be potentially be evaluated for 205 recipients.  
Allelic resolution HLA types across four loci (i.e. HLA-A/-B/-C/-DRB1) were only 
available for 68 (33%) of the 205 recipients. An additional 16 recipient allelic 
resolution HLA types were identified from hard copies of recipient HLA typing 
reports from other H&I laboratories. Eurocord were able to provide an additional 
16 recipient allelic resolution HLA types. It was not possible to contact all 
transplant centres ourselves due to the international agreement that all queries 
must be mediated through Eurocord and requests should not be sent by 
individual laboratories or registries. We did, however, contact UK H&I 
laboratories requesting additional data or pre-transplant samples. Eighteen pre-
transplant DNA samples were requested and received for further HLA typing, as 
detailed in M&M section 2.6.2. Ten samples passed SBT and 8 samples failed due 
to poor quality DNA. Allelic resolution HLA types for a further 34 recipients were 
received from the UK H&I laboratories. 
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As a result of contacting H&I laboratories in England, contacting Eurocord and 
checking the hard copies of recipient files, the number of recipients with allelic 
resolution HLA typing data available for this study increased from 68 to 144. Of 
the 144 transplants, allelic resolution HLA typing at HLA-A, -B, -C and -DRB1 was 
available for only 34 of the corresponding CBUs. PCR-SBT was completed for a 
further 59 CBUs. This brought the total donors and recipients with allelic 
resolution HLA typing at HLA-A, -B, -C and -DRB1 to 93. DNA or tissue was either 
unavailable or of poor quality for the remaining 51 CBUs and further typing was 
not possible.  
In an attempt to increase the size of the cohort available for the retrospective 
survival analyses, the matching criteria was reduced to low resolution for HLA-A, 
-B, and -C and allelic resolution for HLA-DRB1. All of the 205 recipients were typed 
to this degree but not all of the paired CBUs had HLA-C typing data available. HLA-
C PCR-SBT for CBUs was therefore completed where required and HLA-A, -B, -C 
and/or -DRB1 PCR-SBT for maternal samples was also completed. This resulted 
in a final cohort size of 198 recipients, CBUs and mothers HLA typed to a 
minimum of first field at class I and second field at HLA-DRB1. 
Given that DNA was not available for all recipients without allelic level HLA types, 
the feasibility of imputing first field and intermediate resolution HLA types to 
allelic level using HLAMatchmaker was explored (see M&M section 2.6.3). To 
evaluate the accuracy of HLAMatchmaker, CBUs with laboratory-defined allelic 
HLA types were checked against the predicted alleles when allelic HLA types 
were collapsed back to first field. All CBUs with allelic level defined HLA at one or 
more HLA loci were included, regardless of study inclusion eligibility, to increase 
Chapter 5 
L. Powley (2017)   -160- 
the sample size available for concordance checking. There were 458 HLA-A alleles 
evaluated and 78.6% of computational predictions were concordant with 
previous HLA typing, 80.9% were concordant for the 491 HLA-B alleles evaluated 
but only 36.9% were concordant for the 452 HLA-C alleles evaluated (Table 5.1). 
Imputation concordance with previous allelic results was possibly lower than 
expected due to recent advances in HLA typing technology since the development 
of HLAMatchmaker. HLAMatchmaker does not consider the allelic string 
(intermediate HLA typing) when predicting the HLA allele. Prediction of HLA 
alleles also relies on ethnicity data, which is often self-reported and not always 
genetically descriptive. It was therefore decided that concordance was not strong 
enough to use imputed allelic level HLA types from HLAMatchmaker for this 
analysis. 
Table 5.1 Concordance of in silico predicted class I alleles compared to 
HLA tying results. In silico prediction was performed using HLAMatchmaker. 
Locus 
Concordance 
Total 
Concordant Discordant 
HLA-A 360 (78.6) 98 (21.4) 458 
HLA-B 397 (80.9) 94 (19.1) 491 
HLA-C 167 (36.9) 285 (63.1) 452 
Total 924 (66.0) 477 (34.0) 1,401 
 
5.3.2 HLA-A, -B, -C and –DRB1 donor-recipient and NIMA matching 
There were 93 single graft transplants with donor and recipient allelic level four 
loci HLA types (HLA-A, -B, -C and –DRB1). Four loci allelic level HLA match grades 
(graded out of 8) were compared to historic lower level match grades (graded 
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out of 6 based on antigenic HLA-A and –B and allelic level –DRB1) to determine if 
further HLA MMs were revealed from the additional resolution of HLA typing 
(Table 5.2). There were 22 transplants that were 6/6 HLA matched and 68% (n= 
15) were also matched to 8/8 at allelic level. The remaining 32% (n= 7) had a 
single allelic HLA mismatch. HLA mismatched transplants based on historic 
criteria (5/6 or lower) corresponded to a lower four loci allelic match, with 20% 
(n= 19) of the total 93 transplants matched at 4/8 or lower.  
Table 5.2 Allele-resolution (HLA-A, -B, -C, -DRB1) donor-recipient HLA 
matching compared to historic matching (HLA-A and –B at antigen level 
and –DRB1 at allele-level). Class I HLA allele MMs that not identified by lower-
resolution matching are shown in red. Percentages are shown in parenthesis.  
HLA-A, -B 
(antigen) 
and –DRB1 
(allele) 
match 
HLA-A, -B, -C and -DRB1 (allele) match 
Total 
8/8 7/8 6/8 5/8 4/8 3/8 2/8 
6/6 15 (68) 7 (32) 0 0 0 0 0 22 
5/6 - 9 (23) 14 (35) 13 (33) 3 (8) 0 (0) 1 (3) 40 
4/6 - - 4 (13) 14 (47) 8 (27) 4 (13) 1 (3) 30 
3/6 - - - 0 (0) 1 (50) 1 (50) 0 2 
Total 15 (16) 16 (17) 18 (19) 27 (29) 12 (13) 5 (5) 2 (2) 93 
 
The 77 transplants HLA mismatched at allelic level (7/8 or lower) were evaluated 
for a NIMA match and 10 were identified to have an NIMA+ HLA MM. NIMA+ 
transplants did not appear to have a higher degree of allelic level donor-recipient 
HLA matching (7/8 = 1, 6/8 = 3, 5/8 = 2, 4/8 = 3, 3/8 = 0, 2/8 = 1) compared to 
NIMA- transplants but unfortunately the small numbers did not permit statistical 
testing of this observation. 
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The small number of single graft transplants with allelic level HLA types for 
recipients, CBUs and mothers meant further analysis was restricted to matching 
HLA-A, -B and –C antigens and –DRB1 alleles. The final study cohort contained 
168 recipients (and the corresponding CBUs and mothers) that met this criterion. 
Comparison of the historic HLA match grades to the revised HLA match grades 
with HLA-C antigen matching included is shown in Table 5.3. Of the 6/6 HLA 
matched transplants, 84% were also matched at HLA-C to give an 8/8 HLA match 
(n= 42, HLA-A, -B and -C antigen and -DRB1 allele) and the remainder were 7/8 
HLA matched (n= 8). Only 34% of 5/6 (n= 24), 20% of 4/6 (n= 24) and none of 
the 3/6 HLA matched transplants were matched as 7/8, 6/8 or 5/8, respectively. 
Table 5.3 HLA-A, -B and –C antigen and -DRB1 allele donor-recipient HLA 
matching compared to historic matching without HLA-C. HLA-C antigen MMs 
that were not identified by lower-resolution matching are shown in red. 
Percentages are shown in parenthesis. CBT n= 168. 
HLA-A, -B 
(antigen) and –
DRB1 (allele) 
match 
HLA-A, -B, -C (antigen) and -DRB1 (allele) match 
Total 
8/8 7/8 6/8 5/8 4/8 
6/6 42 (84) 8 (16) 0 - - 50 
5/6 - 24 (34) 36 (51) 10 (14) - 70 
4/6 - - 9 (20) 26 (59) 9 (20) 44 
3/6 - - - 0 4 (100) 4 
Total 42 (25) 32 (19) 45 (27) 36 (21) 13 (8) 168 
 
HLA MMs at HLA-A, -B, -C antigens and –DRB1 alleles were next evaluated for a 
NIMA match. Of the 126 HLA mismatched transplants, 16 (12.7%) were NIMA+ 
(Table 5.4). The majority of the NIMA+ transplants were 6/8 (n= 7) or 5/8 HLA 
matched (n= 6), which is not surprising given that a higher number of HLA MMs 
Chapter 5 
L. Powley (2017)   -163- 
increases the number of potential NIMA matches. In this small cohort, NIMA+ 
transplants were not significantly associated with better HLA matching at HLA-A, 
-B, -C (antigen) and -DRB1 (allele) compared to NIMA- transplants (p= 0.767). 
There were 19 NIMA matched antigens/alleles in the 16 NIMA+ cases. The 
majority (n = 9) of NIMA matches occurred at HLA-C, five occurred at HLA-B, three 
occurred at HLA-A and one NIMA match occurred at HLA-DRB1. Notably, the most 
frequent NIMA+ was HLA-C*07 (n = 5), followed by HLA-C*12 (n= 2) and HLA-
A*02 (n= 2), with the remaining NIMA matches only occurring once in the cohort. 
Table 5.4 NIMA matched cases. Donor-recipient HLA MMs are shown in red 
and NIMA matches are shown in green. HLA match is based on HLA-A, -B and -C 
antigens and -DRB1 alleles. N.D, not determined; MM, mismatch. 
Case HLA match NIMA+ MM 
1 6/8 A*01 
2 7/8 A*02 
3 7/8 A*29 
4 6/8 B*08 
5 5/8 B*15 
6 6/8 B*51 
7 4/8 B*52 & C*12 
8 5/8 C*03 
9 6/8 C*07 
10 5/8 B*07 & C*07 
11 6/8 C*07 
12 5/8 C*07 
13 5/8 C*12 
14 6/8 C*15 
15 6/8 DRB1*13 
16 5/8 A*02 
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5.3.3 Donor and recipient demographics 
NHS-CBB CBUs were issued to both paediatric (57%) and adult recipients (43%) 
that were mainly treated in European (75%) and North American (15%) 
transplant centres between 1999 and 2014 (Table 5.5). The majority of 
recipients were male (61%) and European Caucasoid (64%). Indications for 
transplant primarily comprised malignant diseases (70%), that were in first 
(36%) or higher (38%) remission. Non-malignant indications for transplant were 
mainly primary immune deficiencies (15%) such as severe combined 
immunodeficiency (SCID), or inborn errors of metabolism (10%) such as Hurler’s 
syndrome in paediatric recipients. Conditioning regimens included both MAC 
(64%) and RIC protocols (37%). The majority of recipients received ATG before 
day 0 and received cyclosporine and/or a steroid based aGvHD prophylaxis alone 
(50%) or with mycophenolate mofetil (37%). The median post-processing TNC 
dose was 7.2 x 107 per kg recipient weight, 18.4% received a TNC dose less than 
2.5 x 107 per kg, 40.0% received a dose between 2.5 and 5.0 x 107 per kg and 
50.6% received a dose greater than 5.0 x 107 per kg.  
There were some significant differences in demographics between the 8/8 HLA 
matched, NIMA- and NIMA+ HLA mismatched groups. Recipients of an 8/8 HLA 
matched CBU were more likely to be paediatric (86%) compared to NIMA- (48%) 
and NIMA+ HLA mismatched (37%) groups (p >0.0001) and thus were also more 
likely to be treated for non-malignant diseases (67%) compared to compared to 
NIMA- (19%) and NIMA+ (12%) HLA mismatched groups (p >0.0001). Recipients 
of an 8/8 HLA matched CBU were less likely to receive a total body irradiation 
(TBI)-based MAC conditioning regimen (8%) and were more likely to receive a 
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non-TBI based RIC regimen (45%, p= 0.002), without ATG (60%, p= 0.015), likely 
due to their paediatric nature and treatment for non-malignant diseases. NIMA+ 
CBT recipients were more likely to receive a MAC regimen that was TBI based 
(53%) compared to NIMA- HLA mismatched CBT recipients (28%, p= 0.002). 
Table 5.5 Recipient, CBU and transplant characteristics according to 
donor-recipient HLA match status. HLA matching was based on HLA-A, -B, -C 
(antigen) and –DRB1 (allele). 
Variable Total 8/8 
HLA mismatched 
P 
NIMA- NIMA+ 
Number of recipients 168 (100) 42 (25) 110 (65) 16 (10)  
Region (n= 8 unknown) 0.559 
Europe 124 (74) 33 (79) 80 (73) 11 (69)  
United States of America 25 (15) 3 (7) 19 (17) 3 (19)  
Other 19 (11) 6 (14) 11 (10) 2 (13)  
Recipient age <0.0001 
< 16 95 (57) 36 (86) 53 (48) 6 (37)  
> 16 73 (43) 6 (14) 57 (52) 10 (63)  
Recipient gender 0.684 
Male 103 (61) 28 (67) 66 (60) 9 (56)  
Female 65 (39) 14 (33) 44 (40) 7 (44)  
Recipient ethnicity 0.327 
European Caucasoid 107 (64) 28 (67) 70 (64) 9 (56)  
Other 33 (20) 6 (14) 21 (19) 6 (38)  
Unknown/ Not declared 28 (16) 8 (19) 19 (17) 1 (6)  
Recipient CMV serostatus (n= 16 unknown) 0.122 
Negative 86 (57) 25 (64) 56 (57) 5 (33)  
Positive 66 (43) 14 (36) 42 (43) 10 (66)  
Recipient diagnosis <0.0001 
Malignant 117 (70) 14 (33) 89 (81) 14 (88)  
ALL 40 (24) 2 (5) 30 (27) 8 (50)  
AML 34 (20) 4 (10) 26 (24) 4 (25)  
MDS or MDS/MPD 28 (17) 4 (10) 23 (21) 1 (6)  
Lymphoproliferative disorder 7 (4) 1 (2) 5 (5) 1 (6)  
Plasma cell disorder 1 (1) 0 (0) 1 (1) 0 (0)  
Histiocytic disorder 7 (4) 3 (7) 4 (4) 0 (0)  
Non malignant 51 (30) 28 (67) 21 (19) 2 (12)  
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Variable Total 8/8 
HLA mismatched 
P 
NIMA- NIMA+ 
Bone marrow failure 9 (5) 2 (5) 6 (5) 1 (6)  
Haemoglobinopathy 1 (1) 0 (0) 1 (1) 0 (0)  
Primary immune deficiency 25 (15) 18 (43) 6 (6) 1 (6)  
Inborn error of metabolism 16 (10) 8 (19) 8 (7) 0 (0)  
Recipient disease status (n= 39 unknown) 0.135 
1st CR 26 (36) 2 (40) 21 (36) 3 (30)  
2nd or higher CR 28 (38) 0 (0) 22 (38) 6 (60)  
Partial remission 2 (3) 0 (0) 2 (3) 0 (0)  
Relapse 11 (15) 1 (20) 10 (17) 0 (0)  
Refractory disease 6 (8) 2 (40) 3 (5) 1 (1)  
ATG before d0 (n= 42 unknown) 0.015 
No 50 (40) 21 (60) 26 (32) 3 (30)  
Yes 76 (60) 14 (40) 55 (67) 7 (70)  
Conditioning regimen (n= 13 unknown) 0.002 
MAC, TBI based 40 (26) 3 (8) 29 (28) 8 (53)  
MAC, Non-TBI based 58 (38) 15 (39) 41 (41) 2 (13)  
RIC, TBI based 12 (8) 3 (8) 6 (6) 3 (20)  
RIC, non-TBI based 45 (29) 17 (45) 26 (25) 2 (13)  
GvHD prophylaxis (n= 13 unknown) 0.852 
CsA +/- steroids 77 (49.7) 19 (50) 51 (50) 6 (43)  
CsA +/- steroids + MTX 10 (6.5) 1 (3) 7 (7) 2 (14)  
CsA +/- steroids + MMF 58 (37.4) 16 (42) 37 (37) 5 (36)  
Tacrolimus +/- MTX +/- MMF 8 (5.2) 1 (3) 6 (6) 1 (7)  
Other 2 (1.3) 1 (3) 1 (1) 0 (0)  
Year of transplant 0.139 
1999 – 2004 40 (23.8) 7 (17) 28 (25.5) 5 (31.3)  
2005 – 2009 75 (44.6) 21 (50) 44 (40.0) 10 (62.5)  
2009 – 2014 53 (31.5) 14 (33) 38 (34.5) 1 (6.3)  
Post-processing TNC dose per kilogram (x107 / kg) 0.006 
< 2.5 31 (18.4) 5 (11.9) 23 (20.9) 3 (18.8)  
2.5 - 5.0 52 (40.0) 6 (14.2) 38 (34.5) 8 (50.0)  
> 5.0 85 (50.6) 31 (73.8) 49 (44.5) 5 (31.3)  
Abbreviations: ALL, acute lymphoblastic leukaemia; AML, acute myelogenous 
leukaemia; ATG, anti-thymocyte globulin; CMV, cytomegalovirus; CsA; 
cyclosporine A; CR, complete remission; MAC, myeloablative conditioning; MDS, 
myelodysplastic syndrome; MMF, mycophenolate mofetil; MPD, myeloproliferative 
disorder; MTX, methotrexate; RIC, reduced intensity conditioning; TBI, total body 
irradiation; TNC, total nucleated cell. 
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 Clinical outcomes 
5.4.1 Overall survival 
The median follow-up time (or time-to-death) was 17 months (range 1 - 174). 
The probability of OS at 5 years was 76% (95% CI: 64% - 90%) for 8/8 HLA 
matched transplants compared to 53% (95% CI: 43%-64%) for NIMA- and 44% 
(95% CI: 25%-76%) for NIMA+ HLA mismatched transplants (p= 0.04) (Figure 
5.2). However, after risk-adjustment for TNC dose, recipient age, conditioning 
regimen, year of transplant and whether the recipient was being treated for a 
malignant disease, there was no statistical difference in the probability of OS at 5 
years between each HLA match category (p= 0.39).  
Figure 5.2 Overall survival at 5 years according to donor-recipient HLA 
match status. Kaplan-Meier estimates of overall survival were calculated for all 
recipients and were as follows: 8/8, n= 42, 76% (95% CI: 64 - 90); NIMA-, n= 
110, 53% (95% CI: 43 - 64); NIMA+, n= 16, 44% (95% CI: 25 - 76) (p= 0.04). 
Deaths were due to any cause and was reported by Eurocord. HLA matching 
was based on HLA-A, -B, -C (antigen) and –DRB1 (allele). 
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Given that an increasing number of HLA MMs has been shown to have an adverse 
additive effect on the probability of OS (Lee, et al 2007), a sub-group analysis 
according to the number of HLA MMs was performed. The small sample size 
meant 4/8 and 5/8 HLA matches and 6/8 and 7/8 HLA matches were grouped 
together rather than considering each match grade separately. This decision was 
supported by an analysis of allele level HLA matching at HLA-A/-B/-C/-DRB1 on 
outcomes after single CBT for haematological malignancy that found no statistical 
difference in non-relapse mortality between 4/8 and 5/8 HLA matches or 
between 6/8 and 7/8 HLA matches (Eapen, et al 2014). After adding the number 
of MMs to the risk-adjusted model (p= 0.27) there was no difference in 5-year OS 
for NIMA+ transplants compared to NIMA- HLA mismatched CBT (p>0.995).  
HLA-C MMs are reported to have an adverse effect on clinical outcomes after CBT 
(Eapen, et al 2014). This is the first analysis of NIMA matching on clinical 
outcomes after CBT to include HLA-C matching and it is possible the lack of 
statistical difference in the probability of 5-year OS between the different 
matching groups could be because the majority of NIMA+ cases were mismatched 
at HLA-C. A sub-group analysis according to HLA-C matching status was 
performed. After adding whether there was a MM at HLA-C to the risk adjusted 
model (p= 0.65), there was still no difference in 5-year OS (p>0.995). 
5.4.2 Transplant related mortality 
There was no difference in the cumulative incidence of TRM at 5 years for 8/8 
HLA matched transplants (17%, 95% CI: 7%-30%) compared with NIMA- (30%, 
95% CI: 21%-39%) and NIMA+ HLA mismatched transplants (38%, 95% CI: 
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14%-61%), (p= 0.20) (Figure 5.3). After risk-adjustment, there was no 
difference in TRM for each match category (p= 0.71). The number of MMs (p= 
0.15) and whether there was an HLA-C MM (p= 0.79) were added to the risk 
adjusted model in a sub-group of cases with at least one HLA mismatch. There 
was no difference in the cumulative incidence of TRM at 5 years for NIMA+ 
compared to NIMA- HLA mismatched transplants (p= 0.98) in this model. 
Figure 5.3 Transplant-related mortality at 5 years according to donor-
recipient HLA match status. The 5-year cumulative incidence of transplant-
related mortality was as follows: 8/8, n= 42, 17% (95% CI: 7 - 30); NIMA-, n= 
110, 30% (95% CI: 21 - 39); NIMA+, n= 16, 38% (95% CI: 14 – 61) (p= 0.20). 
The competing event for transplant-related mortality was relapse. HLA 
matching was based on HLA-A, -B, -C (antigen) and –DRB1 (allele).  
 
There were a total of 47 deaths attributed to TRM during the first five years 
post-transplant. The causes of TRM are shown in Table 5.6 and primarily 
included infections (40%) and GvHD (21%).  
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Table 5.6 Deaths from transplant-related causes according to donor-
recipient HLA match status. HLA matching was based on HLA-A, -B, -C 
(antigen) and –DRB1 (allele). Deaths from TRM n= 47. Percentages are shown in 
parenthesis. 
TRM 
 HLA mismatched 
Total 
8/8 NIMA- NIMA+ 
Infection 8 (73) 11 (33) 3 (50) 19 (40) 
Bacterial  0 3 0 3 
Viral  7 3 1 8 
Fungal  0 2 0 2 
Parasitic  0 0 1 1 
Unknown  1 3 1 5 
GvHD 1 (9) 6 (18) 3 (50) 10 (21) 
Multi-organ failure 1 (9) 3 (9) 0 (0) 4 (9) 
Cardiac toxicity 0 (0) 3 (9) 0 (0) 3 (6) 
Haemorrhage 0 (0) 2 (6) 0 (0) 2 (4) 
ARDS 1 (9) 1 (3) 0 (0) 2 (4) 
Rejection 0 (0) 2 (6) 0 (0) 2 (4) 
PTLD EBV 0 (0) 1 (3) 0 (0) 1 (2) 
VOD 0 (0) 1 (3) 0 (0) 1 (2) 
Other cause(s) 0 (0) 3 (9) 0 (0) 3 (6) 
Total 11 33 6 47 
Abbreviations: ARDS, acute respiratory distress syndrome; GvHD, graft-versus-
host disease; PTLD EBV, post-transplant lymphoproliferative disorder associated 
with Epstein-Barr Virus; VOD, veno-occlusive disease. 
5.4.3 Relapse 
There was no difference in the cumulative incidence of relapse at 5 years for 8/8 
HLA matched transplants (5%, 95% CI: 1%-15%) compared to NIMA- (18%, 95% 
CI: 11%-26%) and NIMA+ HLA mismatched transplants (25%, 95% CI: 7%-48%) 
(p= 0.08) (Figure 5.4). After risk-adjustment, there was no difference in the 
cumulative incidence of relapse at 5 years between each match category (p= 
0.39). In the sub-group of cases with at least one HLA mismatch, after adding the 
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number of MMs to the risk-adjusted model (p= 0.71), and whether there was a 
MM at HLA-C (p= 0.71), there was no difference in relapse between NIMA+ and 
NIMA- HLA mismatched transplants (p= 0.47). 
Figure 5.4 Relapse at 5 years according to donor-recipient HLA match 
status. The 5-year cumulative incidence of relapse was as follows: 8/8, n= 14, 
5% (95% CI: 1 - 15); NIMA-, n= 89, 18% (95% CI: 11 – 26); NIMA+, n= 14, 25% 
(95% CI: 7 – 48) (p= 0.08). Relapse was diagnosed by the transplant centre as 
recurrence of the original disease and was reported by Eurocord. The 
competing event for relapse was transplant-related mortality. HLA matching 
was based on HLA-A, -B, -C (antigen) and –DRB1 (allele).  
 
5.4.4 Myeloid engraftment 
Myeloid engraftment could not be assessed in nine (5%) recipients for whom 
engraftment and/or graft failure data were not reported. The median time to 
myeloid engraftment, defined as an absolute neutrophil count greater than 0.5 × 
109/l on three consecutive days, was 22 days in the total cohort. The median time 
to myeloid engraftment was 21 days in recipients of 8/8 HLA matched grafts and 
22 days in recipients of NIMA- and 23 days in NIMA+ HLA mismatched grafts. The 
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longest reported time to myeloid engraftment was 48 days after 8/8 HLA 
matched CBT and 43 days after both NIMA- and NIMA+ HLA mismatched CBT. 
There was no difference in the cumulative incidence of myeloid engraftment for 
8/8 HLA matched transplants (97%, 95% CI: 58%-100%) compared to NIMA- 
(84%, 95% CI: 75%-90%) and NIMA+ HLA mismatched transplants (94%, 95% 
CI: 32%-100%) (p= 0.12) (Figure 5.5). However, after risk-adjustment, the 
cumulative incidence of myeloid engraftment was 70% greater for 8/8 matched 
transplants (sub-distribution hazard ratio (SHR) 1.69, 95% CI: 1.11-2.59) but no 
different for NIMA+ (SHR 1.19, 95% CI: 0.79-1.81) compared to NIMA- HLA 
mismatched transplants (p= 0.05). In the sub-group of cases with at least one HLA 
mismatch, the number of MMs (p= 0.56) and whether there was an HLA-C MM (p= 
0.80) was added to the risk-adjusted model. There was no difference in rates of 
myeloid engraftment for NIMA+ compared to NIMA- HLA mismatched 
transplants (p= 0.54) in this model.   
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Figure 5.5 Myeloid engraftment according to donor-recipient HLA match 
status. The 48-day cumulative incidence of myeloid engraftment was as follows: 
8/8, 97% (95% CI: 58 - 100); NIMA-, 84% (95% CI: 75 – 90); NIMA+, 94% (95% 
CI: 32 - 100) (p= 0.12). Myeloid engraftment was defined as an absolute 
neutrophil count greater than 0.5 × 109/l on three consecutive days and was 
reported by Eurocord. The competing event for myeloid engraftment was death. 
HLA matching was based on HLA-A, -B, -C (antigen) and –DRB1 (allele). HLA 
matching was based on HLA-A, -B, -C (antigen) and –DRB1 (allele). 
 
5.4.5 Acute and chronic GvHD 
Nine (5%) recipients for whom engraftment and/or graft failure data were not 
reported were excluded from GvHD analyses. Unfortunately, due to the small 
numbers of NIMA+ cases, all grades of aGvHD were included together in the 
analysis. There was no difference in the cumulative incidence of grade I-IV aGvHD 
for 8/8 HLA matched transplants (54%, 95% CI: 37%-69%) compared to NIMA- 
(52%, 95% CI: 42%-61%) and NIMA+ HLA mismatched transplants (69%, 95% 
CI: 38%-87%) (p= 0.59) (Figure 5.6). After risk-adjustment, there was no 
difference in rates of aGvHD for each match category (p= 0.24).  
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For the sub-group of cases with at least one HLA mismatch, after adding the 
number of MMs to the risk-adjusted model (p= 0.76) and whether there was a 
MM at HLA-C (p= 0.73), there was some difference in rates of aGvHD for NIMA+ 
compared to NIMA- HLA mismatched transplants, (p= 0.07). The hazard of aGvHD 
was 80% greater for NIMA+ (SHR 1.77, 95% CI: 0.95-3.29), compared to NIMA- 
HLA mismatched transplants.  
Figure 5.6 Grade I-IV aGvHD according to donor-recipient HLA match 
status. The 100-day cumulative incidence of grade I – IV aGvHD was as follows: 
8/8, 54% (95% CI: 37 - 69); NIMA-, 52% (95% CI: 42 - 61); NIMA+, 69% (95% 
CI: 38 - 87) (p= 0.59). AGvHD was graded by the transplant centre and was 
reported by Eurocord. The competing event for aGvHD was primary or 
secondary graft failure. HLA matching was based on HLA-A, -B, -C (antigen) and 
–DRB1 (allele).  
 
Of all recipients in the study, 43 had died or experienced graft failure within 100 
days of transplant, two recipients’ follow-up time was less than 100 days, one 
recipient was reported as experiencing cGvHD at 91 days’ post-transplant and 
engraftment and/or graft failure data were not reported for a further eight 
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recipients. Rates of cGvHD were therefore assessed in 114 (69%) recipients 
reported as alive without graft failure at 100 days. Rates of cGvHD for 8/8 HLA 
matched transplants were lower (10%, 95% CI: 3%-25%) compared to NIMA- 
(29%, 95% CI: 19%-40%) and NIMA+ (59%, 95% CI: 7%-90%) HLA mismatched 
transplants (p= 0.04) (Figure 5.7). After risk-adjustment, the hazard of cGvHD 
was 4 times greater for NIMA- transplants (SHR 4.31, 95% CI: 1.09-17.06) and 11 
times greater for NIMA+ transplants (SHR 11.44, 95% CI: 1.92-68.34), compared 
to 8/8 HLA matched transplants (p= 0.03). For the sub-group of cases with at 
least one HLA mismatch, after adding the number of MMs to the risk-adjusted 
model (p= 0.31) and whether there was an HLA-C MM (p= 0.48) the hazard of 
cGvHD was 3 times greater for NIMA+ transplants (SHR 2.94, 95% CI: 1.04-8.29), 
compared to NIMA- HLA mismatched transplants (p= 0.04).  
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Figure 5.7 Chronic GvHD according to donor-recipient HLA match status. 
The 5-year cumulative incidence of cGvHD was as follows: 8/8, 54% (95% CI: 
37 - 69); NIMA-, 52% (95% CI: 42 - 61); NIMA+, 69% (95% CI: 38 - 87) (p= 
0.59). CGvHD was only evaluated in recipients alive at day 100. The competing 
event for cGvHD was primary or secondary graft failure or death without 
cGvHD. CGvHD was graded by the transplant centre and reported by Eurocord. 
HLA matching was based on HLA-A, -B, -C (antigen) and –DRB1 (allele). 
 
5.4.6 Statistical test of power 
The absence of a statistically significant difference in the primary endpoint, OS, 
between NIMA+ and NIMA- HLA mismatched CBT for this cohort contradicted 
previously published retrospective studies (Rocha, et al 2012, van Rood, et al 
2009). Two possibilities for this exist: 1) there is no true difference in OS between 
NIMA+ and NIMA- HLA mismatched transplants in this cohort or 2) there is a 
difference in OS but the statistical methodology failed to detect the difference due 
to a lack of power. The sample size required to detect a statistical difference was 
calculated using a method based on the log-rank test (Collett 2015). 
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OS between the NIMA+ and NIMA- groups was compared assuming an 80% 
power and 5% significance. A ratio of 1:7 NIMA+ to NIMA- cases was assumed 
based on the two published retrospective studies (Rocha, et al 2012, van Rood, et 
al 2009). Rocha et al. reported 5-year OS to be 55% after NIMA+ and 38% after 
NIMA- HLA mismatched CBT. The sample size required to detect a difference in 
OS of this magnitude is 584 (73 NIMA+, 511 NIMA- HLA mismatched cases). The 
study described in this thesis reports only 16 NIMA+ and 112 NIMA- HLA 
mismatched cases, which would only be able to detect a difference of this 
magnitude with 26% power, that is, there would be a 74% chance that I would 
fail to detect a difference if OS probabilities were 55% and 38% for NIMA+ and 
NIMA- HLA mismatched transplants, respectively. To maintain 80% power for 
this sample size would require OS of at least 73% after NIMA+ transplantation if 
OS after NIMA- HLA mismatched transplantation was still 38%. The study 
described in this thesis was underpowered to detect a significant difference in OS 
between NIMA+ and NIMA- HLA mismatched cases comparable to that of 
previous reports in the literature. 
 Discussion 
In recipients with haematological malignancies, NIMA+ grafts have been 
associated with a lower TRM and improved engraftment, leading to reduced 
overall mortality compared with NIMA- HLA mismatched CBT (Rocha, et al 2012, 
van Rood, et al 2009). This analysis by van Rood and colleagues and a second 
analysis confirming the lower incidence of TRM after NIMA matching were 
performed using the historic criteria of HLA-A and –B at antigenic resolution and 
–DRB1 at allelic resolution. Given the recent evidence promoting allelic level HLA 
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matching in CBT, the primary aim of this chapter was to retrospectively 
determine whether NIMA matching at allelic level resolution for HLA-A, -B, -C and 
–DRB1 was associated with improved clinical outcomes after single CBT in 
recipients issued with an NHS-CBB CBU. The majority of recipients, donors and 
mothers were not HLA typed to the resolution required for this study and few 
recipient DNA samples were available for further testing. Unfortunately, despite 
best efforts to complete allelic level typing, the number of donor-recipient pairs 
with allelic resolution was too small (n= 105) to perform an analysis. Statistical 
evaluation of clinical outcomes was performed for HLA matching at antigen 
resolution at HLA-A, -B and -C and allele resolution at –DRB1. 
5.5.1 HLA matching between the recipient, CBU and mother 
For the subset of transplants with donor-recipient allelic level resolution HLA 
tying, the more stringent matching criteria identified substantial additional HLA 
MMs, especially for transplants that were not 6/6 HLA matched based on 
historical criteria. However, 68% of 6/6 HLA matched transplants were also 
matched at 8/8 allelic resolution level. This is higher than a previous report by 
Eapen et al., which found that only 54% of 217 6/6 HLA matched transplants 
were also 8/8 HLA matched at allelic level resolution (Eapen, et al 2014) and is 
possibly a reflection of differences in the populations studied and/or the smaller 
cohort in this study. The NIMA+ group (n= 10) did not appear to have a better 
allelic level resolution matching compared to the NIMA- HLA mismatched group 
(n= 83) but the small cohort restricted statistical testing of this observation. 
However, the degree of antigenic resolution at HLA-A, -B and -C and allele 
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resolution at –DRB1 donor-recipient HLA matching was not significantly higher 
in the NIMA+ group compared to the NIMA- HLA mismatched group. 
This analysis considered NIMA matching at HLA-C and results showed that this 
doubled the number of chance NIMA matches, possibly because HLA-C showed 
the lowest degree of matching (66.6%) compared to the other HLA loci. The lower 
proportion of transplants mismatched at HLA-DRB1 (15.0%) and the 
identification of only one NIMA match at HLA–DRB1 further supports this 
observation. The observation that NIMA matched antigens and alleles were those 
present at higher frequencies in the donor population is not surprising given 
mathematical probabilities and is in agreement with previous reports of NIMA 
matching in CBT (Rocha, et al 2012, van Rood, et al 2009) and the results of 
chapters 3 and 4 (Powley, et al 2016). Taken together, this also helps clarify the 
concern discussed in chapter 3 that high frequency HLA antigens could be less 
likely to be informative for NIMA. It is possible that if there was a lower 
probability that high frequency antigens/alleles would be informative for NIMA 
this would be outweighed by the fact that the NIMA antigens/alleles were already 
present at a high frequency in the NHS-CBB to begin with. 
5.5.2 Analyses of clinical outcomes after NIMA+ CBT  
When the clinical outcomes of NIMA+ transplants were compared to those of 
NIMA- HLA mismatched and 8/8 HLA matched transplants, there was no 
significant difference in the primary endpoint, 5-year OS, in both univariate and 
multi-variate analyses. There was also not a significant difference in the 
probability of 5-year OS between 8/8 matched and HLA mismatched transplants, 
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despite reports to the contrary in the literature (Eapen, et al 2014). This is most 
likely to be due to the small sample size of a total 168 transplants and major 
differences in confounding variables (recipient age, diagnosis, conditioning 
regimen and TNC dose) between groups. Differences between the three 
populations in these confounding variables may have had a significant effect on 
clinical outcomes. For example, recipients of an 8/8 matched CB were 
significantly more likely to have received a unit with a TNC dose greater than 5 x 
107 per kg, which is associated with a faster time to neutrophil engraftment 
(Barker, et al 2010b). Attempts were made to adjust for confounding variables 
through multivariate analyses but this was hampered by the small sample size. 
Because NIMA matching in this cohort occurred by chance, only 16 of these were 
NIMA matched. Statistical analyses showed that to detect a difference in OS at 5% 
significance with 80% power and comparable to that previously reported in the 
literature (Rocha, et al 2012, van Rood, et al 2009), 584 HLA mismatched 
transplants would need to be analysed. At the start of this study it was reasoned 
that a larger sample size would be available because the NHS-CBB has issued over 
500 CBUs for transplantation. However, the recent development of double CBT 
and thus extension of CBT to adult HSCT candidates meant that over half of the 
CBUs were used as part of a double transplant. Very few of these double 
transplants were performed using two NHS-CBB issued CBUs and therefore 
information on the HLA type of the second CBU and the mother was not available. 
Statistical analyses were restricted to the 244 single CBTs but 39 of these did not 
have clinical outcome data and crucially five of those missing outcome data were 
NIMA matched. Of the 205 with outcome data, 168 (81%) were included in the 
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final analyses, with the remainder excluded primarily due to a lack of recipient 
HLA-C typing but also due to the unavailability of maternal and CB DNA for 
further HLA typing. 
Alternatively, the lack of association between NIMA matching and 5-year OS in 
this cohort could be due to biological reasons rather than statistical power. The 
small sample size meant that HLA match grades were grouped together as 1) 8/8, 
2) 7/8 or 6/8 and 3) 5/8 and 4/8 when performing multivariate analyses. This 
grouping was based on a previous publication by Eapen et al., who reported 
comparable probabilities of OS within these groups (Eapen, et al 2014). However, 
previous NIMA analyses have shown the probability of OS for transplants with a 
4/6 + 1 NIMA match graft is comparable to a 5/6 HLA match i.e. the NIMA+ HLA 
MM is permissible (van Rood, et al 2009). It is possible that any benefit of NIMA 
matching on 5-year OS was hidden within the HLA matching group structure in 
the multivariate analysis. Given that the analysis by van Rood et al. reported a 
stronger beneficial effect of NIMA matching in the 5/6 (single mismatch) group, 
it is possible that in this analysis the benefits of 5/6 + 1 NIMA matches were 
masked by the inclusion of 4/6 +1 NIMA matches. However, the univariate 
analysis did not show any effect of NIMA matching and that there was no 
significant difference in the degree of HLA matching between the NIMA+ and 
NIMA- HLA mismatched groups, so this seems unlikely. 
Previous studies have shown a difference in clinical outcome between different 
HLA mismatched loci in adult donor HSCT and CBT (Flomenberg, et al 2004, Lee, 
et al 2007, Petersdorf 2008). The majority of NIMA matches occurred at HLA-C 
and given the previous reports of the particularly detrimental effect of HLA-C 
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MMs compared to MMs at other HLA loci (Flomenberg, et al 2004, Petersdorf, et 
al 2014, Woolfrey, et al 2011), I sought to account for this in the survival analyses. 
However, the presence of an HLA-C MM was not associated with worse clinical 
outcome in this cohort and risk adjustment for this variable made no difference 
to the models. 
Although van Rood and colleagues did not establish the mechanism of improved 
survival after NIMA+ transplantation, the authors reasoned that the benefits 
were likely due to the faster neutrophil recovery and reduced TRM in the NIMA+ 
group (van Rood, et al 2009). In this analysis of NHS-CBB issued CBUs, NIMA 
matching was not associated with improvements in neutrophil recovery or TRM. 
It is possible that the use of CBUs with a high TNC dose (50.6% received a dose 
greater than 5.0 x 107 per kg) offset the detrimental effects of HLA mismatching 
and thus any potential benefit of NIMA matching. A higher TNC dose has 
previously been shown to improve neutrophil recovery after HLA mismatched 
CBT (Barker, et al 2010b) and because of this, it is recommended that CBUs with 
a higher TNC dose are selected when transplanting with a greater degree of 
donor-recipient HLA disparity (Hough, et al 2016). Indeed, unlike van Rood and 
colleagues, where a greater number of recipients received a low TNC dose (van 
Rood, et al 2009), Rocha et al. did not observe a significant effect of NIMA 
matching on neutrophil recovery (Rocha, et al 2012). The small sample size did 
not permit a subset analysis on the influence of NIMA matching on neutrophil 
recovery according to the TNC dose in the NHS-CBB cohort. 
This is the first retrospective analysis to include both malignant and non-
malignant disease indications when evaluating the influence of NIMA matching 
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on clinical outcomes after CBT. It is possible that a beneficial effect of NIMA 
matching was not observed in this study because there is no biological benefit to 
NIMA matching in transplants for non-malignant diseases. There is some 
evidence for a reduced relapse rate after NIMA+ CBT in recipients with malignant 
disease (van Rood, et al 2012, van Rood, et al 2009) and this could have been one 
of the reasons for the improved OS reported for NIMA matching. In non-
malignant disease, any increase in aGvHD is not offset by a GvL effect and thus a 
reduced probability of relapse that could benefit the probability of survival.  
Of some concern is the trend towards a higher risk of grade I-IV aGvHD and 
cGvHD after NIMA+ compared to NIMA- HLA mismatched transplants in the 
multivariate analysis that adjusted for the number of MMs and presence of a MM 
at HLA-C. When unrelated CBT became a clinical procedure, there was concern 
that maternal cells in CB graft might cause GvHD in the recipient. This has not 
been reported in clinical studies but recent evidence suggest maternal cells 
sensitised against the CB inherited paternal antigens could mediate a GvL effect 
if the recipient shares the CB IPA, although the authors did not report a higher 
incidence of aGvHD associated with the reduced incidence of relapse (van Rood, 
et al 2012). The trends towards a higher incidence of aGvHD after NIMA matching 
most probably reflects the inclusion of grade I aGvHD due to the small sample 
size, whereas previous studies have only included grades II-IV. It is also possible 
that due to the heterogeneous nature of the transplants analysed, there were 
some variables affecting the risk of acute and cGvHD that were not adjusted for 
in the statistical analysis.  
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This also contradicts the majority of reports from related haploidentical sibling 
HSCT, where NIMA matching was associated with a lower incidence of aGvHD 
(Ichinohe, et al 2004, van Rood, et al 2002) but is consistent with reports of a 
higher incidence of cGvHD in NIMA+ haploidentical HSCT (Kanda, et al 2009). 
However, the results of related haploidentical HSCT are not directly comparable 
to CBT due to differences in HSC source and the use of a related donor. In related 
haploidentical transplantation, the donor shares a complete HLA haplotype with 
the recipient and so HLA are matched at allelic resolution (unlike this study 
where HLA were matched at antigenic resolution for class I HLA); other HLA loci 
and non-HLA genes not included during matching are also matched. In NIMA+ 
haploidentical HSCT, each HLA MM is also NIMA match, whereas this study 
included grafts with multiple HLA MMs where only one or two were NIMA 
matched. However, there have also been some reports of sensitisation against 
NIMA and the development of severe aGvHD and a frequent occurrence of 
extensive cGvHD after NIMA+ haploidentical sibling HSCT (Kanda, et al 2009). 
Predicting whether sensitization or tolerance towards NIMA will occur remains 
a significant research question. 
It is possible the use of ATG and other in vivo T cell depleting agents also depleted 
Tregs specific for NIMA. In murine studies NIMA specific Tregs have been shown 
to be essential for tolerance towards NIMA (Andrassy, et al 2003, Matsuoka, et al 
2006, Molitor-Dart, et al 2007, Zhang and Miller 1993) and in the clinical setting 
of haploidentical sibling HSCT, the NIMA effect is especially apparent in recipients 
who were not taking cyclosporine (Burlingham, et al 1998). However, in this 
analysis there was no difference in the use of ATG between NIMA+ and NIMA- 
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HLA mismatched transplants and the trend towards a higher incidence of aGvHD 
after NIMA matching does not support this hypothesis.  
5.5.3 Conclusions 
In conclusion, this study agreed with previous reports in that 9 (8%) of 116 HLA-
mismatched transplants were NIMA matched at HLA-A, -B or -DRB1 by chance 
and also identified further chance NIMA matching at HLA-C in 9 cases (2 of which 
were also NIMA matched at HLA-B). The heterogeneous cohort of small sample 
size and low incidence of chance NIMA matching meant that the study was 
considerably underpowered to detect any differences in the clinical outcomes of 
NIMA+ transplants compared to NIMA- HLA mismatched transplants. A large, 
multicentre collaboration, most probably between Eurocord and CIBMTR (as 
done previously) that includes the more recent HLA matching criteria of allelic 
level resolution for both class I and class II is needed to explore the concept of 
NIMA matching in this setting. Furthermore, it is yet to be explored whether 
NIMA matching has an effect in the setting of double CBT. This is of particular 
interest given that the majority of NHS-CBB are now being issued as part of a 
double CBT. 
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Chapter 6 Development of a sensitive q-
PCR assay for the detection and 
quantification of maternal 
microchimaerism in cord blood 
 
Key points 
• Optimisation of a q-PCR assay targeting HLA polymorphism, with a 
sensitivity of 0.01% and in accordance with MIQE publishing guidelines 
• Microchimaerism was detected in 27% of the total 96 CB DNA tested and 
was more likely to occur in CB samples of babies born at earlier 
gestational time points. 
• Microchimaerism was significantly associated with bi-directional 
histocompatibility between the mother and foetus at HLA-A.  
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 Introduction 
The bidirectional exchange of cells at the maternal-foetal interface during 
pregnancy is a normal phenomenon that increases steadily throughout gestation, 
resulting in the presence of maternal cells in healthy, immunocompetent 
offspring (MMc) that can persist well into adult life (Drabbels, et al 2011, 
Loubiere, et al 2006). The presence and degree of MMc has been associated with 
tolerance versus sensitisation towards NIMA in the experimental and 
haploidentical HSCT clinical setting (Ichinohe, et al 2004, Matsuoka, et al 2006, 
Molitor-Dart, et al 2007) but little is known about the clinical relevance of MMc 
in unrelated CBT. Since MMc does not seem to occur in all pregnancies, there are 
likely to be genetic, cellular and/or molecular determinants that control cell 
migration across the placenta and/or the survival of microchimaeric cells in the 
host (Mold, et al 2008). 
When CB was first used as a graft source in HSCT, there was a concern that the 
infusion of maternal cells with the CB graft into the recipient could mediate 
aGvHD (van Rood, et al 2012). The mother of the CB could have been sensitised 
to foetal IPAs during pregnancy and because donors and recipients are HLA 
matched in CBT, these same HLA antigens are likely to also be expressed in the 
recipient. Secondary exposure of maternal cells to these IPAs when infused into 
the recipient could therefore have the potential to elicit a potent immune 
response. Clinical outcomes however, demonstrated that CB was actually 
associated with a lower incidence and severity of aGvHD compared to adult graft 
sources and these concerns were largely forgotten without any attempt to 
correlate the presence MMc of in the graft with clinical outcomes after 
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transplantation (Eapen, et al 2011c, Eapen, et al 2010, Eapen, et al 2007, Rocha, 
et al 2009). More recently, the observation that in haploidentical HSCT, maternal 
grafts were associated with lower relapse rates compared to paternal grafts 
(Stern, et al 2008), led van Rood to hypothesise that MMc present in CB grafts 
could mediate a GvL effect and also possibly, a GvHD response in recipients (van 
Rood, et al 2012). Acute myeloid leukaemia patients who shared one or more 
HLA-A, -B, or -DRB1 antigens with their CB donor's IPAs had a decreased 
incidence of relapse compared to patients that received a non-shared IPA 
transplant (van Rood, et al 2012). Importantly, the anti-leukemic effect of shared 
IPA transplants was not associated with an increased incidence of aGvHD. This 
evidence that maternal cells mediate an anti-leukemic effect in CBT was however, 
indirect and it was assumed that CB grafts were positive for MMc. The cells 
involved and their mechanism(s) of action also remain unknown.  
The availability of sensitive methods to detect microchimaerism is critical to 
investigating its clinical relevance. Historical methods of detection include short 
tandem repeats, fluorescence in situ hybridisation and SSP but the limited 
sensitivity (1 – 5%) of these methods may have underestimated the presence of 
chimaerism and more recently, sensitive molecular methods such as q-PCR that 
target HLA or insertion deletion polymorphisms have been developed (Alizadeh, 
et al 2002, Berry, et al 2004, Eikmans, et al 2014, Lambert, et al 2004, Scaradavou, 
et al 1996). A study quantifying MMc, using sensitive methods, in clinical grade 
CBUs that have been transplanted would therefore be a valuable tool and would 
permit, for the first time, a direct analysis of the influence of MMc in the CB graft 
on recipient clinical outcomes after transplantation in future work.  
Chapter 6 
L. Powley (2017)   -189- 
 Aims 
The aim of this chapter was to develop a sensitive q-PCR assay for the detection 
and quantification of MMc in CB, to determine the levels of MMc in transplanted 
CBUs and to investigate variables associated with its presence and/or absence 
(Figure 6.1). This required the optimisation and validation of a q-PCR assay that 
targeted HLA polymorphisms according to the Minimum Information for 
Publication of Quantitative Real-Time PCR Experiments (MIQE) Guidelines as 
closely as possible (Bustin, et al 2009).  
The optimised q-PCR assay was used to answer the first question: what 
proportion of transplanted CBUs tested positive for MMc? Statistical analyses 
were then performed to answer the second question: what variables are 
associated with the presence of MMc?   
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Figure 6.1 Aims of this research chapter and the questions proposed to 
address this aim 
 
 
  
Aim: to develop a sensitive 
q-PCR assay for the 
detection and 
quantification of MMc in 
CB, to determine the levels 
of MMc in transplanted 
CBUs and to investigate 
variables associated with 
its presence and/or 
absence. 
Optimise and 
validate a 
sensitive q-PCR 
assay targeting 
NIMA HLA for the 
quantification of 
MMc in CB DNA  
What proportion 
of transplanted 
CBUs tested 
positive for MMc?  
Which variables 
are associated 
with the presence 
of MMc?  
• Reaction conditions 
• Specificity 
• Assay performance: 
efficiency, sensitivity, 
precision 
• Maternal-foetal 
histocompatibility 
• Maternal 
demographics 
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 Optimisation of HLA-specific q-PCR assays and 
characterisation of assay performance 
q-PCR assays targeting NIMA HLA were optimised and used to test for and 
quantify MMc in the CB. Theoretical aspects of the assay are described in M&M 
section 2.7 but in brief, standard curves were used to quantify the amount of 
target in unknown samples and this was normalised against the total DNA of the 
sample, quantified by an endogenous control, HCK (also quantified in each 
unknown sample by a standard curve). Initial q-PCR reactions of artificial spiking 
experiments were set up to test the protocol, optimise the conditions and 
characterise the assay performance by following the MIQE guidelines as closely 
as possible (Bustin, et al 2009). 
6.3.1 HLA targets, primer sequences and specificity 
Eleven HLA targets: HLA-A*01, -A*02, -A*11, -A*24, -A*24/A*25, -A*30, -A*33, -
B*08, -B*27, -B*35 and -DRB1*03, were chosen based on the previously reported 
sensitivities of the assays (Drabbels, et al 2011, Eikmans, et al 2014). Forward 
and reverse primer sequences for each of the HLA targets were available from 
Michael Eikmans and colleagues and are given in Table 6.1 (Drabbels, et al 2011, 
Eikmans, et al 2014).  
Primer specificity was tested by setting up q-PCR reactions using DNA samples 
positive for the target of interest. Male platelet donors were chosen because of 
the availability of excess blood for multiple DNA extractions. A dissociation curve 
was run post-amplification, which provides information on the amplicon melting 
temperature (Tm). A single narrow peak was present for all expected positive 
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reactions. Representative examples for each target of interest are shown in 
Figure 6.2. In addition, non-template (water) controls were also run for each 
primer pair and all showed a negative reaction pattern in the dissociation curve. 
No further optimisation of the thermal cycling parameters was necessary.  
Table 6.1 q-PCR HLA-specific primer sequences and amplicon length 
(Drabbels, et al 2011, Eikmans, et al 2014). 
Target  Primer sequence (3’ – 5’) Amplicon length (bp) 
HLA-A    
A*01 F GGTTCTCACACCATCCAGATA 205 
 R CTCTCTGCTGCTCCGCCG  
A*02 F TCCTCGTCCCCAGGCTCT 205 
 R CCCGTCCCAATACTCCGGA  
A*11 F CTTCCTCCGCGGGTACCG 165 
 R CCCTCCAGGTAGGCTCTCT  
A*24 F AAGGATTACATCGCCCTGAAA 125 
 R CCCTCCAGGTAGGCTCTCT  
A*24/A*25 F CCACTCCATGAGGTATTTCTC 200 
 R TTCACTTTCCCTGTCTCCTC  
A*30 F GTGTCCCGGCCCGGCAGT 155 
 R GGTCCCAATACTCAGGCCT  
A*33 F CCACTCCATGAGGTATTTCAC 200 
 R GCCTTCACATTCCGTGTGTT  
HLA-B    
B*08 F CGTGTGGCGGAGCAGGAC 105 
 R CCGCGCGCTCCAGCGTG  
B*27 F CGCCGCGAGTCCGAGAGA 135 
 R GGAGCAGGGTCCGCAGGTC  
B*35 F GACCGGAACACACAGATCTT 85 
 R GCTCTGGTTGTAGTAGCCGC  
HLA-DRB1    
DRB1*03 F TACTTCCATAACCAGGAGGAGA 150 
 R TGCAGTAGTTGTCCACCCG  
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Figure 6.2 HLA-specific q-PCR amplicon dissociation curves. (A) A*01, (B) 
A*02, (C) A*11, (D) A*24, (E) A24/A*25, (F) A*30, (G) A*33, (H) B*08, (I) B*27, 
(J) B*35 and (K) DRB1*03. Q-PCR reactions were set up using male platelet 
donor DNA positive for the target of interest. Amplicons were continuously 
heated from 55⁰C - 95⁰C and temperature (⁰C) was plotted against the 
derivative Reporter (-Rn') to determine the amplicon melting temperature (Tm). 
(A) A*01   (B) A*02   (C) A*11 
 
(D) A*24   (E) A*24/A*25  (F) A*30 
 
(G) A*33   (H) B*08   (I) B*27 
 
(J) B*35   (K) DRB1*03    
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In silico HLA primer specificity testing was previously done by blasting the primer 
sequences on DNA templates for the target genes using the NCBI’s Primer-BLAST 
online tool by colleagues in the Netherlands. Sequence homology between some 
HLA genes meant some primers showed in silico predicted cross-reactivity with 
other allele groups. Primer specificity was therefore further tested by setting up 
q-PCR reactions using a panel of samples both positive and negative for the target 
of interest (see M&M section 2.7). 
Cross reactivity was defined as the presence of a Tm that fell within the range of 
the target of interest. The Tm of positive reactions and the cross-reactive alleles 
identified for each HLA primer pair, together with the in silico predicted cross-
reactivity, are given in Table 6.2. Primers targeting HLA-A*01, -A*11, -B*08 and -
B*35 were predicted to be cross-reactive and this was confirmed in vitro using 
the donor panel. No additional cross-reactivities or false positives were identified 
from in vitro testing. For all future experiments, primers that showed cross-
reactivity were only used if the CB, or the male platelet donors used for standard 
curve generation, had no source of the cross-reactive allele.  
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Table 6.2 HLA q-PCR primer specificity. In silico primer specificity was 
evaluated by blasting the primer sequences on DNA templates for the target 
genes using the NCBI’s Primer-BLAST online tool by colleagues in the 
Netherlands. Primer specificity was tested in vitro by setting up q-PCR reactions 
against a panel of HLA typed male platelet donors positive or negative for the 
target of interest. Melting temperature (Tm) is shown as the mean + standard 
deviation for the expected positive reactions. 
Target Mean Tm (oC) 
Cross reactivity 
In silico q-PCR 
HLA-A    
A*01 90.80 + 0.10 A*11, A*36 A*11 
A*02 91.87 + 0.10 - - 
A*11 89.82 + 0.06 A*02, A*24 A*02, A*24 
A*24 88.95 + 0.04 - - 
A*24/A*25 91.93 + 0.07 - - 
A*30 90.87 + 0.11 - - 
A*33 92.27 + 0.06 - - 
HLA-B    
B*08 87.36 + 0.08 B*41, B*42 B*41, B*42 
B*27 88.55 + 0.08 - - 
B*35 82.73 + 0.10 B*08, B*78 B*08 
HLA-DRB1    
DRB1*03 89.10 + 0.12 - - 
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6.3.2 HLA primer concentration 
The next step of the optimisation process was the selection of the appropriate 
primer concentration based on the efficiencies of the q-PCR reactions. Standard 
curves were generated from serial dilutions created from artificial spiking 
experiments, as described in M&M section 2.7.  
HLA standard curves were tested at a 4.5 pmol, 3.0 pmol and 1.5 pmol of forward 
and reverse primer per reaction as a minimum and additional concentrations 
were tested if necessary. The amplification efficiencies and standard curve 
parameters for each primer pair concentration tested for each HLA target are 
shown in Table 6.3. Primer concentration that gave an efficiency between 90 and 
110% were selected as the optimum concentrations for future experiments. 
These were as follows: A*01, 3.0 pmol; A*02, 1.5 pmol; A*11, 3.0 pmol; A*24, 4.5 
pmol; A*24/A*25, 2.25 pmol; A*30, 1.5 pmol; A*33, 3.0 pmol; B*08, 2.25 pmol; 
B*27, 4.5 pmol; B*35, 1.5 pmol, DRB1*03, 3.0 pmol.  
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Table 6.3 Amplification efficiencies from q-PCR standard curves set-up 
using a variable primer concentration. Standard curves were produced from 
artificial spiking experiments whereby DNA positive for the HLA target of 
interest was diluted in DNA negative for the target. Serial 1:10 dilutions over 
five logs (100%, 10%, 1%, 0.1% and 0.01%) were pipetted from a starting 
quantity of 200ng and an additional 0.05% dilution was also included. q-PCR 
reactions for each dilution and target were set up in duplicate containing a 
variable amount of forward and reverse HLA primer. Red indicates 
amplification efficiency closest to 100% and thus the optimal primer 
concentration selected for future experiments. 
Target 
Amplification efficiency (%) at each primer concentration tested 
4.5 pmol 3.0 pmol 2.25 pmol 1.5 pmol 
HLA-A     
A*01 89 90 - 76 
A*02 83 95 - 98 
A*11 95 97 - 92 
A*24 98 122 - 162 
A*24/A*25 100 103 98 95 
A*30 104 91 - 94 
A*33 95 96 - 95 
HLA-B     
B*08 110 99 96 147 
B*27 94 87 - 80 
B*35 111 112 - 104 
HLA-DRB1     
DRB1*03 98 96 - 106 
 
6.3.3 HLA assay performance 
The sensitivities of the q-PCR assays were determined from the linear dynamic 
range (LDR) and the lowest dilution whereby four out of five replicates of 
expected positives were detected as positive in the q-PCR reaction. A standard 
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curve using artificial chimeric mixes of 100%, 10%, 1%, 0.1%, 0.05%, 0.01%, 
0.005% was set up for each target. The sensitivity of each assay are given in Table 
6.4. Each HLA specific q-PCR assay had a sensitivity of LDR of 0.01% and at least 
4 of the 5 replicates were positive in the q-PCR reaction. 
Table 6.4 Linear dynamic range (LDR) and number of positive replicates 
for q-PCR standard curves assays. Standard curves were produced from 
artificial spiking experiments whereby DNA positive for the HLA target of 
interest was diluted in DNA negative for the target. Serial dilutions (10%, 1%, 
0.1%, 0.05%, 0.01% and 0.005%) were pipetted from a starting quantity of 
200ng. q-PCR reactions for each dilution and target were set up with five 
replicates. LDR was the last point where the curve maintained linearity, defined 
as a coefficient of determination (R2) > 0.99. 
Target LDR (%) 
Positive 
replicates 
HLA-A   
A*01 0.01 5/5 
A*02 0.01 5/5 
A*11 0.01 4/5 
A*24 0.01 4/5 
A*24/A*25 0.01 5/5 
A*30 0.01 4/5 
A*33 0.01 4/5 
HLA-B   
B*08 0.01 4/5 
B*27 0.01 5/5 
B*35 0.01 5/5 
HLA-DRB1   
DRB1*03 0.01 5/5 
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Intra-assay precision was evaluated from the standard curve correlation and 
standard deviation of replicates. Representative amplification plots and standard 
curves of triplicate 1:10 serial dilutions over five logs for each HLA specific q-PCR 
assay are shown in Figure 6.3 and Figure 6.4 respectively. The mean Cq values 
and standard deviations for each standard curve are shown in Table 6.5 and the 
standard curve properties are given in Table 6.6. Each standard curve showed 
excellent intra-assay precision. All standard curves showed an R2 > 0.99 and the 
standard deviation of individual replicates for each experiment were within the 
acceptable range. 
Chapter 6 
L. Powley (2017)   -200- 
Figure 6.3 Representative HLA q-PCR amplification plots for standard curves. (A) A*01, (B) A*02, (C) A*11, (D) A*24, (E) 
A*25/A*24, (F) A*30, (G) A*33, (H) B*08, (I) B*27, (J) B*35 and (K) DRB1*03. Standard curves were produced from artificial spiking 
experiments whereby DNA positive for the HLA target of interest was diluted in DNA negative for the target. Serial 1:10 dilutions over 
five logs (100%, 10%, 1%, 0.1% and 0.01%) were pipetted from a starting quantity of 200ng and set up in triplicate. 
(A) A*01    (B) A*02     (C) A*11    (D) A*24 
       
(E) A*24/A*25   (F) A*30     (G) A*33    (H) B*08 
      
(I) B*27    (J) B*35     (K) DRB1*03 
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Figure 6.4 Representative HLA q-PCR standard curves. (A) A*01, (B) A*02, 
(C) A*11, (D) A*24, (E) A*24/A*25, (F) A*30, (G) A*33, (H) B*08, (I) B*27, (J) 
B*35 and (K) DRB1*03. Standard curves were produced from artificial spiking 
experiments whereby DNA positive for the HLA target of interest was diluted in 
DNA negative for the target. Serial 1:10 dilutions over five logs (100%, 10%, 1%, 
0.1% and 0.01%) were pipetted from a starting quantity of 200ng and an 
additional 0.05% dilution was also included. q-PCR reactions for each dilution 
and target were set up in triplicate.  
(A) A*01     (B) A*02     
   
(C) A*11     (D) A*24 
   
(E) A*24/A*25    (F) A*30 
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Figure 6.4 continued 
(G) A*33     (H) B*08   
  
(I) B*27     (J) B*35 
  
(K) DRB1*03      
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Table 6.5 HLA q-PCR quantitation cycle (Cq) results for representative standard curves. Standard curves were produced from 
artificial spiking experiments whereby DNA positive for the HLA target of interest was diluted in DNA negative for the target. Serial 1:10 
dilutions over five logs (100%, 10%, 1%, 0.1% and 0.01%) were pipetted from a starting quantity of 200ng and an additional 0.05% 
dilution was also included. q-PCR reactions for each dilution and target were set up in triplicate. Cq values are shown as the mean ± 
standard deviation (S.D.) for three replicates. 
Target 
Mean Cq ± S.D. for each target quantity 
1 0.1 0.01 0.001 0.0005 0.0001 
HLA-A             
A*01 21.831 ± 0.276 24.712 ± 0.188 28.232 ± 0.248 32.092 ± 0.265 32.862 ± 0.333 36.033 ± 0.538 
A*02 18.777 ± 0.120 22.071 ± 0.163 25.441 ± 0.148 29.395 ± 0.397 30.506 ± 0.296 32.373 ± 0.817 
A*11 21.179 ± 0.102 24.622 ± 0.023 27.937 ± 0.171 31.837 ± 0.640 32.753 ± 0.420 34.998 ± 0.948 
A*24 21.523 ± 0.036 24.365 ± 0.068 27.643 ± 0.097 31.128 ± 0.520 32.060 ± 0.298 35.034 ± 0.929 
A*24/A*25 20.758 ± 0.086 24.652 ± 0.065 28.063 ± 0.208 31.385 ± 0.193 32.296 ± 0.361 34.067 ± 0.187 
A*30 20.240 ± 0.143 22.876 ± 0.071 26.299 ± 0.097 29.492 ± 0.140 30.751 ± 0.312 33.183 ± 0.419 
A*33 21.024 ± 0.099 24.347 ± 0.023 27.709 ± 0.059 31.347 ± 0.093 32.186 ± 0.171 34.912 ± 0.516 
HLA-B             
B*08 18.938 ± 0.043 21.521 ± 0.223 24.672 ± 0.161 27.937 ± 0.269 29.175 ± 0.475 31.691 ± 0.826 
B*27 21.586 ± 0.036 24.861 ± 0.037 28.152 ± 0.170 32.172 ± 0.861 32.588 ± 0.340 35.540 ± 0.998 
B*35 21.703 ± 0.042 25.505 ± 0.226 28.402 ± 0.021 31.249 ± 0.174 32.185 ± 0.293 35.259 ± 1.148 
HLA-DRB1             
DRB1*03 21.354 ± 0.115 24.323 ± 0.092 27.716 ± 0.043 31.074 ± 0.073 32.053 ± 0.126 34.691 ± 0.373 
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Table 6.6 Representative HLA q-PCR standard curves properties. Standard 
curves were produced from artificial spiking experiments whereby DNA 
positive for the HLA target of interest was diluted in DNA negative for the target. 
Serial 1:10 dilutions over five logs (100%, 10%, 1%, 0.1% and 0.01%) were 
pipetted from a starting quantity of 200ng and an additional 0.05% dilution was 
also included. q-PCR reactions for each dilution and target were set up in 
triplicate. 
Target Slope Intercept R2 
HLA-A    
A*01 -3.643 21.132 0.993 
A*02 -3.484 18.690 0.994 
A*11 -3.495 21.140 0.992 
A*24 -3.352 21.194 0.990 
A*24/A*25 -3.352 21.108 0.995 
A*30 -3.365 20.497 0.998 
A*33 -3.424 21.414 0.997 
HLA-B    
B*08 -3.199 18.564 0.990 
B*27 -3.478 21.439 0.991 
B*35 -3.184 20.495 0.999 
HLA-DRB1    
DRB1*03 -3.330 21.153 0.998 
 
6.3.4 HCK optimisation and assay performance 
HCK was chosen as the endogenous control for calculating the total starting 
template present in a reaction. The HCK primers were shown to be specific for 
HCK in vitro (Figure 6.5A). HCK was optimised to a primer-limiting 
concentration and after a trial of 4 pmol (E = 119%), 2 pmol (E = 116%), 1 pmol 
(E = 97%) and 0.5 pmol (E = 70%) of each primer per reaction, 1 pmol was 
selected for all future experiments. At this concentration, amplification was 
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exponential (Figure 6.5B-C) with excellent intra-assay precision (Table 6.7). 
The standard curve properties were as follows: slope, -3.378; intercept, 23.209 
and R2 > 0.990. 
 
Figure 6.5 Representative HCK q-PCR A) dissociation curve, B) 
amplification plot and c) standard curve. Standard curves were produced 
from artificial spiking experiments whereby DNA positive for the HLA target of 
interest was diluted in DNA negative for the target. Male donors were serially 
diluted six times by 1:2 in H2O from a starting quantity of 250 ng and q-PCR 
reactions were set up in duplicate for each dilution.   
(A)       
 
(B)      (C) 
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Table 6.7 HCK q-PCR quantitation cycle (Cq) results for the representative 
standard curve. Standard curves were produced from artificial spiking 
experiments whereby DNA positive for the HLA target of interest was diluted in 
DNA negative for the target. Male donors positive were serially diluted six times 
by 1:2 in H2O from a starting quantity of 250 ng and q-PCR reactions were set 
up in duplicate for each dilution. Cq values are shown as the mean ± standard 
deviation (S.D.).  
Quantity Mean Cq ± S.D. 
1 22.644 ± 0.010 
0.5 23.152 ± 0.176 
0.25 24.124 ± 0.035 
0.125 25.264 ± 0.037 
0.0625 26.283 ± 0.014 
0.03125 27.515 ± 0.022 
 
 MMc in clinical grade CB samples 
6.4.1 Detection and quantification of MMc in CB by q-PCR 
The optimised HLA specific q-PCR assays were used to test for the presence of 
MMc in a cohort of clinical grade CBUs. MMc was detected by testing for the 
presence of NIMA DNA in the CB DNA. The first step was to evaluate mothers for 
the presence of one or more HLA alleles with a primer available for targeting. 
There were 175 CB-maternal pairs evaluated and nine mothers did not possess 
one or more of the HLA targets with primers available. The HLA types of the 
remaining 166 CB and mothers were compared to identify the NIMA. The 
maternal HLA allele was either not the CB NIMA (i.e. it was the IMA), or it was not 
possible to identify whether it was the NIMA (i.e. non-informative due to 
maternal homozygosity or 0 MM to the CB), in a further 70 cases and these were 
therefore unable to be evaluated for the presence of MMc. The frequency of 
maternal HLA alleles for each of the q-PCR targets and how often these were the 
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IMA, NIMA or non-informative are shown in Table 6.8. Of the targets evaluated, 
maternal HLA-A*01 and -A*02 were most often non-informative for NIMA (23% 
and 28%, respectively). There were 96 CB samples with an informative NIMA 
HLA that was available as a q-PCR assay target and these were tested for MMc 
using the HLA specific q-PCR assay.  
Samples were tested for MMc by targeting the NIMA at HLA-A (n= 69), -B (n= 23) 
or –DRB1 (n= 4) (Table 6.8). Twenty-seven percent (n= 26) were positive for 
MMc and 73% (n= 70) were negative for MMc. In those testing positive, the 
proportion of maternal DNA in the CBU varied from 0.01% to 2.3% and the 
median quantity of those positive was 0.05% (Figure 6.6).  
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Table 6.8 Informativity of maternal HLA alleles for NIMA and the incidence 
of MMc above 0.01% in CB. A total of 175 CB-maternal pairs were evaluated 
for the presence of an allele that was informative NIMA for which a q-PCR assay 
was available. MMc was quantified in 96/175 CB samples by a q-PCR absolute 
quantification method that calculates the quantity of NIMA HLA template from 
the quantity of the reference, HCK and to a sensitivity of 0.01%. 
Target Mother 
IMA/IPA MMc 
Non-
informative 
IMA NIMA 
Total 
tested 
Negative Positive 
A*01 66 15 (23) 25 (38) 26 (39) 14 12 (86) 2 (14) 
A*02 74 21 (28) 29 (39) 24 (32) 22 19 (86) 3 (14) 
A*11 28 4 (14) 7 (25) 17 (61) 12 5 (42) 7 (58) 
A*23 5 0 (0) 1 (20) 4 (80) 2 2 (100) 0 (0) 
A*24 28 3 (11) 16 (57) 9 (32) 9 6 (33) 3 (66) 
A*25 5 0 (0) 4 (80) 1 (20) 0 - - 
A*30 12 2 (17) 3 (25) 7 (58) 7 7 (100) 0 (0) 
A*33 11 2 (18) 6 (55) 3 (27) 3 3 (100) 0 (0) 
B*08 44 3 (7) 20 (45) 21 (48) 12 5 (42) 7 (58) 
B*27 10 0 (0) 4 (40) 6 (60) 3 3 (100) 0 (0) 
B*35 29 6 (21) 12 (41) 11 (38) 8 4 (50) 4 (50) 
DRB1*03 53 9 (17) 19 (36) 25 (47) 4 4 (100) 0 (0) 
Total - - - - 96 70 (73) 26 (27) 
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Figure 6.6 Quantity of MMc in CB. MMc was quantified in 96 CB samples using 
a q-PCR absolute quantification method that calculates the quantity of NIMA 
HLA template from the quantity of the reference, HCK and to a sensitivity of 
0.01%. The means of triplicate HLA and duplicate HCK q-PCR were used to 
determine the proportion of MMc in the samples. 
 
6.4.2 Characteristics of CBUs and mothers 
The main characteristics of the CBU and maternal pairs included in the study are 
given in Table 6.9. Demographics were not available for all those tested. In those 
where data was available, the median age of mothers was 31, the majority 
entered labour naturally (n= 21, 88%) and experienced vaginal delivery as 
opposed to a caesarean section (n= 36, 77%). The median year of birth was 2001, 
the majority of new-borns were Caucasian (n= 55, 65%) and the majority were 
delivered at 39 weeks or later (n= 58, 81%). No significant differences in 
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maternal and new-born characteristics were identified between the CBUs 
positive or negative for MMc, except gestational age. A smaller proportion of new-
borns were delivered before 39 weeks in the MMc negative group (n= 7, 13%) 
compared to the positive group (n= 7, 35%; p= 0.03).   
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Table 6.9 Characteristics of mothers and their CBUs. Percentages are given in 
parenthesis. 
 Total 
MMc  
Positive Negative P 
Mother     
Age (years) (n= 40)    0.70 
Mean 31 30 31  
Range 19 - 42 25 – 37 19 - 42  
Gravida (n= 13)    0.07 
Primi 5 (38) 1 (50) 4 (36)  
Multi 8 (62) 1 (50) 7 (64)  
Induction (n= 24)    0.48 
No 21 (88) 3 (100) 18 (86)  
Yes 3 (12) 0 (0) 3 (14)  
Method of delivery (n= 47)    0.73 
Vaginal 36 (77) 8 (73) 28 (78)  
Caesarean section 11 (23) 3 (27) 8 (22)  
New-born     
Year of birth (n= 96)    0.99 
Median 2001 2001 2001  
Range 1996 - 2012 1996 - 2009 1996 - 2012  
Gender (n= 96)    0.83 
Male 50 (52) 14 (54) 36 (51)  
Female 46 (48) 12 (46) 34 (49)  
Ethnicity (n= 85)    0.25 
Caucasian 55 (65) 17 (71) 38 (62)  
Asian 17 (20) 6 (25) 11 (18)  
Black 5 (6) 0 (0) 5 (8)  
Mixed 8 (9) 1 (4) 7 (11)  
Gestational age (n= 72)    0.03 
Pre- and early-term (<38 weeks) 14 (19) 7 (35) 7 (13)  
Term or longer (>39 weeks) 58 (81) 13 (65) 45 (87)  
Total nucleated cell count (x107) (n= 91)   0.21 
Average 189 168 189  
Range 48 - 589 57 - 303 48 - 589  
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6.4.3 Association of MMc with maternal-foetal HLA allele frequencies and 
histocompatibility 
The HLA-A, -B, -C and -DRB1 IMA, IPA and NIMA allele frequencies of maternal-
foetal pairs positive or negative for MMc were compared. HLA-A NIMA allele 
frequencies significantly differed between MMc positive and MMc negative 
groups (p= 0.033) and comparison of column proportions revealed this 
difference was due to a higher frequency of NIMA HLA-A*11 in the MMc positive 
group. However, significant differences in HLA-A frequencies between the groups 
were not observed for the CBU IMA (p= 0.598) or IPA alleles (p= 0.744). Maternal-
foetal pairs positive or negative for MMc showed comparable HLA allele 
frequencies at HLA-B (NIMA: p= 0.499, IMA: p= 0.971, IPA: p= 0.294), -C (NIMA: 
p= 0.722, IMA: p= 0.920, IPA: p= 0.839) and -DRB1 (NIMA: p= 0.393, IMA: p= 
0.836, IPA: p= 0.265).  
Table 6.10 HLA-A, -B, -C and -DRB1 IMA and IPA and NIMA allele 
frequencies of maternal-foetal pairs positive or negative for MMc 
 NIMA IMA IPA 
  
MMc 
neg 
MMc 
pos 
Total 
MMc 
neg 
MMc 
pos 
Total 
MMc 
neg 
MMc 
pos 
Total 
HLA-A                   
A*01 27 21 25 14 26 17 19 26 20 
A*02 30 16 27 22 16 20 13 32 17 
A*03 2 11 4 16 11 14 19 5 16 
A*11 8 37 14 6 0 5 8 5 7 
A*23 3 0 2 0 5 1 2 0 1 
A*24 9 16 11 11 11 11 6 11 7 
A*25 0 0 0 2 5 2 2 0 1 
A*26 0 0 0 5 5 5 5 5 5 
A*29 2 0 1 6 5 6 2 0 1 
A*30 11 0 8 5 0 4 3 0 2 
A*31 3 0 2 5 0 4 2 0 1 
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 NIMA IMA IPA 
  
MMc 
neg 
MMc 
pos 
Total 
MMc 
neg 
MMc 
pos 
Total 
MMc 
neg 
MMc 
pos 
Total 
A*32 2 0 1 2 0 1 3 0 2 
A*33 5 0 4 2 5 2 8 5 7 
A*68 0 0 0 5 11 6 11 11 11 
A*74 0 0 0 2 0 1 0 0 0 
HLA-B                   
B*07 9 0 7 11 13 11 15 8 13 
B*08 18 33 22 11 13 11 9 8 9 
B*13 3 4 3 2 4 2 0 4 1 
B*14 0 4 1 3 0 2 6 0 4 
B*15 5 8 6 8 13 9 11 8 10 
B*18 5 0 3 3 8 4 5 0 3 
B*27 9 0 7 3 0 2 5 8 6 
B*35 11 13 11 11 8 10 5 4 4 
B*37 2 0 1 0 0 0 0 4 1 
B*38 0 0 0 3 4 3 3 4 3 
B*39 0 0 0 3 0 2 0 0 0 
B*40 5 13 7 8 8 8 9 4 8 
B*41 0 0 0 2 0 1 0 0 0 
B*42 0 0 0 0 0 0 2 0 1 
B*44 8 13 9 18 25 20 12 8 11 
B*45 2 0 1 2 0 1 0 0 0 
B*48 3 0 2 0 0 0 0 0 0 
B*49 2 0 1 0 0 0 2 8 3 
B*50 2 0 1 0 0 0 0 4 1 
B*51 5 4 4 5 0 3 0 4 1 
B*52 2 0 1 3 0 2 5 8 6 
B*53 2 0 1 2 0 1 5 0 3 
B*55 2 0 1 5 0 3 0 4 1 
B*56 0 4 1 0 0 0 2 0 1 
B*57 6 4 6 2 4 2 5 4 4 
B*58 5 0 3 0 0 0 3 4 3 
HLA-C                   
C*01 2 6 3 5 6 5 2 6 3 
C*02 5 0 3 2 0 2 5 0 3 
C*03 17 6 14 17 6 14 15 12 14 
C*04 20 18 19 10 6 9 15 6 12 
C*05 7 6 7 12 6 10 15 6 12 
C*06 12 0 9 2 12 5 2 18 7 
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 NIMA IMA IPA 
  
MMc 
neg 
MMc 
pos 
Total 
MMc 
neg 
MMc 
pos 
Total 
MMc 
neg 
MMc 
pos 
Total 
C*07 22 41 28 24 29 26 17 24 19 
C*08 5 6 5 2 0 2 7 6 7 
C*12 2 6 3 10 18 12 10 12 10 
C*14 2 6 3 0 0 0 0 0 0 
C*15 2 6 3 5 6 5 5 6 5 
C*16 2 0 2 10 12 10 5 6 5 
C*17 0 0 0 0 0 0 2 0 2 
HLA-DRB1 
  
  
              
DRB1*01 11 9 11 5 13 7 8 9 8 
DRB1*03 31 35 32 13 9 12 15 4 12 
DRB1*04 15 13 14 20 13 18 13 17 14 
DRB1*07 13 9 12 16 26 19 8 22 12 
DRB1*08 0 0 0 5 0 4 8 0 6 
DRB1*09 0 4 1 2 0 1 2 0 1 
DRB1*10 0 0 0 3 0 2 0 0 0 
DRB1*11 7 9 7 7 4 6 11 13 12 
DRB1*12 3 0 2 3 4 4 3 0 2 
DRB1*13 7 13 8 7 4 6 13 4 11 
DRB1*14 2 9 4 3 0 2 2 13 5 
DRB1*15 11 0 8 15 17 15 16 17 17 
DRB1*16 0 0 0 2 9 4 0 0 0 
 
It was reasoned that maternal-foetal compatibility could be an important factor 
in MMc and this relationship was investigated. The mother was deemed 
compatible from the perspective of the foetus (HvG direction) if none of the 
maternal alleles differed in the foetus (the mother was homozygous or a 0 MM to 
the foetus). The foetus was deemed compatible from the perspective of the 
mother (GvH direction) if none of the foetal alleles different in the mother (the 
foetus was homozygous or a 0 MM to the mother). Results are shown in Table 
6.11. Maternal compatibility from the foetal perspective at HLA-A (p= 0.096), -B 
(p= 0.970), -C (p= 0.610) or -DRB1 (p= 0.176) was not significantly associated 
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with MMc. Similarly, foetal compatibility from the maternal perspective at HLA-A 
(p= 0.091), -B (p= 0.957), -C (p= 0.783) or -DRB1 (p= 0.982) was not significantly 
associated with MMc.  
At the maternal-foetal interface, there is a two-way interaction between the 
mother and foetus without mutual rejection. Bidirectional compatibility, defined 
as dual compatibility from each other’s perspective (by only including 0 MM 
between the mother and foetus) was therefore also evaluated for an association 
with MMc. Bidirectional compatibility at HLA-B, -C and -DRB1 had no effect on the 
incidence of MMc. Intriguingly, however, bidirectional compatibility at HLA-A 
was significantly associated with an increased incidence of MMc (OR, 3.900; 95% 
CI, 1.075 - 14.144; p= 0.029).  
Table 6.11 CBU-maternal HLA compatibility for those positive and 
negative for MMc. Percentages are given in parenthesis. 
 Number (%) Statistics 
 Positive Negative Total OR (95% CI) P 
Mother compatible from foetus’ perspective   
HLA-A 6/26 (23.1) 7/70 (10.0) 13/96 (13.5) 2.700 (0.813 - 8.972) 0.096 
HLA-B 2/26 (7.7) 5/67 (7.5) 7/93 (7.5) 1.033 (0.188 - 5.691) 0.970 
HLA-C 6/19 (31.6) 13/51 (25.5) 19/70 (27.1) 1.349 (0.425 - 4.279) 0.610 
HLA-DRB1 3/26 (11.5) 19/70 (27.1) 22/96 (22.9) 0.350 (0.094 - 1.302) 0.106 
Foetus compatible from mother’s perspective   
HLA-A 10/26 (38.5) 15/70 (21.4) 25/96 (26.0) 2.292 (0.865 - 6.074) 0.091 
HLA-B 3/26 (11.5) 8/67 (11.9) 11/93 (11.8) 0.962 (0.234 - 3.947) 0.957 
HLA-C 7/19 (36.8) 17/51 (33.3) 24/70 (34.3) 1.167 (0.389 - 3.501) 0.783 
HLA-DRB1 6/26 (23.1) 16/70 (22.9) 22/96 (22.9) 1.013 (0.348 - 2.950) 0.982 
Bidirectional compatibility between foetus and mother  
HLA-A 6/26 (23.1) 5/70 (7.1) 11/96 (11.6) 3.900 (1.075 - 14.144) 0.029 
HLA-B 1/26 (3.8) 1/67 (1.5) 2/93 (2.2) 2.640 (0.159 - 43.840) 0.483 
HLA-C 2/19 (10.5) 9/51 (17.6) 11/70 (15.7) 0.559 (0.107 - 2.809) 0.467 
HLA-DRB1 3/26 (11.5) 8/70 (11.4) 11/96 (11.5) 1.011 (0.247 - 4.143) 0.988 
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 Discussion 
The aim of this chapter was to develop a sensitive q-PCR assay for the detection 
and quantification of MMc in CB, to determine the levels of MMc in transplanted 
CBUs and to investigate variables associated with its presence. This is a valuable 
tool that will enable a direct analysis of the influence of MMc in the CB graft on 
recipient clinical outcomes after transplantation in future work.  
6.5.1 Successful development of a sensitive q-PCR assay that targets HLA 
polymorphisms according to MIQE Guidelines 
HLA alleles were chosen as targets for chimaerism detection in the q-PCR assays 
because the HLA types of CBUs and mothers were readily available. This meant 
financially and time-costly prior genotyping of CBUs and mothers, to identify 
informative polymorphisms, was not required. Q-PCR was chosen because of its 
sensitivity and indeed, the assay was optimised and validated successfully to 
detect 0.01% of minor DNA within a major DNA component. The optimisation 
process included the determination of primer specificity, selection of target and 
endogenous control (HCK) primer concentration and determination of PCR 
efficiency. Each of the 11 primer pairs (HLA-A*01, -A*02, -A*11, -A*24, -A*24/A*25, 
-A*30, -A*33, -B*08, -B*27, -B*35 and -DRB1*03) were tested for specificity in vitro 
by setting up q-PCR reactions using a panel of HLA typed male platelet donors. 
Analysis of dissociation curves confirmed the primers were specific. In cases 
where there was cross-reactivity (HLA-A*01, -A*11, -B*08 and -B*35), the primers 
were only used in MMc quantification if there was no potential source of the 
cross-reactive allele from the mother or CBU. PCR efficiencies were determined 
by the generation of standard curves and after optimisation of the primer 
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concentration, each of the q-PCR assays demonstrated high amplification 
efficiencies (greater than 90%), with an R2>0.99, indicating that the thermal 
cycling parameters were optimised. This also meant that each of the q-PCR assays 
were able to accurately and reliably quantify MMc across 5 logs of magnitude, to 
a sensitivity of 0.01%, demonstrated by the proportion of expected positive 
replicates testing positive in the assay and precision of the assay (standard 
deviation of replicates). 
6.5.2 Detection of MMc in clinical grade CBUs 
In this study, 27% (n= 26/96) of CBUs tested positive for NIMA HLA DNA in a q-
PCR assay. Intriguingly, MMc was significantly associated with histocompatibility 
at HLA-A but only when compatibility was from the perspective of both the 
mother and foetus, i.e. in both the GvH and HvG direction (for example, if both the 
mother and foetus expressed HLA-A*01, *02). Class I compatibility may be 
important for enabling maternal cells to survive in the foetus due to the absence 
of a foetal class I mediated CD8+ CTL response directed against NIMA and indeed, 
MMc has been shown to induce allospecific regulation of the direct or semi-direct 
pathway of the CTL response (Burlingham, et al 1995, Moretta, et al 1999). 
However, several other studies have consistently demonstrated the lack of 
regulation of the direct pathway CTL response against NIMA (Akiyama, et al 
2011, Hadley, et al 1990, Roelen, et al 1995). 
The observation that MMc was not associated with histocompatibility in the HvG 
perspective yet was associated with bidirectional compatibility from both the 
mother and foetal perspective is intriguing and requires the assumption that the 
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maternal cells transferred are functioning. Some evidence is able to support this 
hypothesis. In CBT, maternal cells sensitised against foetal IPAs have been 
proposed to mediate a GvL response in CBT for patients with malignant disease 
(van Rood, et al 2012). Maternal renal grafts have also been associated with poor 
clinical outcomes, possibly because the tolerogenic NIMA effect has been out-
weighted by an anti-IPA effector response elicited by passenger maternal 
lymphocytes, in what is termed the “NIMA paradox;” although the effects of 
passenger lymphocytes in renal grafts has not been extensively studied (Lim, et 
al 2016, Opelz 1990, van Rood and Claas 2000). Some awareness of the functional 
capabilities of chimeric cells can be gleaned from maternal cells isolated from 
children with SCID. These maternal microchimaeric cells have been shown to 
express HLA molecules and T cell activation markers (Muller, et al 2001) but do 
not seem to function in vitro when stimulated with alloantigen (Thompson, et al 
1984), possibly due to a limited T cell receptor repertoire (Knobloch, et al 1991). 
However, MMc has been associated with GvHD in SCID patients, demonstrating 
functionality in vivo (Muller, et al 2001). Interestingly, GvHD does not develop in 
all SCID patients with detectable MMc, suggesting a regulatory response may 
control maternal engrafted lymphocytes.  
Recent evidence from a prospective study in a living-related renal transplant 
population suggests pre-transplant immune regulation to NIMA was able to 
benefit clinical outcome of mother to child renal transplants but only if regulation 
was reciprocated on the maternal (anti-IPA) side (Jankowska-Gan, et al 2012). 
Why MMc was associated with bidirectional compatibility at HLA-A remains 
unclear. It has been hypothesised that maternal microchimaeric cells are 
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involved in the reprogramming of DCs towards a tolerogenic state and induce 
anergy via the indirect pathway, thus permitting the survival of maternal 
microchimaeric cells and amplification of MMc and tolerance (Bracamonte-Baran 
and Burlingham 2015). Whether HLA-A plays a specific role in MMc or was just 
the only locus to be statistically significant due to the heterogeneity of HLA and 
small sample size also remains unclear. Other studies have identified an 
association of MMc with compatibility at the class II antigens, HLA-DRB1 and -
DQB1 but not at class I (Berry, et al 2004, Lambert, et al 2004). The reasons for 
these differences between studies are unclear but may be in part due to the 
heterogeneous nature of the HLA types present in the CBUs included in this study. 
HLA-DQB1 typing was unavailable for CBUs and mothers in this cohort. Analysis 
of maternal-foetal compatibility at the epitope level, as opposed to antigen 
compatibility, may also provide further information. 
MMc was not detected in all CB donors and the factors associated with the 
presence of MMc remain unclear. NK cells play an important role during 
pregnancy, possibly mediated through the expression of killer immunoglobulin-
like receptors (KIRs) that bind to HLA ligands and result in either inhibition or 
activation of a natural killer cell responses. Foetal-maternal KIR compatibility has 
been studied extensively from the perspective of maternal allorecognition of the 
foetus, with studies demonstrating a role in pre-eclampsia and recurrent 
miscarriage (Hiby, et al 2004, Parham and Moffett 2013). Foetal-maternal KIR 
compatibility could also play a role in the opposite direction: foetal 
allorecognition of the mother and MMc. Further work could therefore explore 
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frequencies and combinations of activating and inhibitory KIR genes and their 
ligands and the presence and levels of MMc. 
The NIMA HLA detected could be cellular DNA or cell-free circulating DNA. 
Although studies of cell-free DNA in CB have not been published, mothers are 
known to harbour cell-free circulating DNA of foetal origin during pregnancy and 
recently this has been exploited for non-invasive antenatal testing of foetal 
genetic abnormalities (Benn 2016). Chimeric cell-free circulating DNA of donor 
origin has also been detected in the urine of solid organ recipients (Gielis, et al 
2015). If NIMA HLA detected in q-PCR was of cellular origin, it is not known 
whether transfer of maternal cells to the foetus occurred during an 
active/passive transfer during pregnancy or whether the maternal cells entered 
the CB during labour or during the CB harvest. 
Considerable evidence suggests the presence of MMc in CB occured during 
pregnancy. MMc has been detected in both healthy adults (Lambert, et al 2004) 
and pre-term foetuses (Mold, et al 2008). In this study, MMc was significantly 
associated with gestational age, with 50% (n= 7/14) of CBUs belonging to babies 
born at 38 weeks or less testing positive for MMc, compared to 22% (n= 13/58) 
of babies born at 39 weeks or later. However, in those that were positive for MMc, 
there was no correlation with the quantity of MMc and gestation (data not 
shown). Other studies have also found no statistical association between 
gestation, maternal age or parity and the incidence or quantity of MMc in CB 
(Berry, et al 2004, Scaradavou, et al 1996). Intriguingly, the levels of foetal Tregs 
also decrease during foetal development and it is hypothesised that during this 
time, when stimulated with alloantigen, the foetus transitions from being prone 
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to tolerance induction towards an effector function, in what is termed the layered 
immune system hypothesis (Mold, et al 2010). Tolerance towards NIMA is 
associated with Tregs specific for maternal alloantigens and this tolerance can be 
lost in the absence of sufficient MMc exposure (Dutta, et al 2009, Matsuoka, et al 
2006, Molitor-Dart, et al 2007). This highlights the need for further studies into 
tolerance towards NIMA and the dynamics of MMc and Tregs during foetal 
development.  
An alternative explanation to the active/passive transfer of maternal cells during 
pregnancy is that maternal cells were transferred during labour (for example, 
placental tearing) or during the CB collection and processing. However, no 
statistically significant associations between MMc and the method of delivery, 
induction status or year of birth (banking practices and centre experience has 
changed considerably over time) were identified; although these were only 
available for a subset of the cohort. Speculation about maternal contamination 
during the CB collection process could be gleaned from the observation that in 
this study, despite the use of a more sensitive detection method, 27% of CBUs 
tested positive for MMc compared to a previous report of 38% that used SSP for 
detection (Scaradavou, et al 1996). The lower than expected proportion of CBUs 
positive for MMc could be because clinical grade CBUs were tested. Studies that 
used research grade CBUs could have a higher incidence of maternal 
contamination during the CB collection process, with those CBUs more likely to 
not be suitable for banking and thus were instead available for research 
purposes.  
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The detection of HLA that matched the CB NIMA may also not be of maternal 
origin. Contamination in the laboratory may have occurred, particularly because 
these were historical DNA samples that would have been tested multiple times in 
the laboratory, giving numerous opportunities for contamination. Strict 
precautions were taken whilst I was testing the DNA samples, such as the use of 
filter tips but this does not rule out contamination at earlier time points. 
Furthermore, the NIMA HLA was also assumed to be of maternal origin but it is 
also feasible that this originated from an older sibling (Dierselhuis, et al 2014). 
MMc was not statistically associated with parity but this information was only 
available for a small subset of the cohort. 
6.5.3 Limitations and further work 
The HLA targets that were selected for q-PCR assays were common amongst the 
cohort studies and one or more targets were present in 95% (n= 166/175) 
mothers evaluated. However, only 96 (57%) of these CBUs could be tested for the 
presence of MMc because the maternal HLA was not the NIMA or it was not 
informative when compared to the CBU HLA. Several improvements could be 
made to the panel of primers available for microchimaerism detection and 
quantification. The HLA marker panel should be expanded to include additional 
specificities, especially at class II HLA loci. Primers specific for other HLA targets 
were available from colleagues in the Netherlands but were not selected due to 
low sensitivity. Redesign of some primers and further optimisation of reaction 
parameters may therefore be required.  
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The study population included is biased towards CBU-maternal pairs where the 
NIMA HLA was informative and it is possible that MMc levels in CBUs that were 
compatible to the mother and thus were excluded from experiments, differed to 
those reported. Non-HLA polymorphic markers could also be included, such as 
Insertion/Deletion (InDel) polymorphisms (Alizadeh, et al 2002). q-PCR assays 
that target three InDel polymorphisms, S-03, S-06 and S-11A have been optimised 
and validated (see Appendix C). However, these targets were not included for 
MMc analysis because 1) a screen for these polymorphisms showed low 
informativity, 2) an additional genotyping step was required prior to chimaerism 
analysis and 3) InDel q-PCR was not compatible with the HLA q-PCR conditions 
and thus the assays were not directly comparable. 
If the q-PCR assays are to be introduced routinely in the H&I laboratory, other 
amendments could be made to improve workflow. Each of the HLA and HCK q-
PCR assays were optimised to a similar amplification efficiency, which will permit 
the relative quantification of chimaerism by comparison of HLA and HCK Cq 
values, without the requirement of running standard curves on each PCR plate. 
Relative quantification is generally preferred over the absolute quantification 
(which uses the standard curve method) method used in this thesis because it 
offers a higher through-put. The inclusion of standard curves currently takes up 
half of the 96 well plate and only 8 samples of unknown chimaerism quantity can 
be run in triplicate per plate. The comparative Cq method could permit around 14 
samples in triplicate per plate. Another advantage of optimising the HLA and HCK 
q-PCR assays to a similar amplification efficiency is the future possibility of 
multiplexing the reactions. This will control for well-well variations between HLA 
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and HCK amplification, further increase the number of samples per plate and also 
allow multiple informative markers to be tested simultaneously. Multiplexing the 
assay would however, require a change in chemistry from SYBR Green to TaqMan 
probes with multiple fluorophores, which can be more expensive but also offer 
enhanced specificity.     
The development of digital droplet PCR technology has permitted more sensitive 
analyses of chimaerism (Eikmans, et al 2014). Using this method, a single DNA 
molecule is captured within water in oil droplet partitions and after thermal 
cycling to end-point PCR, each droplet is read to determine the proportion of 
droplets with positive amplification. This allows the absolute number of starting 
copies to be accurately determined and the use of TaqMan probes corresponding 
to two different alleles, the relative proportion of each allele in the sample can be 
determined. The use of digital droplet PCR also provides the significant 
advantage that quantification is not limited by amplification efficiencies because 
data capture occurs at end-point PCR and thus would be more feasible for a larger 
panel of informative polymorphic markers. 
6.5.4 Conclusions 
A q-PCR assay was developed for the detection and quantification of MMc in CB 
by the targeting of NIMA HLA polymorphisms. When this was used to quantify 
MMc in CB samples, 27% (n= 26/96) tested positive for MMc. The presence of 
MMc was not associated with the majority of maternal characteristics studied but 
appeared to be detected more frequently in the CB of babies born at 38 weeks or 
less. Given that Tregs are also present at higher quantities in the foetus during 
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earlier stages of gestation, further work should explore the role of Tregs in the 
development of MMc in humans, to supplement existing studies in the mouse. 
Further work should also expand on the observation that the presence of MMc 
seemed to require two-way compatibility between the mother and foetus. The q-
PCR assay will also serve as a valuable tool that will enable a direct analysis of the 
influence of MMc in the CB graft on recipient clinical outcomes after 
transplantation and testing of the hypothesis that MMc mediates a GvL effect in 
recipients.  
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 Aims, major findings and further work 
Donor-recipient HLA matching is crucial in the success of allogeneic unrelated 
HSCT (Eapen, et al 2011b, Lee, et al 2007, Petersdorf 2008) but the extensive 
polymorphism of HLA and their population-specific distribution influences the 
availability of a MUD, especially for non-Caucasian patients (Gragert, et al 2014). 
CB has been shown to extend the availability of a suitably HLA matched donor for 
ethnic minorities but TRM and aGvHD remain a challenge following HLA 
mismatched CBT (Barker, et al 2010a, Barker, et al 2010b, Eapen, et al 2014). 
Alternative HLA matching strategies: for example, the consideration of 
permissible HLA MMs such as NIMA, are therefore clinically needed. The central 
aim of this thesis was to explore the role of NIMA matching in unrelated CBT, with 
regards to donor availability and clinical outcome and to also develop a sensitive 
method to quantify the levels of MMc present in CBUs. 
7.1.1 Generation of virtual phenotypes (chapter 3) and the provision of 
virtual full matches for patients (chapter 4)  
The first aim of this thesis (chapter 3) was to define the HLA-A, -B and -DRB1 
NIMA of banked CBUs with maternal HLA types available, to generate VPs derived 
from the NIMA and to evaluate whether these increase the number and diversity 
of HLA phenotypes available for donor searches. A population genetics analysis 
of mothers and CBUs identified significant diversity in the representation of HLA 
alleles and haplotypes. Local algorithms were developed to identify the NIMA and 
to calculate the VPs derived from the 4,671 CBUs with maternal HLA types 
banked in the NHS-CBB. The actual number of phenotypes obtained from 4,671 
CBUs increased 14.2-fold compared to the possible maximum 26-fold by the 
Chapter 7 
L. Powley (2017)   -228- 
generation of VPs due to incidences of non-informative NIMA. Maternal 
homozygosity and CBU-maternal 0 MM were generally comparable between HLA 
loci but differed at the population level. This meant that proportionally, a higher 
number of VPs were generated for BLK and MIX CBUs compared to CAU and ASI 
CBUs. A greater degree of HLA diversity was also present amongst BLK and MIX 
CBUs and maternal HLA typing CBUs from these groups may provide the greatest 
benefit to the size and diversity of the NHS-CBB, with minimal financial costs and 
also the greatest benefit to patients; especially given BLK patients are at a 
significant disadvantage with regards to donor availability. Knowledge of the 
probability of the NIMA being informative based on information from the CB HLA 
type could also aid the decision on whether to perform maternal HLA typing in 
patient specific cases. This could be particularly useful in situations whereby only 
a mismatched CB donor is available for a patient and the maternal HLA type is 
not available to check for a NIMA match. In these cases, it would also be beneficial 
if a “NIMA match probability” tool was available, where the mismatched patient 
allele is checked against the frequency of NIMA alleles within the donor ethnic 
group. The algorithms developed in the thesis and the analysis of NIMA allele and 
haplotype frequencies are the first steps in the development of such a tool.  
The primary aim of chapter 4 was to determine whether the inclusion of VPs, to 
provide VFMs, can improve donor availability for patients of various ethnicities 
requiring CBT. Donor searches were performed on both the BBMR and BMDW 
registries for 457 patients. VFMs were available for patients without an IFM and 
thus when incorporated into the inherited match donor search strategy, VFMs, 
with adequate TNC dose, were able to extend the availability of a suitable donor 
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for patients requiring a transplant and in particular, for patients of ethnicities 
other than EC. VFMs from the BBMR doubled the cumulative availability of a 
matched donor for EC patients and tripled the availability for OE patients. VFMs 
from the BBMR also significantly increased donor availability for difficult to 
match patients with one or more infrequent HLA alleles. These findings provide 
evidence for the existence of VPs as true phenotypes in the patient population 
that were not yet present in the BBMR or BMDW registries.  
The NHS-CBB aims to expand the number of banked CBUs to 50,000 but models 
suggest a 6/6 HLA match will be identified for only 9% of non-North West 
European patients based on an inventory of this size (Querol, et al 2009) and the 
introduction of more stringent HLA matching criteria is likely to further restrict 
availability. This thesis has shown that VPs provided a significant increase to the 
size of the donor pool and were able to provide VFMs for patients without an IFM. 
The generation of VPs and the prospective consideration of NIMA matches in CBT 
therefore seems to be a feasible alternative or complementary approach to 
increasing the number of banked CBUs in the NHS-CBB to improve donor 
availability. 
There are current plans to retrospectively explore VFM donor availability for all 
sequential patients whereby a donor search was previously administered 
through Anthony Nolan over a four-year period (over 9,000 patients). This will 
capture patients that may not have proceeded to transplant due to the lack of a 
suitable donor and the large number of patients will permit further stratification 
of various ethnic groups. We are currently developing a tool that searches the 
virtual and inherited phenotypes of CB donors listed with the BBMR to identify 
Chapter 7 
L. Powley (2017)   -230- 
IFM and VFMs. This tool builds on the current study in that it estimates allelic 
resolution inherited and NIMA matches and HLA-A, -B, -C and -DRB1, from 
estimated second field HLA types, based on allele and haplotype frequencies. It 
also identifies mismatched donors that are only partially NIMA matched such as 
where one of two MMs is a NIMA match (6/8 + 1 NIMA). Furthermore, the 
automation of donor searches as opposed to manual searches using the BMDW 
Match Programs will enable the capture and analysis of NIMA matching in more 
detail, such as the likelihood of NIMA matching individual HLA alleles (such as 
HLA-A*02:01).  
Continued periodic analyses of both inherited and virtual phenotypes of CB 
donors in the BBMR should be adopted. This will allow the monitoring of the 
diversity present amongst the VPs and whether these are providing additional 
diversity to the phenotypes present amongst the entire CB donor population in 
the BBMR. It is well established for inherited phenotypes that as the number of 
phenotypes increases, the proportion of these that are new phenotypes not yet 
represented decreases because only the less frequent phenotypes are not yet 
present. It is unclear whether this will be observed for VPs and if so, what the 
optimum virtual registry size will be. It is possible that once a certain threshold 
is reached, only VPs from ethnic groups underrepresented in the BBMR will 
provide a significant cost-benefit and the decision could be made to stop 
performing maternal HLA typing of Caucasian CB donors, especially since these 
were less likely to be informative for NIMA. These decisions are particularly 
important when there is a need to sustain the economic future of public CBBs 
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given the decreasing utilisation of CB donors (Magalon, et al 2015, Niederwieser, 
et al 2016, Passweg, et al 2016). 
7.1.2 Association of NIMA matching with clinical outcomes (chapter 5) 
The primary aim of chapter 5 was to retrospectively determine whether NIMA 
matching for HLA-A, -B, -C and –DRB1 had any effect on clinical outcomes after 
single CBT in recipients with malignant and non-malignant disease. 
Unfortunately, the cohort was not of sufficient sample size to achieve an adequate 
statistical power able to detect differences in outcome between NIMA and non 
NIMA matched transplants. This highlights the need for a multi-centre 
international collaboration that considers NIMA matching in the context of four 
loci allelic resolution donor-recipient matching, especially given that I identified 
NIMA matches at HLA-C. 
The effect of NIMA matching in the context of the updated recommended criteria 
of allelic resolution matching at HLA-A, -B, -C and -DRB1 remains unknown. An 
observational retrospective study using registry data is in my opinion, the more 
feasible option to providing scientific evidence regarding the NIMA effect in CBT, 
compared the gold standard of a randomised, prospective clinical trial for several 
reasons. There is often a prohibitive financial cost associated with clinical trials 
and the niche field of NIMA matching will mean it is not a priority. Recruitment 
would likely be difficult and although half of patients had a VFM from BMDW, this 
would likely decrease once further HLA typing and other variables such as CBB 
are considered. Therefore at least half of patients will be excluded from 
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enrolment before other demographics such as disease indication are even 
considered.  
A retrospective study offers the unique advantage that large numbers of 
heterogeneous patients can be followed for long periods of time, providing a 
more realistic estimate of the influence of NIMA matching and analyses of late 
complications after CBT, such as cGvHD. A Eurocord-CIBMTR collaboration 
combining data from the NYCB, NHS-CBB and other banks would provide a large 
cohort available for analyses. If more CBBs are recruited to provide maternal HLA 
types of transplanted CBUs, more specific research questions could be asked, 
such as the impact of patient disease indication (malignant versus non-
malignant) or disease risk and whether there is any difference between NIMA 
matching at class I versus class II HLA loci or whether additional numbers of 
NIMA matches provide an additive effect.  
The effect of NIMA matching in double CBT has also not yet been addressed and 
would be worthwhile given adults are unlikely to be considered for a single graft 
given the difficulty in achieving adequate cell dose. However, such a study will be 
difficult to conduct. Consideration of NIMA matching would require the maternal 
HLA types of both CBUs to be defined, which could be difficult given that the two 
units could have come from different CBBs that may differ in policy. Analyses of 
HLA matching in double CBT are already complex and it is unclear whether 
matching between the two units should be considered (Ballen and Lazarus 2016, 
Tees, et al 2016). Given that NIMA matching has been associated with improved 
engraftment in single CBT (van Rood, et al 2009), would NIMA matching in double 
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CBT affect unit dominance? Or could NIMA matching between the two CBUs lead 
to tolerance and the persistence of dual chimaerism?  
7.1.3 Maternal microchimaerism in cord blood (chapter 6) 
The primary aim of chapter 6 was to develop a sensitive q-PCR assay for the 
detection and quantification of MMc in CB, to determine the levels of MMc in 
transplanted CBUs and to investigate variables associated with its presence 
and/or absence. An absolute quantification method, that used standard curves 
were used to quantify the amount of NIMA HLA target in unknown samples, 
normalised against the total template DNA of the sample, quantified by an 
endogenous control, HCK. Initial q-PCR reactions of artificial spiking experiments 
were set up to test the protocol, optimise the conditions and characterise the 
assay performance by following the MIQE guidelines. The assays had a sensitivity 
of 0.01%.  
This thesis detected MMc in 27% of 96 CB samples tested and found that MMc 
occurred more frequently in CB samples of babies born at 38 weeks or less. MMc 
is critical in the generation of NIMA-specific tolerance, likely through the 
generation of NIMA-specific Tregs (Dutta, et al 2009, Mold, et al 2008, Molitor-
Dart, et al 2008). If MMc levels diminish with increasing gestation, it is possible 
the reduced level of exposure could negatively affect tolerance; especially given 
the foetus is proposed to transition towards an environment that favours an 
effector response during later gestational time points, which may not promote 
development of NIMA specific Tregs (Mold, et al 2008, Mold, et al 2010). Although 
clinical evidence in CBT is not available to support this, it may be that NIMA 
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matching in CBT is only beneficial to recipient outcomes in the context of MMc 
and indeed, NIMA matched donors have previously been selected on the basis of 
MMc in historic cases of haploidentical transplantation (Ichinohe, et al 2004). The 
selection of NIMA matched CB donors of babies born at earlier gestational time 
points may provide increased opportunity for the MMc to be present, although 
gestational information is not readily available during donor selection.   
MMc was also significantly associated with compatibility at HLA-A but only when 
compatibility was from the perspective of both the mother and foetus, i.e. in both 
the GvH and HvG direction. This raises the possibility that there is a two-way 
interaction between maternal microchimaeric cells and the foetus that permits 
the passage and/or survival of MMc in the foetal host. Such bi-directional 
alloreactivity has been implicated as necessary for the tolerance of maternal 
renal grafts (Jankowska-Gan, et al 2012). Functional capacity of MMc in CB grafts 
has also been linked to a GvL response in recipients with one or more IPA matches 
to the CB in transplantation (van Rood, et al 2012). If additional clinical evidence 
becomes available to support this hypothesis, there may be disease specific cases 
where a CB donor positive for MMc is preferred over a donor with undetectable 
levels of MMc. Selection of CB donors born to babies of earlier gestational time, 
that are compatible to the mother in both the GvH and HvG direction and are 
matched to the patient IPA therefore may benefit patients with malignant disease. 
Tolerance towards NIMA due to sufficient levels and/or quality of MMc appears, 
in the majority of cases, to be restricted to indirect pathways of allorecognition, 
without effect on the direct pathway, as discussed in the introduction (Akiyama, 
et al 2011, Bracamonte-Baran, et al 2017, Claas, et al 1988, Hadley, et al 1990, 
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Jankowska-Gan, et al 2012, Roelen, et al 1995, van Halteren, et al 2009). This 
split-tolerance towards NIMA is proposed to confer a reproductive advantage but 
is of significance in the transplantation setting (Bracamonte-Baran, et al 2017, 
Kinder, et al 2015). Female mice show an increased incidence in acute rejection 
of NIMA+ heart allografts compared to males in the absence of 
immunosuppression in mice (Molitor-Dart, et al 2008). Although no differences 
between male and female recipients of NIMA matched transplants in humans 
have been observed, NIMA matched grafts are associated with complications at 
early time points compared to NIPA and yet have a long term survival benefit in 
both renal and haploidentical transplantation (Burlingham, et al 1998, Kanda, et 
al 2009). Thus the hypothesised reproductive advantage conferred from a higher 
level of MMc in the development of Tregs may come at a significant cost in that it 
leads to stronger semi-direct pathway, responsible for higher acute rejection 
(Bracamonte-Baran, et al 2017, Kinder, et al 2015). The challenge to 
transplantation will be to manage this split-tolerance so that the natural MMc 
induced Treg mediated tolerance will benefit the recipient whilst the functional 
alloreactivity pathway is managed, possibly through targeted 
immunosuppression at specific time points.  
A retrospective survival analysis of MMc and recipient outcomes after CBT could 
test for an association between the two and could also test the hypothesis that 
maternal cells sensitised against CB IPAs elicit a GvL response in the recipient 
(van Rood, et al 2012). The significant efforts of this research in the development 
of a central database containing maternal, CB and recipient demographics and 
clinical outcome provides an opportunity to perform such a retrospective 
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analysis. Adequate statistical power could be achieved if the panel of q-PCR 
microchimaerism markers is expanded and/or a collaboration with other CBBs 
are formed. An obvious example of a collaborative environment is the 
International Histocompatibility Working Group, which has fostered an 
international exchange of biological materials, clinical data and methodologies to 
advance our knowledge of histocompatibility and transplantation since the 
beginning of the field. 
7.1.4 Haploidentical HSCT as an opportunity to study the relationship 
and immunological consequences of NIMA, MMc and Tregs 
The recent decline in CBT and upwards trend in related haploidentical donor 
transplantation due to improved conditioning regimens, economic feasibility and 
donor accessibility and speed, warrant re-exploration of NIMA and donor choice 
in the modern era of haploidentical transplantation (Bertaina, et al 2017). Clinical 
trials and single centre studies could provide valuable information on the clinical 
outcomes of transplants using different types of haploidentical donors (parents, 
NIMA or NIPA matched sibling), either as a specific study or as a side arm. Non-
registry studies would permit prospective analyses of more intricate concepts.  
For example, immune regulation status of donor-recipient pairs, especially 
indirect pathway responses towards donor cell lysates containing all HLA and 
minor histocompatibility NIMAs, could be evaluated prior to transplant 
(Jankowska-Gan, et al 2012). The contribution of Tregs towards the regulation of 
alloreactivity against NIMA could also be measured by the recovery of effector 
functions and/or proliferation when Tregs are removed or added into the assay. 
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MMc levels could also be quantified and tested for an association with pre-
transplant bi-directional alloreactivity. The results of these assays could be used 
to test for an association between pre-transplant immune regulation and clinical 
outcomes after HSCT. Ultimately, this could be used to provide insight into the 
prediction of whether tolerance or sensitisation towards NIMA is likely to occur 
in specific donor-recipient cases. Furthermore, co-infusing selected or expanded 
Tregs have recently been shown to prevent lethal aGvHD in haploidentical HSCT 
(Di Ianni, et al 2011) and this concept could be tested in cases of NIMA matched 
grafts and especially those where pre-transplant assessment predicted 
sensitisation, rather than tolerance, towards NIMA. 
 Additional applications of methodologies described 
in this thesis 
There are several extensions to the methodologies and tools developed and their 
application in general to other clinical scenarios. Some are presented below, 
together with a description of how these have already been implemented or 
practical suggestions for their implementation. 
7.2.1 HLA haplotype identification 
The identification of CB donor HLA haplotypes has several clinical uses in 
transplantation. In adult donor HSCT, donor-recipient HLA haplotype matching 
has shown improved clinical outcomes compared to matching HLA phenotypes 
alone (Petersdorf, et al 2007). It is possible that additional MHC polymorphisms 
not considered in matching are allogeneic, given that MUD HSCT confers an 
increased risk of GvHD compared to HLA identical sibling donor HSCT (Yakoub-
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Agha 2016). Furthermore, the CB IPA and IMA can also be distinguished by 
comparison of maternal and CBU HLA types. Early evidence suggests the anti-
leukemic effect of CBT is due to the transfer of anti-IPA maternal immune cells in 
the CB graft to the recipient and IPA matching may be beneficial (van Rood, et al 
2012). Knowledge of haplotype segregation will permit further analyses into the 
influence of donor-recipient IPA matching on recipient outcomes after CBT and 
the possibility of including IPA in the BMDW Match Programs. 
Comparison of maternal and CB HLA types has also provided an important 
additional quality assurance step in the collection and banking of NHS-CBB CBUs. 
Although a rare occurrence, it is possible for the incorrect HLA type of CBUs to be 
reported and listed with registries, for reasons such as sample mix up during 
laboratory testing. The identity of the CBU is confirmed prior transplantation by 
the completion of confirmatory HLA typing on an additional blood segment 
attached to the CBU itself but the identification of a quality incident from identity 
confirmation could be many years after the CBU was processed and banked. 
However, if the mother’s HLA type is defined during the processing and initial 
testing stage of banking, a comparison to the CBU HLA type can also be made 
during this time. The H&I laboratory at Colindale has now introduced an 
additional quality step to the process of HLA typing CB donors: each batch of CB 
HLA typing results are run through an algorithm (based on the one described in 
this thesis) to compare CB-maternal HLA types and identify any discrepancies, 
prior to the listing of donors with BBMR and BMDW. 
Automated calculation of HLA haplotype segregation could also be used as a tool 
in family studies for related-donor transplantation. At present, identification of 
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HLA identical and haploidentical matched related donors is generally performed 
manually and automation of this analysis would increase efficiency. The NMDP 
has implemented an “HLA pedigree analysis tool” (www.pedigree.haplostats.org) 
where the HLA types of a patient and their relatives can be entered to identify 
matched donors. The tool could also be coupled with HLA haplotype frequencies 
to predict missing HLA typing at individual loci (such as HLA-C). Comparison of 
allele strings between related individuals could also be used to eliminate non-
shared alleles from ambiguous typing data and provide an HLA typing result with 
an improved resolution.  
7.2.2 Retrospective analyses of clinical outcomes of recipients issued 
with a CBU from the NHS-CBB 
The NHS-CBB holds the UKs largest observational studies of clinical information 
on CBT, with data available for over 500 issued CBUs over a twenty-year period 
that can be used for research purposes. At the start of this research, information 
that was not required for donor selection but could be relevant for research 
purposes, was not held in a central location and data was held across multiple 
electronic and paper sources. This restricted the ease of completing research 
studies using the available data. 
During the course of this research, I have developed a controlled, standardised, 
central database that holds all relevant donor and recipient information. Clinical 
outcome data has been quality checked and manipulated for ease of future 
statistical analyses (e.g. grouping of similar disease indications together, 
calculation of time-to-event with the inclusion of censoring at follow-up and 
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competing events). HLA typing data from Eurocord and NHSBT has been 
combined to complete missing information and manipulated to a consistent, 
standardised format suitable for data mining. Allelic resolution HLA typing was 
also made available for a significant proportion of recipients and donors. 
Calculations performed during this research, such as donor-recipient HLA match 
grades have also been added. I have also collaborated with the statistics 
department, who will now look after the CBT data in much the same way as 
currently in place for solid organ transplantation. Looking forward, this means 
that future researchers will not need repeat very time-consuming processes 
required before they can even begin to address any research questions and the 
sharing of data between departments will hopefully improve, leading to more 
beneficial research that will ultimately improve patient care. 
7.2.3 Post-transplant monitoring of chimaerism 
Chimaerism monitoring plays an important role in post-transplant monitoring 
such as in the identification and monitoring of relapse, GvHD, graft failure and 
unit dominance in double CBT (Clark, et al 2015). The results can influence 
clinical decisions, such as whether to increase in immunosuppression or perform 
a donor lymphocyte infusion. The q-PCR assay for chimaerism detection and 
quantification could also be used for post-transplant monitoring. DNA extraction 
from different cell lineages would also allow chimaerism quantification of 
purified cell populations, such as B cells for monitoring disease relapse in a 
patient with a B cell lymphoma.   Chimaerism analyses for clinical purposes 
should report the coefficient of variance for a minimum of three informative 
markers (Clark, et al 2015) and thus a q-PCR assay that targeted polymorphisms 
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other than HLA (of which most loci are matched in HSCT), such as InDel 
polymorphisms, may be more suited for clinical use. A InDel specific q-PCR assay 
was optimised and validated as part of this thesis (see Appendix C) and the panel 
of markers could readily be expanded. 
 Conclusions and recommendations 
Based on the findings of this thesis and the existing evidence in the literature, 
recommendations for maternal HLA typing of banked CBUs, selection of a NIMA 
matched donor and further analysis of clinical outcomes are given in Table 7.1. 
This thesis has shown that performing maternal HLA tying of banked CBUs and 
identification of the CB NIMA led to a significant increase in the donor pool by the 
generation of VPs. These VPs were able to extend the availability of a suitable 
donor for patients requiring a transplant and in particular, for patients of 
ethnicities other than EC. This suggests the prospective provision of a NIMA 
matched CB donor is feasible, although there is a need for clinical evidence that 
supports NIMA matching in the modern era of allelic matching at HLA-A, -B, -C 
and -DRB1 in CBT. This thesis has also contributed through the development of a 
sensitive q-PCR assay for MMc quantification and by the identification of 
gestation and maternal-foetal bi-directional alloreactivity as factors associated 
with the presence of MMc. Given that recent literature suggests that the 
tolerogenic response to NIMA is dependent on the level or type of MMc and that 
these microchimaeric cells may elicit a GvL response in CBT, an assay that 
quantifies MMc will be of use in the testing for an association with MMc and 
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clinical outcomes after CBT and in the future, MMc may even be considered 
during donor selection. 
Table 7.1 Recommendations 
1) Maternal HLA typing of NHS-CBB donors 
a) The NHS-CBB should continue to perform maternal HLA typing 
b) This should especially be performed for CBUs of Black and Mixed ethnicity 
c) Typing should be performed at high resolution for HLA-A, -B, -C and -DRB1 
2) UK cord blood donor selection  
a) NIMA matching should be considered in the absence of a fully matched CB 
donor for patients with malignant disease 
b) This should include careful weighting of other graft selection factors e.g. TNC 
dose, CBB accreditation status, ABO matching and DSA 
c) The CB advisory committee must be included in any discussions of selecting a 
NIMA matched donor  
d) The time taken to identify a suitable donor should not be extended for the 
purposes of trying to identify a NIMA match 
3) NIMA matching and recipient clinical outcomes after cord blood 
transplantation 
a) Studies of NIMA matching should be based on allelic resolution HLA-A, -B, -C 
and -DRB1 
b) Malignant and non-malignant indications should be analysed separately 
c) This should be an international, multi-centre collaboration, such as a joint 
Eurocord-CIBMTR analysis 
4) Cord blood maternal microchimaerism and recipient clinical outcomes after 
transplantation 
a) A standard method of chimaerism detection with comparable sensitivity 
between laboratories should be utilised 
b) Donor-recipient shared IPA status should be taken into consideration 
c) The effect of T cell depletion (e.g. use of ATG) should be included 
d) This should be an international, multi-centre collaboration, such as the IHWG 
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Supplementary Table A.I CBU and maternal HLA-A allele frequencies. Frequencies were calculated by a direct count from 4,671 
CBUs and their mothers and are given as percentages. *Total also includes frequencies in OE and UNK groups. 
 CAU (n= 2,831) ASI (n= 790) SEA (n= 47) BLK (n= 256) MIX (n= 605) Total* (n= 4,671) 
  CBU Mother CBU Mother CBU Mother CBU Mother CBU Mother CBU Mother 
A*01 16.32 16.83 12.15 12.53 14.75 15.16 1.06 2.13 8.59 8.40 14.21 14.71 
A*02 29.94 28.17 16.08 14.37 26.27 24.74 26.60 30.85 19.34 18.16 24.96 24.30 
A*03 13.07 13.58 6.39 5.95 11.07 11.22 3.19 2.13 10.35 9.38 9.17 9.17 
A*11 5.76 5.99 15.32 15.19 7.58 7.78 24.47 17.02 1.56 2.73 7.19 7.52 
A*23 1.61 1.75 0.82 0.76 2.24 2.23 - - 10.35 10.74 3.64 2.89 
A*24 8.55 8.53 16.84 17.15 10.13 10.50 25.53 24.47 3.32 3.13 10.00 12.40 
A*25 1.96 2.21 0.13 0.06 1.39 1.53 1.06 - - - 1.16 1.24 
A*26 3.11 3.25 4.68 4.81 3.23 3.43 1.06 2.13 0.78 1.56 3.14 3.55 
A*29 4.12 4.42 1.52 1.08 3.35 3.48 1.06 1.06 2.54 3.71 3.06 2.56 
A*30 2.07 2.42 2.15 2.09 3.06 2.93 1.06 1.06 13.87 11.13 4.55 3.31 
A*31 2.98 2.51 2.41 2.22 2.61 2.30 2.13 3.19 0.78 0.78 1.74 1.82 
A*32 4.12 4.10 3.23 3.61 3.66 3.70 1.06 2.13 1.17 1.17 3.47 3.31 
A*33 1.29 1.27 10.25 11.27 3.46 3.73 11.70 12.77 5.47 4.69 3.22 3.97 
A*34 0.09 0.09 0.51 0.95 0.45 0.50 - - 2.93 2.54 0.99 0.99 
A*36 0.02 0.02 - - 0.30 0.26 - - 2.93 3.32 0.91 0.50 
A*43 - - - - - 0.02 - - - - - 0.08 
A*66 0.44 0.34 0.06 - 0.55 0.43 - - 1.95 2.54 0.99 0.58 
A*68 4.24 4.33 7.22 7.78 5.25 5.50 - - 10.16 10.35 6.12 6.36 
A*69 0.18 0.18 0.06 0.06 0.14 0.14 - - 0.20 0.20 0.08 0.08 
A*74 0.16 0.04 0.13 0.06 0.44 0.39 - - 2.93 4.88 1.24 0.66 
A*80 - - 0.06 0.06 0.09 0.04 - - 0.78 0.59 0.17 - 
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Supplementary Table A.II CBU and maternal HLA-B allele frequencies. Frequencies were calculated by a direct count from 4,671 
CBUs and their mothers and are given as percentages. *Total also includes frequencies in OE and UNK groups. 
 CAU (n= 2,831) ASI (n= 790) SEA (n= 47) BLK (n= 256) MIX (n= 605) Total* (n= 4,671) 
  CBU Mother CBU Mother CBU Mother CBU Mother CBU Mother CBU Mother 
B*07 13.92 14.38 5.76 5.25 11.37 11.58 2.13 3.19 9.38 8.79 9.42 9.50 
B*08 10.54 11.27 5.57 4.56 8.93 9.27 - - 3.52 4.88 8.76 8.68 
B*13 2.23 2.24 2.85 2.91 2.31 2.39 7.45 3.19 1.17 0.98 2.40 3.06 
B*14 3.78 3.92 0.70 0.57 2.90 3.01 - 1.06 2.34 2.34 2.48 2.48 
B*15 6.91 6.38 9.68 9.49 8.08 7.77 17.02 12.77 12.50 13.67 8.18 8.18 
B*18 5.16 4.91 2.85 3.29 4.30 4.30 - - 2.15 2.73 3.64 4.21 
B*27 4.12 3.85 1.58 1.71 3.39 3.29 4.26 3.19 1.37 1.17 3.47 3.97 
B*35 8.05 7.82 13.04 13.35 9.33 9.06 6.38 7.45 8.40 5.86 10.58 10.17 
B*37 1.36 1.43 3.29 2.97 1.67 1.71 3.19 3.19 0.59 0.59 1.40 1.74 
B*38 2.15 2.38 1.52 1.77 1.94 2.10 1.06 2.13 0.39 0.39 1.90 2.07 
B*39 1.78 1.96 0.44 0.63 1.58 1.67 3.19 1.06 2.15 1.76 1.57 1.65 
B*40 6.43 6.43 13.73 12.91 7.60 7.54 11.70 12.77 1.95 0.98 7.02 7.60 
B*41 0.76 0.87 0.63 0.57 0.91 0.95 - - 1.37 2.34 1.65 1.32 
B*42 0.09 0.05 - - 0.46 0.39 - - 4.69 4.69 0.99 0.66 
B*44 15.70 15.95 6.27 7.66 12.86 13.17 4.26 5.32 7.42 6.45 11.07 11.24 
B*45 0.53 0.44 0.19 0.13 0.72 0.71 - - 2.73 3.52 1.32 1.57 
B*46 0.04 0.04 0.25 0.13 0.19 0.22 6.38 9.57 - - 0.33 0.50 
B*47 0.34 0.37 0.06 0.13 0.28 0.28 - - 0.78 0.39 0.08 - 
B*48 0.05 0.04 0.57 0.51 0.16 0.14 2.13 3.19 - - - - 
B*49 1.50 1.11 0.51 0.63 1.41 1.17 - - 1.95 2.73 1.82 1.40 
B*50 0.90 0.85 1.71 1.46 1.13 1.04 - - 0.78 0.98 1.82 1.32 
B*51 4.84 4.31 9.24 7.78 5.90 5.32 10.64 10.64 6.05 5.66 5.95 5.54 
B*52 1.04 1.06 7.28 8.29 2.48 2.56 5.32 7.45 2.34 1.76 2.73 2.23 
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 CAU (n= 2,831) ASI (n= 790) SEA (n= 47) BLK (n= 256) MIX (n= 605) Total* (n= 4,671) 
  CBU Mother CBU Mother CBU Mother CBU Mother CBU Mother CBU Mother 
B*53 0.44 0.42 0.19 - 1.21 0.98 - - 10.35 9.18 2.56 1.49 
B*54 0.02 0.04 0.00 0.06 0.05 0.09 1.06 2.13 - - 0.25 0.25 
B*55 1.77 1.87 1.96 2.22 1.69 1.97 4.26 5.32 0.20 0.39 1.57 2.56 
B*56 0.62 0.49 0.38 0.44 0.62 0.52 1.06 1.06 - - 0.91 0.83 
B*57 4.08 4.10 5.19 5.89 4.28 4.39 2.13 - 5.86 6.05 3.88 3.80 
B*58 0.83 0.99 4.43 4.62 2.02 2.25 5.32 4.26 7.62 9.77 1.98 1.74 
B*67 - - 0.06 0.06 0.02 0.03 1.06 1.06 - - - 0.08 
B*73 0.02 0.02 0.06 - 0.06 0.05 - - 0.59 0.59 - 0.08 
B*78 0.02 - - - 0.02 - - - - - 0.08 - 
B*81 - 0.02 - - 0.07 0.07 - - 0.98 0.98 0.17 0.08 
B*82 - - - - 0.02 0.02 - - 0.39 0.39 - - 
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Supplementary Table A.III CBU and maternal HLA-DRB1 allele frequencies. Frequencies were calculated by a direct count from 
4,671 CBUs and their mothers and are given as percentages. *Total also includes frequencies in OE and UNK groups. 
 CAU (n= 2,831) ASI (n= 790) SEA (n= 47) BLK (n= 256) MIX (n= 605) Total* (n= 4,671) 
  CBU Mother CBU Mother CBU Mother CBU Mother CBU Mother CBU Mother 
DRB1*01 11.76 10.88 3.73 3.61 9.61 9.05 3.19 4.26 6.45 8.01 9.09 8.60 
DRB1*03 11.82 12.56 8.92 8.42 11.38 11.70 2.13 1.06 13.09 13.67 12.31 11.57 
DRB1*04 18.28 17.15 9.75 10.19 15.42 14.78 13.83 9.57 6.25 5.08 12.81 14.21 
DRB1*07 13.33 14.54 13.42 14.87 12.79 14.01 7.45 10.64 8.79 9.57 12.23 12.98 
DRB1*08 2.35 2.74 1.08 1.52 2.69 2.99 3.19 4.26 8.59 8.59 3.64 3.55 
DRB1*09 1.15 1.18 1.39 1.33 1.42 1.49 10.64 13.83 1.95 1.95 1.82 1.98 
DRB1*10 0.83 0.71 5.38 5.38 1.91 1.93 3.19 3.19 2.73 4.10 1.90 2.07 
DRB1*11 8.92 8.28 9.49 10.70 9.63 9.13 8.51 7.45 10.35 10.74 12.31 9.75 
DRB1*12 1.93 2.19 4.62 4.87 2.57 2.93 14.89 15.96 2.15 2.93 1.82 2.98 
DRB1*13 10.12 10.67 8.29 8.99 10.60 10.75 7.45 4.26 20.51 17.97 12.07 11.16 
DRB1*14 2.70 2.79 8.48 7.66 3.84 3.77 8.51 4.26 0.98 1.37 4.21 4.30 
DRB1*15 14.62 14.43 24.56 21.46 16.28 15.77 13.83 19.15 16.41 14.45 14.38 15.29 
DRB1*16 2.19 1.89 0.89 1.01 1.85 1.71 3.19 2.13 1.76 1.56 1.40 1.57 
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Supplementary Figure A.I Cumulative frequency of CBU IMA/IPA and NIMA 
HLA A~B~DRB1 haplotypes according to broad population. Haplotypes 
were identified by comparing maternal and CBU HLA types in an identical-by-
descent algorithm. The CBU IMA/IPA and NIMA haplotypes were combined to 
form a single dataset. Frequencies were calculated by a direct count and ranked 
in descending order. *Total also includes OE and UNK. 
 
Supplementary Table A.IV Average cumulative CBU IMA/IPA and NIMA 
HLA A~B~DRB1 haplotype frequencies in each broad population. 
Haplotypes were identified by comparing maternal and CBU HLA types in an 
identical-by-descent algorithm. The CBU inherited and NIMA haplotypes were 
combined to form a single dataset. Frequencies are given as percentages and 
were calculated by a direct count and ranked in descending order. *Total also 
includes OE and UNK. 
 
Population  
Total* CAU ASI SEA BLK MIX 
Rank       
10 21.88 13.79 23.96 8.58 14.15 16.40 
25 31.04 23.22 39.58 16.50 21.59 23.92 
50 40.75 34.60 65.62 26.40 30.08 32.24 
100 51.52 48.56 - 42.90 42.25 42.47 
250 68.45 70.80 - 70.96 64.61 59.89 
500 82.77 - - -   74.31 
Average       
Mean 0.07 0.14 1.20 0.23 0.14 0.05 
Median 0.03 0.06 1.04 0.17 0.07 0.02 
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Supplementary Table A.V Frequency (F) of the top 10 ranking CBU IMA/IPA and NIMA HLA A~B~DRB1 haplotypes in each 
population and comparison to other NHS-CBB and NMDP populations. Haplotypes were identified by comparing maternal and CBU 
HLA types in an identical-by-descent algorithm. The CBU inherited and NIMA haplotypes were combined to form a single dataset. 
Frequencies are given as percentages and ranked in descending order. Frequencies in the NHS-CBB were calculated by a direct count. 
Second field frequencies in the NMDP were estimated by a modified version of the expectation-maximisation algorithm (Gragert, et al 
2013), downloaded from http://frequency.nmdp.org/NMDPFrequencies2011/. These were collapsed back to first field and frequencies 
were re-calculated. Comparisons were made between the NHS-CBB CAU and the NMDP CAU populations, between the NHS-CBB ASI and 
NMDP Asia and Pacific Islander populations and between the NHS-CBB BLK and NMDP African American populations.  
 NHS-CBB CBU inherited and NIMA population 
NMDP 
  CAU  ASI SEA BLK MIX 
  Rank F (%) Rank F (%) Rank F (%) Rank F (%) Rank F (%) Rank F (%) 
CAU                         
A*01~B*08~DRB1*03 1 6.59 19 0.57 - - 14 0.50 1 5.17 1 6.01 
A*03~B*07~DRB1*15 2 2.93 71 0.29 - - 24 0.50 3 1.20 2 3.06 
A*02~B*44~DRB1*04 3 2.80 - - - - 7 0.66 2 1.91 3 2.17 
A*29~B*44~DRB1*07 4 2.13 558 0.06 - - - - 6 0.92 6 1.45 
A*02~B*07~DRB1*15 5 1.91 43 0.40 - - 15 0.50 5 0.99 4 1.94 
A*01~B*57~DRB1*07 6 1.37 2 1.84 - - 40 0.33 4 1.13 8 1.07 
A*02~B*15~DRB1*04 7 1.37 185 0.11 - - 151 0.17 12 0.57 5 1.47 
A*03~B*35~DRB1*01 8 1.07 27 0.52 - - 67 0.33 26 0.42 7 1.25 
A*02~B*08~DRB1*03 9 0.92 33 0.46 - - - - 22 0.42 10 0.79 
A*02~B*57~DRB1*07 10 0.78 198 0.11 - - 58 0.33 154 0.14 14 0.68 
ASI                         
A*33~B*44~DRB1*07 696 0.03 1 2.87 6 2.08 - - 15 0.57 2 1.91 
A*01~B*57~DRB1*07 6 1.37 2 1.84 - - 40 0.33 4 1.13 5 1.46 
A*26~B*08~DRB1*03 180 0.11 3 1.55 - - 265 0.17 106 0.21 25 0.58 
A*02~B*40~DRB1*15 56 0.25 4 1.49 - - 49 0.33 18 0.50 9 0.90 
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 NHS-CBB CBU inherited and NIMA population 
NMDP 
  CAU  ASI SEA BLK MIX 
  Rank F (%) Rank F (%) Rank F (%) Rank F (%) Rank F (%) Rank F (%) 
A*01~B*37~DRB1*10 114 0.14 5 1.21 35 1.04 - - 10 0.57 16 0.79 
A*11~B*52~DRB1*15 173 0.11 6 1.21 - - 214 0.17 426 0.07 39 0.40 
A*24~B*15~DRB1*12 978 0.02 7 1.03 58 1.04 - - 65 0.28 10 0.88 
A*33~B*58~DRB1*03 478 0.05 8 1.03 80 1.04 341 0.17 235 0.14 1 2.13 
A*24~B*15~DRB1*15 427 0.05 9 0.80 59 1.04 - - 472 0.07 20 0.72 
A*01~B*40~DRB1*15 - - 10 0.75 - - - - - - 75 0.24 
SEA                         
A*02~B*46~DRB1*09 - - 127 0.17 1 5.21 - - 348 0.07 3 1.68 
A*11~B*15~DRB1*04 205 0.10 28 0.52 2 3.13 - - 403 0.07 17 0.78 
A*02~B*40~DRB1*11 83 0.19 51 0.34 3 2.08 - - 336 0.07 52 0.33 
A*24~B*35~DRB1*15 342 0.06 23 0.57 4 2.08 259 0.17 99 0.21 37 0.42 
A*24~B*48~DRB1*12 - - 149 0.17 5 2.08 - - - - 265 0.08 
A*33~B*44~DRB1*07 696 0.03 1 2.87 6 2.08 - - 15 0.57 2 1.91 
A*02~B*40~DRB1*09 391 0.05 - - 7 2.08 - - - - 23 0.60 
A*11~B*15~DRB1*14 - - 137 0.17 8 2.08 - - - - 130 0.15 
A*33~B*13~DRB1*15 - - - - 9 2.08 - - - - 527 0.04 
A*01~B*52~DRB1*15 78 0.19 84 0.23 10 1.04 - - 43 0.28 172 0.12 
BLK                         
A*30~B*42~DRB1*03 - - - - - - 1 1.65 39 0.35 1 1.73 
A*34~B*44~DRB1*15 - - - - - - 2 0.99 111 0.21 8 0.61 
A*01~B*07~DRB1*03 - - - - - - 3 0.83 257 0.07 1399 0.01 
A*30~B*57~DRB1*13 - - - - - - 4 0.83 600 0.07 17 0.46 
A*66~B*58~DRB1*15 - - - - - - 5 0.83 692 0.07 19 0.41 
A*68~B*15~DRB1*13 705 0.03 679 0.06 - - 6 0.83 - - 48 0.24 
A*02~B*44~DRB1*04 3 2.80 - - - - 7 0.66 2 1.91 10 0.54 
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 NHS-CBB CBU inherited and NIMA population 
NMDP 
  CAU  ASI SEA BLK MIX 
  Rank F (%) Rank F (%) Rank F (%) Rank F (%) Rank F (%) Rank F (%) 
A*02~B*51~DRB1*08 105 0.16 - - - - 8 0.66 150 0.14 371 0.06 
A*23~B*15~DRB1*03 947 0.02 - - - - 9 0.66 438 0.07 82 0.20 
A*23~B*44~DRB1*07 15 0.65 476 0.06 - - 10 0.66 9 0.71 104 0.18 
MIX                         
A*01~B*08~DRB1*03 1 6.59 19 0.57 - - 14 0.50 1 5.17 - - 
A*02~B*44~DRB1*04 3 2.80 - - - - 7 0.66 2 1.91 - - 
A*03~B*07~DRB1*15 2 2.93 71 0.29 - - 24 0.50 3 1.20 - - 
A*01~B*57~DRB1*07 6 1.37 2 1.84 - - 40 0.33 4 1.13 - - 
A*02~B*07~DRB1*15 5 1.91 43 0.40 - - 15 0.50 5 0.99 - - 
A*29~B*44~DRB1*07 4 2.13 558 0.06 - - - - 6 0.92 - - 
A*02~B*44~DRB1*07 12 0.73 70 0.29 14 3.13 - - 7 0.78 - - 
A*30~B*13~DRB1*07 18 0.59 12 0.75 74 - 290 0.17 8 0.78 - - 
A*23~B*44~DRB1*07 15 0.65 476 0.06 - - 10 0.66 9 0.71 - - 
A*01~B*37~DRB1*10 114 0.14 5 1.21 35 - - - 10 0.57 - - 
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Supplementary Table A.VI NHS-CBB CBU IMA/IPA and NIMA HLA 
A~B~DRB1 haplotypes ranking in the bottom 25th centile of the 
corresponding estimated frequencies in the NMDP. Haplotypes were 
identified by comparing maternal and CBU HLA types in an identical-by-descent 
algorithm. The CBU inherited and NIMA HLA haplotypes were combined to form 
a single dataset. Frequencies are given as percentages and ranked in descending 
order. Frequencies in the NHS-CBB were calculated by a direct count. Second 
field frequencies in the NMDP were estimated by a modified version of the 
expectation-maximisation algorithm (Gragert, et al 2013), downloaded from 
http://frequency.nmdp.org/NMDPFrequencies2011/. These were collapsed 
back to first field and frequencies were re-calculated. The 75th centile covered 
the top 75% of the population when ranked in descending order of haplotype 
frequency. 
  NHS-CBB NMDP 
  F (%) Rank F (%) Rank 
CAU         
Below NMDP 75th centile         
A*29~B*37~DRB1*03 0.01593 1106 0.00009 4783 
A*33~B*55~DRB1*03 0.01593 1285 0.00009 4866 
A*33~B*78~DRB1*01 0.01593 1287 0.00001 6110 
A*36~B*35~DRB1*15 0.01593 1290 0.00007 4979 
A*68~B*48~DRB1*12 0.01593 1337 0.00003 5608 
A*74~B*53~DRB1*16 0.01593 1365 0.00007 4963 
Not seen in NMDP Caucasian         
A*30~B*81~DRB1*13 0.01593 1179 - - 
ASI         
Below NMDP 75th centile         
A*01~B*18~DRB1*08 0.05747 304 0.00031 3493 
A*23~B*49~DRB1*10 0.05747 479 0.0002 3772 
A*29~B*39~DRB1*13 0.05747 557 0.00007 4523 
A*30~B*08~DRB1*10 0.05747 566 0.00028 3561 
A*31~B*57~DRB1*12 0.05747 595 0.00032 3480 
A*66~B*51~DRB1*11 0.05747 670 0.00017 3887 
Not seen in NMDP Asia and Pacific 
Islander 
  
    
A*01~B*47~DRB1*15 0.05747 321 - - 
A*01~B*73~DRB1*14 0.05747 340 - - 
A*03~B*08~DRB1*12 0.05747 399 - - 
A*23~B*14~DRB1*11 0.05747 475 - - 
A*25~B*27~DRB1*13 0.05747 524 - - 
A*25~B*40~DRB1*13 0.05747 525 - - 
A*74~B*45~DRB1*10 0.05747 711 - - 
SEA         
Below NMDP 75th centile         
A*31~B*14~DRB1*07 1.04167 28 0.00029 3542 
Not seen in NMDP Asia and Pacific 
Islander 
  
    
A*25~B*55~DRB1*14 1.04167 72 - - 
BLK         
Below NMDP 75th centile         
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  NHS-CBB NMDP 
  F (%) Rank F (%) Rank 
A*01~B*73~DRB1*08 0.33003 41 0.00037 4754 
A*26~B*57~DRB1*09 0.16502 270 0.00012 5495 
A*30~B*41~DRB1*10 0.16502 300 0.00031 4879 
A*31~B*07~DRB1*08 0.16502 314 0.00031 4888 
A*68~B*81~DRB1*04 0.16502 400 0.0001 5644 
A*74~B*51~DRB1*14 0.16502 415 0.00009 5741 
Not seen in NMDP African American 
  
    
A*03~B*47~DRB1*08 0.16502 198 - - 
A*03~B*73~DRB1*10 0.16502 209 - - 
A*26~B*38~DRB1*10 0.16502 268 - - 
A*69~B*51~DRB1*11 0.16502 402 - - 
Not seen in any NMDP population 
  
      
A*23~B*73~DRB1*07 0.16502 244 - - 
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Supplementary Table A.VII Heterozygous CBU-Maternal 0 MM for the top 10 ranking x, y allele combinations at HLA-A, -B and –
DRB1. Frequencies of individual heterozygous x, y allele combinations were calculated by a direct count. 0 MM are when the CBU and 
mother have identical first field x, y alleles at an HLA locus. Results show the number of 0 MM out of the total x, y alleles in each 
population. Total also includes OTH and UNK categories. 
Rank 
Total CAU ASI SEA BLK MIX 
x, y 0 MM x, y 0 MM x, y 0 MM x, y 0 MM x, y 0 MM x, y 0 MM 
HLA-A 
1 *01, *02 79/392 *01, *02 63/297 *02, *24 6/40 *02, *11 3/10 *02, *30 2/12 *01, *02 11/46 
2 *02, *03 58/275 *02, *03 48/219 *11, *24 7/38 *11, *24 1/5 *02, *03 2/11 *02, *24 6/31 
3 *02, *24 39/229 *02, *24 24/140 *02, *11 12/34 *02, *24 1/3 *02, *23 2/10 *02, *68 7/23 
4 *02, *11 37/184 *02, *11 17/111 *11, *33 5/32 *02, *33 1/3 *01, *02 2/9 *02, *30 3/22 
5 *01, *03 18/153 *01, *03 13/106 *01, *02 2/31 *24, *33 1/3 *02, *68 2/9 *01, *03 4/21 
6 *02, *68 24/135 *02, *32 13/84 *01, *11 5/30 *11, *33 0/2 *23, *30 1/9 *02, *03 3/21 
7 *01, *24 15/126 *02, *68 13/82 *24, *33 2/27 *01, *33 0/1 *03, *23 0/9 *01, *11 6/20 
8 *03, *24 14/111 *01, *24 9/74 *01, *24 3/26 *11, *32 0/1 *01, *03 0/8 *01, *24 2/19 
9 *02, *32 17/108 *02, *29 8/70 *02, *33 4/26 *02, *25 0/1 *01, *68 0/8 *02, *11 3/18 
10 *01, *11 15/107 *03, *24 10/67 *03, *24 1/26 *02, *03 0/1 *02, *33 2/7 *02, *23 2/13 
HLA-B 
1 *07, *44 15/139 *07, *44 11/116 *35, *51 6/26 *15, *27 0/3 *15, *35 0/7 *08, *44 2/13 
2 *08, *44 24/133 *08, *44 21/106 *15, *40 4/25 *13, *51 0/2 *15, *44 0/7 *35, *40 2/12 
3 *07, *08 15/106 *07, *08 13/91 *35, *40 3/22 *13, *52 0/2 *15, *53 0/7 *40, *44 1/12 
4 *15, *44 5/100 *15, *44 5/70 *35, *52 3/20 *15, *35 0/2 *35, *53 0/6 *07, *35 1/12 
5 *40, *44 10/88 *40, *44 8/63 *15, *51 3/18 *15, *39 0/2 *07, *58 2/6 *07, *44 2/12 
6 *35, *44 9/85 *35, *44 7/62 *40, *52 2/18 *13, *35 0/1 *15, *57 0/5 *35, *51 0/11 
7 *08, *35 7/83 *07, *15 4/55 *15, *35 3/17 *13, *46 0/1 *35, *58 0/5 *15, *35 0/10 
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Rank 
Total CAU ASI SEA BLK MIX 
x, y 0 MM x, y 0 MM x, y 0 MM x, y 0 MM x, y 0 MM x, y 0 MM 
8 *07, *35 8/79 *07, *40 8/53 *15, *57 0/14 *13, *58 0/1 *44, *53 0/5 *15, *51 2/10 
9 *07, *15 5/74 *08, *35 4/52 *08, *35 2/14 *15, *44 0/1 *51, *58 0/5 *08, *15 0/10 
10 *15, *35 5/73 *18, *44 6/47 *40, *51 1/13 *15, *46 0/1 *07, *15 1/5 *15, *44 0/9 
HLA-DRB1 
1 *04, *15 33/218 *04, *15 20/145 *07, *15 13/54 *09, *11 1/3 *03, *13 4/18 *13, *15 1/24 
2 *07, *15 34/197 *04, *07 22/120 *04, *15 8/41 *09, *14 0/3 *13, *15 3/13 *03, *11 2/22 
3 *04, *07 27/172 *01, *04 15/119 *14, *15 6/39 *11, *15 0/2 *03, *15 1/13 *11, *15 2/21 
4 *03, *15 26/161 *03, *04 23/117 *11, *15 3/31 *12, *15 0/2 *11, *13 1/12 *04, *07 2/21 
5 *03, *04 26/153 *07, *15 19/112 *03, *15 6/24 *12, *16 1/2 *04, *13 0/11 *03, *15 3/19 
6 *03, *07 25/148 *03, *07 15/106 *13, *15 3/23 *14, *15 0/2 *07, *15 1/11 *03, *07 1/19 
7 *04, *13 16/144 *03, *15 16/102 *10, *15 1/21 *03, *13 0/2 *11, *15 3/10 *04, *11 1/18 
8 *01, *04 16/141 *04, *13 11/101 *12, *15 6/20 *07, *12 1/2 *08, *13 0/10 *07, *15 1/18 
9 *13, *15 15/136 *01, *07 13/99 *03, *07 9/20 *01, *13 0/1 *01, *13 1/7 *01, *13 2/17 
10 *01, *15 15/131 *01, *15 11/89 *04, *07 0/20 *01, *15 0/1 *01, *15 0/7 *03, *13 0/17 
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Appendix B – Chapter 4 supplementary material 
Table B.I Virtual 6/6 matched CB donor availability according to patient 
ethnicity.  
Patient Ethnicity 
CB donor search strategy 
BBMR BMDW 
European Caucasoid 86/274 (31.4%) 136/274 (50.0%) 
Other ethnicity 17/67 (25.4%) 30/67 (44.8%) 
• Non-European Caucasoid 10/35 15/35 
• Black 2/13 6/13 
• Southeast Asian 1/6 2/6 
• Mixed 4/13 7/13 
Unknown/ Not Declared 27/116 (23.3%) 55/116 (47.4%) 
All Ethnicities 130/457 (28.4%) 221/457 (48.4%) 
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Table B.II Patient HLA-A, -B and -DRB1 allele frequencies. Allele frequencies were calculated by a direct count method. Patient n= 457. 
HLA-A HLA-B HLA-DRB1 
Allele F (%) 
Cumulative 
F (%) 
Allele F (%) 
Cumulativ
e F (%) 
Allele F (%) 
Cumulativ
e F (%) 
Allele F (%) 
Cumulativ
e F (%) 
A*02 24.7 24.7 B*44 15.0 15.0 B*50 1.1 93.7 DRB1*04 17.9 17.9 
A*01 16.1 40.8 B*07 10.6 25.6 B*56 1.0 94.6 DRB1*15 12.8 30.7 
A*03 10.8 51.6 B*15 8.1 33.7 B*41 0.9 95.5 DRB1*07 12.0 42.8 
A*24 10.2 61.8 B*08 7.9 41.6 B*45 0.9 96.4 DRB1*13 11.6 54.4 
A*11 8.1 69.9 B*35 7.9 49.5 B*53 0.9 97.3 DRB1*03 10.7 65.1 
A*68 5.5 75.4 B*51 6.9 56.3 B*42 0.7 97.9 DRB1*11 9.3 74.4 
A*26 4.6 80.0 B*40 5.9 62.3 B*47 0.5 98.5 DRB1*01 8.1 82.5 
A*33 4.0 84.0 B*14 3.6 65.9 B*48 0.4 98.9 DRB1*14 4.5 87.0 
A*29 3.3 87.3 B*27 3.6 69.5 B*60 0.2 99.1 DRB1*08 3.5 90.5 
A*32 2.7 90.0 B*57 3.3 72.8 B*62 0.2 99.3 DRB1*16 3.1 93.5 
A*30 2.5 92.6 B*18 3.1 75.8 B*73 0.2 99.6 DRB1*12 3.0 96.5 
A*31 2.4 95.0 B*38 2.6 78.4 B*46 0.1 99.7 DRB1*09 1.9 98.4 
A*23 2.2 97.2 B*52 2.6 81.1 B*54 0.1 99.8 DRB1*10 1.6 100.0 
A*25 1.2 98.4 B*58 2.4 83.5 B*67 0.1 99.9    
A*34 0.5 98.9 B*49 2.3 85.8 B*81 0.1 100.0    
A*36 0.3 99.2 B*39 2.2 88.0       
A*66 0.3 99.6 B*13 1.8 89.7       
A*74 0.3 99.9 B*55 1.5 91.2       
A*69 0.1 100.0 B*37 1.3 92.6       
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Table B.III Availability of a virtual 6/6 matched CB donor from BMDW 
according to patient HLA-A, -B and -DRB1 alleles. 
 BMDW virtual 6/6  
 Yes No Total 
HLA-A    
A*01 82 (55.8) 65 (44.2) 147 
A*02 136 (60.2) 90 (39.8) 226 
A*03 57 (57.6) 42 (42.4) 99 
A*11 27 (36.5) 47 (63.5) 74 
A*23 7 (35) 13 (65) 20 
A*24 47 (50.5) 46 (49.5) 93 
A*25 3 (27.3) 8 (72.7) 11 
A*26 14 (33.3) 28 (66.7) 42 
A*29 12 (40) 18 (60) 30 
A*30 7 (30.4) 16 (69.6) 23 
A*31 10 (45.5) 12 (54.5) 22 
A*32 5 (20) 20 (80) 25 
A*33 13 (35.1) 24 (64.9) 37 
A*34 1 (20) 4 (80) 5 
A*36 0 (0) 3 (100) 3 
A*66 0 (0) 3 (100) 3 
A*68 20 (40) 30 (60) 50 
A*69 0 (0) 1 (100) 1 
A*74 1 (33.3) 2 (66.7) 3 
HLA-B    
B*07 72 (74.2) 25 (25.8) 97 
B*08 43 (59.7) 29 (40.3) 72 
B*13 8 (50) 8 (50) 16 
B*14 16 (48.5) 17 (51.5) 33 
B*15 36 (48.6) 38 (51.4) 74 
B*18 12 (42.9) 16 (57.1) 28 
B*27 11 (33.3) 22 (66.7) 33 
B*35 36 (50) 36 (50) 72 
B*37 4 (33.3) 8 (66.7) 12 
B*38 6 (25) 18 (75) 24 
B*39 7 (35) 13 (65) 20 
B*40 30 (55.6) 24 (44.4) 54 
B*41 2 (25) 6 (75) 8 
B*42 1 (16.7) 5 (83.3) 6 
B*44 80 (58.4) 57 (41.6) 137 
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B*45 3 (37.5) 5 (62.5) 8 
B*46 0 (0) 1 (100) 1 
B*47 0 (0) 5 (100) 5 
B*48 1 (25) 3 (75) 4 
B*49 7 (33.3) 14 (66.7) 21 
B*50 4 (40) 6 (60) 10 
B*51 28 (44.4) 35 (55.6) 63 
B*52 6 (25) 18 (75) 24 
B*53 2 (25) 6 (75) 8 
B*54 0 (0) 1 (100) 1 
B*55 4 (28.6) 10 (71.4) 14 
B*56 2 (22.2) 7 (77.8) 9 
B*57 15 (50) 15 (50) 30 
B*58 4 (18.2) 18 (81.8) 22 
B*60 1 (50) 1 (50) 2 
B*62 1 (50) 1 (50) 2 
B*67 0 (0) 1 (100) 1 
B*73 0 (0) 2 (100) 2 
B*81 0 (0) 1 (100) 1 
HLA-DRB1    
DRB1*01 34 (45.9) 40 (54.1) 74 
DRB1*03 51 (52) 47 (48) 98 
DRB1*04 102 (62.2) 62 (37.8) 164 
DRB1*07 57 (51.8) 53 (48.2) 110 
DRB1*08 5 (15.6) 27 (84.4) 32 
DRB1*09 1 (5.9) 16 (94.1) 17 
DRB1*10 2 (13.3) 13 (86.7) 15 
DRB1*11 42 (49.4) 43 (50.6) 85 
DRB1*12 6 (22.2) 21 (77.8) 27 
DRB1*13 50 (47.2) 56 (52.8) 106 
DRB1*14 15 (36.6) 26 (63.4) 41 
DRB1*15 69 (59) 48 (41) 117 
DRB1*16 9 (32.1) 19 (67.9) 28 
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Appendix C – Chapter 6 supplementary material 
Table C.I InDel marker panel characteristics.  InDel targets were chosen 
from a list of published polymorphic markers previously used in q-PCR assays 
for the detection of chimaerism. S-03, S-06 and S-11A were chosen because they 
were reported to be the most informative in a previously tested population 
(Alizadeh, et al 2002). 
Target 
Chromosome 
location 
 Primer sequence (3’ – 5’) 
Amplicon 
length 
(bp) 
Mean 
amplicon 
Tm (oC) 
S-03 6q F CTTTTGCTTTCTGTTTCTTAAGGGC 223 85.38 ± 0.20 
  R TCAATCTTTGGGCAGGTTGAA   
S-06 1p F CAGTCACCCCGTGAAGTCCT 106 84.24 ± 0.23 
  R TTTCCCCCATCTGCCTATTG   
S-11A 11 F TAGGATTCAACCCTGGAAGC 189 81.10 ± 0.31 
  R CCAGCATGCACCTGACTAACA   
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Table C.II InDel q-PCR thermal cycling parameters trialled with iQ-SYBR 
Green Supermix. InDel specific q-PCR reactions were not compatible with the 
SYBR Select MasterMix (Life technologies) used for the HLA specific assays, 
possibly due to a non-optimal MgCl2 concentration in the master mix. InDel q-
PCR reactions were set up using the iQ-SYBR Green Supermix (Bio-Rad) and by 
following the Netherlands recommended thermal cycling protocol for controls 
positive and negative for S-03, S-06 and S-11A.  The Netherlands InDel protocol 
again did not show exponential amplification for any target (data not shown) 
and it was clear that the InDel thermal cycling protocol required further 
optimisation. The recommended thermal cycling protocol for the iQ-SYBR Green 
Supermix (Bio-Rad) was next trialled, which has a shorter initial denaturation 
step (5 minutes) compared to the Netherlands InDel thermal cycling protocol. 
 
Netherlands 
protocol 
Bio-Rad protocol Final protocol 
Parameter 
Temp. 
(⁰C) 
Time 
Temp. 
(⁰C) 
Time 
Temp. 
(⁰C) 
Time 
Initial denaturation 95 10:00 95 5:00 95 5:00 
Cycling (x40)       
Denaturation 95 0:45 95 0:15 95 0:15 
Annealing 65 1:00 55 – 65* 1:00 63 1:00 
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Figure C.I InDel q-PCR primer annealing temperature gradient 
dissociation curves. Primer annealing temperatures: (A) 56oC, (B) 58oC, (C) 
60oC, (D) 62oC, (E) 64oC and (F) 66oC. Q-PCR reactions were set up using male 
platelet donor DNA positive for the target of interest and using a variable 
primer annealing temperature. Amplicons were continuously heated from 55⁰C 
- 95⁰C and temperature (⁰C) was plotted against the derivative Reporter (-Rn') 
to determine the amplicon melting temperature (Tm).  
S-03   S-06          S-11A 
(A) 56oC 
 
(B) 58oC 
 
(C) 60oC 
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Figure C.I continued. 
(D) 62oC 
 
(E) 64°C 
 
(F) 66°C 
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Figure C.II S-03 q-PCR primer annealing temperature gradient dissociation 
curves for serial dilution and negative samples. Primer annealing 
temperatures: (A) 62oC, (B) 63oC and (C) 64oC. Serial dilutions A: 100%, B: 
10%, C: 1%, D: 0.1%, E: 0.01% and F: 0.001%) were pipetted from a starting 
quantity of 200ng. Negative controls included were G: DNA negative for the 
target of interest and H: non-template water control. Amplicons were 
continuously heated from 55⁰C - 95⁰C and temperature (⁰C) was plotted against 
the derivative Reporter (-Rn') to determine the amplicon melting temperature 
(Tm). The dissociation curves indicated the presence of a specific amplicon for 
serial dilutions over 5 logs at a primer annealing of 63oC only and this 
temperature was selected for all future optimisations and experiments.  
(A) 62°C          (B) 63°C   (C) 64°C
 
 
 
 
 
Figure C.III HCK 63°C primer annealing q-PCR dissociation curve  
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Table C.II InDel primer concentration optimisation by comparison of q-
PCR amplification efficiencies. Standard curves were produced from artificial 
spiking experiments whereby DNA positive for the polymorphic target of 
interest was diluted in DNA negative for the target. Serial 1:10 dilutions over 
five logs (100%, 10%, 1%, 0.1% and 0.01%) were pipetted from a starting 
quantity of 200ng and an additional 0.05% dilution was also included. q-PCR 
reactions for each dilution and target were set up in duplicate containing a 
variable amount of forward and reverse HLA primer. Red indicates 
amplification efficiency closest to 100% and thus the optimal primer 
concentration selected for future experiments. 
Target 
PCR efficiency (%) at each primer concentration tested 
4.5 pmol 3.0 pmol 1.5 pmol 
S-03 99 99 83 
S-06 103 98 87 
S-11A 85 99 90 
 
Table C.III HCK primer concentration optimisation by comparison of q-
PCR amplification efficiencies. Standard curves were produced from artificial 
spiking experiments whereby DNA was diluted in water. Serial 1:2 dilutions 
over six logs were pipetted from a starting quantity of 200ng. q-PCR reactions 
for each dilution and target were set up in duplicate containing a variable 
amount of forward and reverse HLA primer. Red indicates amplification 
efficiency closest to 100% and thus the optimal primer concentration selected 
for future experiments. 
Primer concentration (pmol) PCR efficiency (%) 
1.50 122 
1.00 109 
0.75 133 
0.50 - 
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Table C.IV Sensitivity of each InDel q-PCR assay. Standard curves were 
produced from artificial spiking experiments whereby DNA positive for the 
polymorphic target of interest was diluted in DNA negative for the target. Serial 
dilutions (10%, 1%, 0.1%, 0.05%, 0.01% and 0.005%) were pipetted from a 
starting quantity of 200ng. q-PCR reactions for each dilution and target were set 
up with five replicates. The linear dynamic range (LDR) was the last point 
where the curve maintained linearity, defined as a coefficient of determination 
(R2) > 0.99. 
Target LDR (%) Positive replicates 
S-03 0.01 5/5 
S-06 0.01 5/5 
S-11A 0.01 5/5 
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Figure C.IV Representative InDel q-PCR amplification plots (1) and standard curves (2). (A) S-03, (B) S-06 and (C) S-11A. Standard curves 
were produced from artificial spiking experiments whereby DNA positive for the HLA target of interest was diluted in DNA negative for 
the target. Serial dilutions (100%, 10%, 1%, 0.1%, 0.05% and 0.01%) were pipetted from a starting quantity of 200ng and set up in 
triplicate.  
(A) S-03     (B) S-06     (C) S-11A 
(1) 
                             
(2) 
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Table C.V InDel q-PCR quantitation cycle (Cq) results for representative standard curves. Standard curves were produced from 
artificial spiking experiments whereby DNA positive for the polymorphic target of interest was diluted in DNA negative for the target. 
Serial dilutions (100%, 10%, 1%, 0.1%, 0.05% and 0.01%) were pipetted from a starting quantity of 200ng and set up in triplicate. Cq 
values are shown as the mean ± standard deviation (S.D.) for three replicates. 
Target 
Mean Cq ± S.D. for each target quantity 
100% 10% 1% 0.1% 0.05% 0.01% 
S-03 18.262 ± 0.156 20.578 ± 0.023 24.168 ± 0.045 27.617 ± 0.148 28.187 ± 0.119 29.953 ± 0.377 
S-06 18.444 ± 0.175 20.505 ± 0.017 23.673 ± 0.099 27.144 ± 0.409 28.415 ± 0.104 30.757 ± 0.585 
S-11A 16.956 ± 0.037 19.217 ± 0.066 22.497 ± 0.049 26.345 ± 0.131 27.502 ± 0.290 29.198 ± 0.555 
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Table C.VI Representative InDel q-PCR standard curves properties. 
Standard curves were produced from artificial spiking experiments whereby 
DNA positive for the polymorphic target of interest was diluted in DNA negative 
for the target. Serial dilutions (100%, 10%, 1%, 0.1%, 0.05% and 0.01%) were 
pipetted from a starting quantity of 200ng and set up in triplicate. 
Target Slope Intercept R2 
S-03 -3.047 18.083 0.993 
S-06 -3.110 17.937 0.990 
S-11A -3.213 16.497 0.990 
 
 
Table C.VII Informativity of InDel polymorphisms for NIMA in the CBU and 
maternal pairs evaluated. 
 
Total 
genotyped 
Informativity 
Informative 
Non-
informative 
S-03 66 8 (12) 58 (88) 
S-06 66 14 (21) 52 (79) 
S-11A 66 13 (20) 53 (80) 
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Appendix F – Travel grants 
BSHI Travel Bursary – To attend World Cord Blood Congress V and Innovative 
Cell Therapies, Monaco 2015 (£400) 
Netcord Travel Award – To attend World Cord Blood Congress V and 
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BSI Travel Bursary – To attend 11th International Summer School for 
Immunogenetics, Colorado, USA 2014 (£800) 
EFI Bursary – To attend 11th International Summer School for 
Immunogenetics, Colorado, USA 2014 (€750) 
 
 
